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ABSTRACT 
 
The main aim of this thesis was to address outstanding questions in the treatment of adults and 
children in low/middle-income settings using data from the DART and ARROW trials. DART and 
ARROW both investigated whether delivery of ART in Africa with or without routine monitoring 
of CD4 counts led to similar outcomes in terms of efficacy. In addition ARROW investigated 
different numbers of drugs at ART initiation. Despite work already carried out on these data, 
many important clinical and epidemiological questions remained. 
I have investigated the patterns of mortality in DART and ARROW using flexible parametric 
models to assess the change in hazard of death over time, overall and for specific causes of 
death. Deaths were most commonly related to HIV disease both during the first year after ART 
initiation and subsequently. HIV-related deaths after 1 year on ART were also the main driver of 
long-term differences between CD4 vs. no-CD4 monitoring strategies. The contribution of HIV-
related-malignancies, likely triggered by pre-cancerous events occurring before ART initiation, 
and longer-term ART mortality highlights the importance of earlier HIV diagnosis and access to 
care. Low but increasing risks of deaths from trauma/suicide in adults highlight the importance 
of long-term psychosocial support and empowering patients to manage their own treatment. 
Analysis comparing the DART STI/CT (structured treatment interruption/continuous therapy) 
randomised groups showed that interrupting ART is associated with lower CD4 counts and 
poorer clinical outcomes over the long-term even after returning to ART. These findings suggest 
that substantially greater efforts should be devoted to reducing the risk of any treatment 
interruption, including strengthening supply chain management, early contact of patients not 
attending drug refill visits and making short supplies of ART available for patients who travel.  
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Chapter 1: Introduction 
1.1. Human immunodeficiency virus  
1.1.1. Background to HIV 
HIV (Human immunodeficiency virus) is a member of the retrovirus family, specifically a 
lentivirus. Unlike most viruses that store their genetic material on long double strands of DNA 
(Deoxyribonucleic acid), the genes of a retrovirus are made up of a single strand of RNA 
(Ribonucleic Acid). This small difference means that HIV replication is more complicated than 
that of many other viruses and HIV can only replicate inside a human cell. The life cycle of HIV 
(Figure 1.1.1) [1] starts when a virus particle attaches itself to a human cell via a special protein 
on the outside of the cell called CD4; the viral envelope which covers the protein shell of a virus 
then fuses with the cell membrane and the HIV genetic code is released into the human cell 
where it is transcribed from RNA to DNA. It then travels to the cell’s nucleus and integrates with 
the human DNA. The cell is then ‘programmed’ to make new HIV genetic material and proteins. 
The new proteins are cut up by the HIV protease (a protein cutting enzyme) to make functional 
new HIV particles. 
 
Figure 1.1.1 The HIV Life Cycle (reproduced from [1]) 
 
These cells with CD4 proteins on their surface are white blood cells known as T helper cells. 
They are part of the human immune system helping the body to fight infection by moving 
throughout the body, identifying and destroying germs such as bacteria and viruses. This aspect 
of immune system health can be monitored by counting the number of CD4 cells in a microlitre 
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of blood. A normal CD4 count is from 500 to 1500 cells/μL of blood; however, it is more 
important to pay attention to the pattern of results than to any one test result, because counts 
can vary substantially around acute illness. Someone infected with HIV will have a slow decline 
in CD4 count. As CD4 counts decline the immune system gets weaker, is less able to fight off 
infections, and this is when people are most likely to become unwell. Although CD4 counts 
indicate the risk of developing illness, some people can have high CD4 counts and still get 
infections that healthy people would fight off. Others can have low CD4 counts and have few 
complications, at least for a while [2].  
HIV infection leads to low levels of CD4 through three main mechanisms 1) direct viral killing of 
infected cells, 2) increased rates of apoptosis (programmed cell death) in infected cells and 
bystander cells (cells in the nearby environment that may not themselves be directly infected), 
and 3) the killing of infected CD4 cells by CD8 cytotoxic lymphocytes that recognise infected 
cells. When CD4 counts decline to below a critical level (<350 cells/μL) [3] the body’s immunity 
declines and people become more susceptible to opportunistic infections (OIs), infections that 
would not usually occur in someone with a healthy immune system. These OIs and particular 
cancers which are more common in HIV-infected people form the definition of “AIDS” (acquired 
immune deficiency syndrome), indicating severe disease. “AIDS” is a definition from the US 
Centers for Disease Control (CDC). WHO have defined equivalent clinical criteria to diagnose 
the progression of HIV disease; stage 1 is asymptomatic disease and stage 4 is equivalent to a 
clinical diagnosis of AIDS [4]. AIDS/WHO stage 4 is the final stage of HIV disease at which point 
the immune system is so severely damaged that the person can no longer fight infection. If left 
untreated, HIV/AIDS leads to progressively greater immune system failure, life-threatening OIs, 
cancers and eventually death.  
1.1.2. Transmission of HIV 
HIV is only transmitted via bodily fluids such as semen, vaginal secretions, breast milk and 
blood (including menstrual blood). Blood contains the highest concentration of the virus followed 
by semen, vaginal secretions and then breast milk. HIV can be transferred from a HIV-infected 
mother to the baby during pregnancy, birth or breast-feeding; this is known as mother to child 
transmission (MTCT). The following ‘bodily fluids’ are not infectious; saliva, tears, sweat, faeces 
and urine [5]. Activities that allow HIV transmission include unprotected sexual activity and 
direct blood contact, including injecting drug needles, blood transfusions, accidents in health 
care settings, and treatments with certain blood products, including factor VIII products (clotting 
agents commonly used to treat haemophiliacs). From the late 1970s to the mid-1980s, over 
4500 people with haemophilia became infected with HIV through receiving infected blood 
products. Many of these people have developed AIDS and died; of the 1,243 people in the UK 
with haemophilia who were known to become infected with HIV, less than 250 are still alive in 
2016 [6].  
Sexual transmission via heterosexual activity accounts for the majority of newly infected 
individuals in low/middle income countries (LMIC). People who inject drugs suffer 
disproportionately, particularly in Eastern Europe. In the absence of any intervention, 15-45% of 
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infants will be infected through MTCT, with most infections occurring during birth; however this 
rate can be reduced to 5% or less with effective treatment given during pregnancy, delivery and 
breastfeeding. In 2016, 24% of pregnant women did not have access to treatment to prevent 
transmission to their children and in that same year around 160,000 children became infected 
with HIV [7]. Despite this, breastfeeding now accounts for the majority of MTCT [8]. 
1.1.3. Prevalence  
HIV/AIDS was first clinically diagnosed in the USA in 1981; how many people were already 
infected at this time or how long the virus had been in humans is not clear as there are other 
rare diseases with similar symptoms to HIV/AIDS. The number of adults (aged 15-49) and 
children in the world living with HIV has risen from 8 million in 1990 to 37 million by the end of 
2016 [9]. It is estimated that 0.8% of adults aged 15-49 years are living with HIV worldwide, with 
the largest population (25.5 million) being in Africa; East and Southern Africa account for over 
50% of all adults living with HIV in the world. [10, 11] (Figure 1.1.2). Overall, prevalence in 
adults (age 15-49) is higher among men who have sex with men (MSM) than those who have 
sex with women (MSW) and it is estimated than on average the prevalence among MSM in 
capital cities is 13 times higher than in the general population [12]. Certain groups such as sex 
workers also have significantly higher HIV prevalence rates. For example, in 2016 in Lesotho, 
the reported HIV prevalence among the general population was 25%, the second highest in the 
world, and prevalence was even higher among sex workers at 72% and men who have sex with 
men at 33% [13].  
In the heterosexual population, HIV continues to mainly affect women across all regions, likely 
because of younger age at sexual debut, older partners and socio-economic dependence on 
male partners. Other factors related to a larger proportion of women having HIV is violence 
towards women, their first sexual experience being forced, marriage before 18 years of age, the 
inability to protect themselves from HIV infection and having little knowledge about HIV. In 
2015, globally, 51% of people living with HIV were women [14]. 
At the end of 2003, there were an estimated 2.6 million children under 15 years of age living 
with HIV infection worldwide; 2.2 million in sub-Saharan Africa. Worldwide this had increased to 
around 3.3 million in 2011 [15], but has since decreased to just 2.1 million at the end of 2016; 
the majority of these being in sub-Saharan Africa [9].  
People infected with HIV have an increased risk of tuberculosis (TB) due to their vulnerable 
immune system; without treatment they have a 20-30 times higher lifetime risk of developing 
active TB, compared with people without HIV [11]. In 2016 there were 10.4 million new cases of 
TB worldwide, with 10% of these estimated to have been in people with HIV. There were 
374,000 deaths from TB in those infected with HIV, 86% of these being in Africa [16]. Although 
treatable, HIV and TB each speed the other's clinical progression. Because they share modes 
of transmission, hepatitis B (HBV) and hepatitis C (HCV) are also common among persons who 
are at risk of or living with HIV infection. For example, in the US a third of people infected with 
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HIV are co-infected with HBV or HCV [17]. In west and south Africa, 36% of HIV infected people 
are co-infected with HBV; HCV is less common with an estimated 3.6% of HIV infected 
individuals being infected with HCV in sub-Saharan Africa [18]. 
Figure 1.1.2 Prevalence of HIV among adults in 2016 (reproduced from [19]) 
  
1.1.4. Incidence  
In 2016 there were 1.8 million newly HIV-infected individuals worldwide (16% decline since 
2010; 11% decline in adults alone) [10]. The sharpest decline in new HIV infections was seen in 
sub-Saharan Africa where there was a 56% decline among children and a 29% decline among 
adults from 2010-2016 [13]. Despite this there were still 790,000 new HIV infections in sub-
Saharan Africa in 2016, accounting for 46% of the adults and children newly diagnosed with HIV 
in 2016. In sub-Saharan Africa, 56% of new infections among adults were in women aged 15 
years and older; 66% of infections in women aged 15 years and older are among women aged 
15-24 [14]. In 2014 UNAIDS developed a 90-90-90 treatment target to end AIDS globally, which 
aims at 90% of people living with HIV knowing their status, 90% of HIV diagnosed receiving 
treatment and 90% of those on HIV treatment achieving viral suppression [20]. In 2016, in East 
and Southern Africa, it was estimated that 76% of people with HIV knew their status, of those 
79% were on antiretroviral therapy and 83% of those were virally suppressed [21]. 
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1.1.5. Deaths and survival 
In 2016 there were 1.1 million deaths worldwide related to HIV. In sub-Saharan Africa this was 
790,000; 72% of all deaths in the region. HIV related mortality has fallen significantly since 2004 
where it was more than double this in sub-Saharan Africa [21]. The main reason for this decline 
is likely to be enormous widening of access to effective antiretroviral treatment (ART) in sub-
Saharan Africa and worldwide over the last decade [22]. There has also been the introduction of 
the test and treat strategy in 2015 which means people are tested and then hopefully treated 
straight away regardless of their CD4 count [23]. This has meant that patients are treated 
earlier, which has shown to improve clinical outcome [24]. In the absence of treatment, life 
expectancy is severely reduced; median survival time after infection with HIV is estimated to be 
4 to 12 years without treatment, depending on age at infection [25]. The median survival rate 
after diagnosis of HIV-AIDS in LMIC where treatment is not available ranges between 6 and 19 
months [26]. Children in Africa typically present with symptoms in the first year of life and by one 
year one-third will have died without treatment and by age two at least half [27]. 
However, with effective treatment, started early enough, survival may be prolonged significantly. 
In 2010, the UK CHIC study published data regarding life expectancy in the UK [28] showing 
that life expectancy for a HIV-infected individual on treatment has improved by over 15 years 
during 1996-2008, but is still 13 years lower than that of the general UK population. They 
showed that mortality rates have decreased such that, compared with the general population, 
the risk of death in successfully treated patients is similar to that of people with unhealthy 
lifestyles (such as heavy smoking, drinking or obesity). The ART Cohort Collaboration reported 
in 2008 [29] that in high income countries, life expectancy has improved by 81% since 1996, 
with HIV infected adults aged 20 years expecting to live for another 49 years. However, in LMIC 
less data are available and few population data are available for comparison. Mills et al [30] 
reported in July 2011 a crude mortality rate of 3.2 deaths per 100 person years (PYs) in a 
cohort of 22,315 persons who initiated HIV treatment in Uganda between 2000 and 2009. Life 
expectancy in the whole cohort was a further 27 years at 20 years of age, and a further 28 
years at 35 years of age, with men having a consistently shorter life expectancy than women (a 
further 19 years for men, but 31 years for women from 20 years of age). Longer life expectancy 
was associated with increasing baseline CD4 counts at ART initiation [30]. More recently, in 
2013 Nakagawa et al. [31] reviewed literature on life expectancy in several countries (UK, US, 
Uganda and Netherlands) from 2010 onwards and found that with earlier diagnosis, access to 
ART and good lifelong adherence, people with HIV can expect to have a life expectancy which 
is nearly the same as that of people who are HIV negative. They also found modelling studies 
that suggest life expectancy could improve further with an increased uptake of HIV testing, 
better antiretroviral regimens and treatment strategies, and the adoption of healthier lifestyles by 
those living with HIV. They found that earlier diagnosis is one of the most important factors 
associated with better life expectancy. However, as people live longer with HIV, further research 
is needed on how to treat an ageing HIV population – this is one of the new challenges of 
treating those with HIV.  
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1.1.6.  Treatment of HIV 
At this present time there is no cure for HIV; as discussed above, with treatment HIV may be 
managed as a chronic condition. The standard treatment for HIV is combination antiretroviral 
therapy (ART), one of the most important advances in the history of HIV/AIDS. The first 
antiretroviral (ARV) drug was approved in 1986, zidovudine (ZDV), and was taken as 
monotherapy (single ARV drug) which was only partly efficacious. In 1991 several more drugs 
of a similar class (nucleoside reverse transcriptase inhibitors, NRTIs) became available, and 
from 1991-1995 HIV-infected people were treated with dual therapy which again was only 
partially efficacious. Unless HIV viral load (VL) is suppressed to very low levels, HIV can 
become resistant to a drug. Resistance to one drug can also lead to resistance to another 
(cross-resistance). Mono and dual therapy did not suppress VL enough, so resistance 
developed and the drugs became ineffective. In 1995-6, two new classes of antiretrovirals (non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)) became 
available and people moved to 3-drug combination therapy (2NRTI+PI or 2NRTI+NNRTI). This 
combination treatment suppresses VL so much that development of resistance to the drugs is 
reduced, and in some cases viral replication may be stopped completely. This new combination 
therapy was also known as highly active antiretroviral therapy (HAART), and in 1997 became 
the standard of care.  
When I started my MPhil in 2011, the main types of ARVs used in combination ART in first-line 
therapy in LMIC were:  
1) Nucleoside reverse transcriptase inhibitors (NRTIs) which suppress the replication of 
retroviruses by interfering with the reverse transcriptase enzyme, which is encoded from 
the genetic material of the virus and transcribes retroviral RNA into DNA (Figure 1.1.1); 
without this process the viral genome cannot become incorporated in the host cell. The 
chemical structure of a NRTI consists of a modified version of a natural nucleoside. NRTIs 
include zidovudine (ZDV), lamivudine (3TC), emtricitabine (FTC) and abacavir (ABC).  
2) Nucleotide reverse transcriptase inhibitors (NtRTIs), which act as NRTIs, but have an 
additional phosphate group. Tenofovir (TDF) is a NtRTI.  
3) Non-nucleoside reverse transcriptase inhibitors (NNRTI) – these are similar to NRTIs in 
the sense that they inhibit the transcription of the viral DNA, however they are unable to 
incorporate into the viral DNA so they simply attach themselves to the reverse 
transcriptase and inhibit its movement – nevirapine (NVP) and efavirenz (EFV) are 
NNRTIs. In LMIC, NNRTIs are recommended for first-line treatment with NRTIs [32].  
4) Protease inhibitors (PIs) which block the protease enzyme and prevent the cell from 
producing new viruses. In LMIC PIs are recommended for second-line treatment [32]. 
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Other classes of ARVs (integrase inhibitors (II) such as raltegravir or dolutegravir, fusion 
inhibitors such as maraviroc) were not recommended as preferred first- or second-line treatment 
[27], until the guidelines were updated in 2016.  
1.1.7. Guidelines for treatment 
In 2002 WHO released their first guidelines for taking a public health approach to the scale up 
of ART [33], covering treatment initiation criteria and recommending therapies and management 
of patients on treatment. During the time of the DART and ARROW trials, subsequent updated 
guidelines were published in 2006 and 2010 [27, 34]; a summary of which can be found in Table 
1.1.1. Since then, and since the DART and ARROW trials were closed, the guidelines were 
updated in 2013, 2015 and 2016 [32]. The 2006 update changed the thresholds for treatment 
initiation with the aim of having all those who needed ART (based on an ART initiation threshold 
of CD4 <200 cells/μL) having access by the end of 2010 [34]. In 2010, the threshold was 
increased to <350 cells/μL, substantially increasing the numbers defined as being in need of 
ART [27]. In 2013 the guidelines were updated so the threshold for ART initiation was increased 
to ≤500 cells/µL, but giving priority to those with severe/advanced disease or CD4 ≤350 cells/µL 
[35]. In 2016 the guidelines removed this threshold and it is now recommended that all those 
diagnosed with HIV should start treatment regardless of WHO clinical stage and at any CD4 
count [32]; this was based on the results of the START trial [36]. In addition (as discussed 
previously) the aim is for 90% of people with HIV to be aware of their status, 90% of those 
should be receiving ART and 90% of those should be reaching viral suppression (VL≤50 
copies/L) [37].  
In summary, the current WHO 2016 guidelines recommend that all HIV-infected children, 
adolescents and adults, including pregnant women, regardless of their WHO clinical stage or 
CD4 count should initiate ART. As a priority ART should be initiated in all children ≤2 years of 
age or children younger than 5 years who are WHO stage 3/4 or CD4 count ≤750 cells/µL or 
CD4% <25, and any children ≥5 years with WHO stage 3/4 or CD4 count ≤350 cells/µL; this 
priority is also given to HIV-infected adolescents and adults [32].  
Current guidelines recommend [32] that HIV infected patients start on a first-line therapy that 
should consist of 2NRTI + (NNRTI or II), one of which should be tenofovir (or abacavir for 
children) plus lamivudine (or emtricitabine); the recommended NNRTI is efavirenz. Alternative 
first-line regimens can include zidovudine as an NRTI or nevirapine as the NNRTI or the 
replacement of the NNRTI with the integrase inhibitor dolutegravir. Dolutegravir is not 
recommended for pregnant or breast feeding women or children. Stavudine should be 
discontinued in first-line regimens due to its well-known metabolic toxicities. On failure of first-
line therapy patients should move onto second-line therapy that consists of a ritonavir-boosted 
PI+2NRTIs, one of which should be zidovudine or tenofovir, based on their first-line therapy. 
Current management recommends that all patients should have CD4 cell count testing to 
optimise pre-ART care and those receiving ART should have access to laboratory monitoring 
consisting of HIV VL (at 6 months and 12 months after initiating ART and every 12 months 
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thereafter) and CD4 cell count every 6 months until patient is stable on ART. Management 
recommendations during the period that DART and ARROW were active are outlined in Table 
1.1.2.  
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Table 1.1.1 Changing recommendations for criteria to initiate ART in LMIC over the period when the DART and ARROW trials were active 
 Year of treatment recommendation 
Age*  2002 [33] 2006 [34, 38] 2010 [27, 38] 
Adults Initiate ART if: 
 WHO stage 4 regardless of CD4 count 
 WHO stage 1/2/3 with CD4<200 cells/μL 
 WHO stage 2/3 TLC<1200 cells/μL if CD4 
unavailable 
 WHO stage 4 irrespective of TLC if CD4 
unavailable 
 
 TB/HIV co-infection – finish TB treatment 
before initiating ART unless high risk of 
progression 
 HIV+, asymptomatic 
o Initiate ART if CD4 ≤200 cells/μL 
irrespective of WHO clinical stage  
 HIV+, symptomatic 
o WHO 4 irrespective of CD4 
o CD4 200-350 cells/μL consider treatment 
and initiate before it drops to <200 
o WHO stage 2/3 and CD4 ≤200 cells/μL 
o WHO stage 3 if CD4 not available 
 HIV+, pregnant 
o WHO 1/2 and CD4 ≤200 cells/μL (do not 
treat if CD4 unavailable) 
o WHO 3 and CD4 ≤350 cells/μL  
 Co-infected with TB 
o CD4 ≤350 cells/μL 
o Can be delayed if CD4 ≥200 cells/μL 
 HIV+, asymptomatic 
o Initiate ART if CD4 ≤350 cells/μL 
irrespective of WHO clinical stage 
 HIV+, symptomatic 
o Initiate ART if WHO clinical stage 3/4 
irrespective of CD4 
o Initiate ART if WHO clinical stage 2 and 
CD4 ≤350 cells/μL 
 Patients co-infected with HIV and TB should 
start ART as soon as possible after TB 
treatment irrespective of CD4 cell count 
 Patients who require treatment for their HBV 
infection, irrespective of CD4 count 
Infants (<18 months) 
Initiate ART if HIV infection has been 
virologically confirmed and: 
 WHO paediatric stage 3 
 WHO stage 1/2 and CD4<20% 
 When virological confirmation unobtainable 
then WHO stage 3 and CD4<20% 
(no stage 4 defined) 
(<12 months) 
Initiate ART if: 
 WHO 3/4 irrespective of CD4 
 WHO 2 and CD4 <25% or <1500 cells/μL or 
TLC <4000 cells/μL when CD4 not available 
 WHO 1 and CD4 <25% or <1500 cells/μL or 
do not treat when CD4 not available 
Initiate ART in first year of life irrespective of 
CD4 count or WHO clinical stage 
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Table 1.1.1 Changing recommendations for criteria to initiate ART in LMIC over the period when the DART and ARROW trials were active (continued) 
Children 2002 2006 2010 
12-35 
months
  
(>18 months) 
Initiate ART if: 
 WHO stage 3 regardless of CD4 % 
 WHO 1/2 and CD4<15% 
  
(12-35 months) 
Initiate ART if: 
 WHO 3/4 if CD4 not available 
 WHO 4 irrespective of CD4 
 WHO 3 and CD4 <20% or <750 cells/μL if child has TB, LIP 
(lymphocytic interstitial pneumonia), oral hairy leukoplakia or 
thrombocytopenia 
Initiate ART irrespective of CD4 count 
or WHO clinical stage 
36-59 
months 
(36-59 months)  
 Initiate ART as 12-35 months but CD4 guided treatment 
based on <15% or <350 cells/μL; use TLC <2500 cells/μL if 
CD4 not available 
Initiate ART with CD4 count ≤750 
cells/μL or CD4% <25, whichever is 
lower, irrespective of WHO clinical 
stage 
≥5 years   Initiate ART as 12-35 months but CD4 guided treatment 
based on <15% or <200 cells/μL, use TLC <2000 cells/μL if 
CD4 not available (but only up to 8 years)† 
As with adults, initiate ART if CD4 
≤350 cells/μL irrespective of WHO 
clinical stage 
TLC – Total lymphocyte count, *categories based on most recent guidelines, †Little evidence for children >8 years
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Table 1.1.2 Changing management recommendations over the period when the DART and ARROW trials were active 
  2002 2006 2010 
A
du
lts
 
Tests  Minimum lab test is HIV 
antibody test, haemoglobin and 
haematocrit 
 Basic recommended tests 
include WBC, hepatitis, 
hepatotoxicity 
 Desirable tests include bilirubin, 
serum lipid and CD4 count 
 Clinical monitoring is essential 
 Where laboratory monitoring is 
limited, close clinical monitoring 
is crucial 
 Haemoglobin at ART initiation (for those on 
ZDV at baseline, weeks 4, 8, and 12) 
 WBC and differential at initiation (at 4,8, and 
12 weeks is optional) 
 CD4 cell count testing at initiation, every six 
months (may need to be more often if patient 
appears to be unwell) 
 Full chemistry as required (every six months 
for those receiving second-line drugs) 
 Viral load as and when required but should 
not be used for treatment decision making 
 All patients should have access to CD4 cell-count 
testing to optimise pre-ART care and ART 
management 
 HIV RNA (viral load) testing is recommended to 
confirm suspected treatment failure 
 Drug toxicity monitoring should be symptom 
directed 
Management  Countries are encouraged to 
use CD4 cell counts in ART 
programmes and consider low 
cost CD4 methodologies 
 CD4 % can be used instead of 
CD4 counts (CD4<15% = CD4 
200 cells/μL. TLC ok when CD4 
cannot be measured. 
 Assessment of VL not 
considered essential 
 
 Patients on ART should be monitored 
clinically every 2, 4, 8, 12 and 24 weeks after 
starting ART, then every 6 months thereafter 
 Contact with healthcare team trained to 
manage is recommended with referral to 
physician if needed 
 Pay attention to any reduction in frequency 
of infections or increased toxicities 
 Laboratory monitoring is not a prerequisite for the 
initiation of ART 
 CD4 and viral load (VL) testing are not essential 
for monitoring patients on ART 
 Symptom-directed laboratory monitoring for safety 
and toxicity is recommended for those on ART 
 If resources permit use VL: 
o as a targeted approach to confirm suspected 
treatment failure based on immunological 
and/or clinical criteria 
o in a routine approach, every 6 months, with 
objective to detecting failure earlier than 
would be the case if using immunological 
and/or clinical criteria to define failure 
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Table 1.1.2 The changing management recommendations over the period when the DART and ARROW trials were active (continued) 
In
fa
nt
s 
an
d 
ch
ild
re
n 
Tests  As with adults but %CD4 instead of CD4  As with adults but %CD4 instead of CD4  As with adults but %CD4 instead of CD4 
 Viral load should be used whenever 
possible to confirm suspected clinical or 
immunological failure 
Management  As with adults VL is not a useful test as 
children have raised HIV RNA levels 
anyway 
 Frequency of clinical monitoring depends 
on response to ART, at least at weeks 2, 
4, 8 and 12 after starting ART, then every 
2-3 months after stabilisation on therapy 
 Assessment of CD4 every 6 months 
 TLC not suitable 
 For those on ZDV, haemoglobin (weeks 4, 
8, 12) is recommended  
 For those on nevirapine, liver function 
tests during the first few months 
 The inability to provide such monitoring 
should not prevent children from receiving 
ART 
 Clinical monitoring depends on response 
to ART 
o Infants, at weeks 2, 4, 8 then every 4 
weeks 
o Children, at weeks 2,4,8,12, then 
every 2-3 months 
 Where clinical monitoring is unavailable 
monitoring should be targeted to 
assessment of clinical events 
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Table 1.1.2 The changing management recommendations over the period when the DART and ARROW trials were active (continued) 
  2002 2006 2010 
A
du
lts
 
Tr
ea
tm
en
t 
 Treatment should be standardised 
 Single first-line and limited number 
of second-line regimens: first-line 
 ZDV/3TC/EFZ or ZDV/3TC/NVP 
(for pregnant women consider EFZ 
only in addition to ZDV and 3TC) 
 ZDV/3TC/ABC 
 ZDV/3TC/RTV-PI or ZDV/3TC/NFV 
 Other dual nucleoside 
combinations can be substituted 
for ZDV/3TC, including stavudine 
(d4T)/3TC, d4T/didanosine (ddI) 
and ZDV/ddI, depending on 
country-specific preferences.  
 ZDV and d4T should never be 
used together because of proven 
antagonism between these drugs 
 Dual NRTI combination of d4T/ddI 
should only be used during 
pregnancy when no other 
alternatives exist, because of the 
potential increased risk of lactic 
acidosis with this combination in 
pregnant women. 
First-line: 
 Adults and adolescents 
o ZDV or TDF + 3TC (or FTC) + EFV or NVP 
 HIV+, pregnant 
o ZDV + 3TC + NVP 
 HIV/TB co-infection 
o ZDV or TDF + 3TC (or FTC) + EFV 
 HIV/HBV co-infection 
o TDF + 3TC (or FTC) + EFV 
Second-line: 
 Adults and adolescents 
o ABC + ddl or TDF + ABC or ddl +3TC or TDF 
+3TC (±ZDV) + ATV/r or FPV/r or IDV/r or 
LPV/r or SQV/r 
 HIV+, pregnant 
o As adults and adolescents but different 
boosted PI (LPV/r or NFV or SQV/r) 
 HIV/TB co-infection 
o As adults and adolescents but PI is LPV/r or 
SQV/r with adjusted ritonavir (RTV)* 
 HIV/HBV co-infection 
o 3TC and/or TDF containing regimens 
 ZDV, TDF, ABC or d4T. 
 Stavudine (d4T) is now recommended at the dose 
of 30 mg twice daily for all adult and adolescent 
patients regardless of body weight 
 
First-line: 
 Adults and adolescents 
o No change but where d4T is used as principal option 
for starting ART there should be a plan to move 
towards ZDV or TDF based regimens 
 HIV+, pregnant 
o ZDV + 3TC + NVP (or EFV, but not during first 
trimester) 
o See guidelines for women with prior MTCT regimens 
 HIV/TB co-infection 
o ZDV or TDF + 3TC (or FTC) + EFV (recommended 
within 8 weeks of start of TB treatment) 
 HIV/HBV co-infection 
o Require regimens that contain both TDF + 3TC (or 
FTC) + EFV 
Second-line: 
 Adults and adolescents 
o TDF (if ZDV used first-line) or ZDV (if TDF used first-
line) + 3TC (or FTC) + ATV/r or LPV/r  
 HIV+, pregnant 
o As adult and adolescent 
 HIV/TB co-infection 
o If rifabutin available then same as adults, else same 
NRTI backbone as adults plus LPV/r or SQV/r with 
adjusted dose of RTV 
 HIV/HBV co-infection 
o ZDV+TDF+3TC(or FTC)+ATV/r or LPV/r 
28 
 
Table 1.1.2 The changing management recommendations over the period when the DART and ARROW trials were active (continued) 
  2002 2006 2010 
In
fa
nt
s/
 
C
hi
ld
re
n 
Tr
ea
tm
en
t 
 ZDV, 3TC, d4T, DDI and ABC have 
formulations appropriate for children 
 Combinations ZDV/3TC and ZDV/3TC/ABC 
only available in tablet 
 NVP liquid formulation 
 EFZ children >3 years 
 Syrups and solutions remain necessary for treating 
infants and very young children 
 Solid formulations (parts of scored tablets or 
combination preparations for older children 
 Regimen of 2 NRTI plus 1 NNRTI: 
o ZDV + 3TC + NVP/ EFV 
o d4T + 3TC + NVP /EFV 
o ABC + 3TC + NVP/ EFV 
 Infant or child <24 months not exposed to 
ARVs: NVP + 2 NRTI 
 Infant or child <24 months exposed to 
NNRTI: LPV/r + 2 NRTI 
 Infant or child <24 months with unknown 
ARV exposure: NVP + 2 NRTI 
 Children 24 months to 3 years: NVP + 2 
NRTI 
 Children >3 years: NVP or EFV + 2 NRTI 
*see guidelines for dosing [27, 33, 34, 38] 
 
Note: ABC=abacavir, ddl=didanosine, d4T=stavudine, TDF=tenofovir, ZDV=zidovudine, 3TC=lamivudine, FTC=emtricitabine, NVP=nevirapine, EFV=efavirenz, 
ATV/r=ritonavir-boosted atazanair, FPV/r= ritonavir-boosted fosamprenavir, IDV/r= ritonavir-boosted indinavir,  LPV/r= ritonavir-boosted lopinavir, NFV=nelfinavir, 
SQV/r= ritonavir-boosted saquinavir,
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1.1.8. Numbers on treatment and coverage 
In 2002 it was estimated that there were 6 million people in LMIC who needed ART (based on a 
CD4 threshold for ART initiation of <200 cells/μL), but only 230,000 had such access (50% of 
these were in Brazil), with only 50,000 on ART of the 4.1 million in need in sub-Saharan Africa 
[34, 39]. The major gap between need and access led WHO to set a target of 3 million 
individuals receiving ART by the end of 2005, known globally as the “3 by 5” plan. As shown in 
Figure 1.1.4 this target was not met, but nevertheless the numbers on ART in LMIC had still 
increased to over 1 million by the end of 2005, ~0.8 million in sub-Saharan Africa, and have 
continued to increase substantially thereafter. Figure 1.1.3 shows the progress in scaling up of 
ART since 2002 until the end of 2011 where ART had reached 8 million people [15]. In 2016 
19.5 million people infected with HIV were receiving ART; 11.7 million in sub-Saharan Africa 
[40]. 
Figure 1.1.3 People receiving ART in low- and mid- income countries 2002-2011 
(reproduced from [15]) 
 
 
Since the guidance on treatment update in 2016, recommending that all HIV positive individuals 
start treatment regardless of their CD4 count, the coverage of ART in HIV positive individuals in 
East and Southern Africa has increased to 61% in adults and 51% in children [21] (Figure 
1.1.4). 
  
DART trial 
started 
ARROW trial 
started 
My MPhil 
started DART/ARROW 
ended 
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Figure 1.1.4 Antiretroviral therapy coverage and number of AIDS-related deaths in East 
and Southern Africa (adults and children) (reproduced from [40]) 
 
 
Table 1.1.3 ART coverage in sub-Saharan Africa 2002, 2006, 2011 and 2016 
  2002 [39]  2006 [41] 2011 [42] 2016 [11] 
Adults ART 
coverage 
1%  28%  56% 61% 
CD4 
treatment 
threshold CD4<200 
cells/μL 
CD4<200 
cells/μL 
CD4<350 
cells/μL 
Start ART 
regardless of 
CD4 count 
(priority given to 
those with CD4 
<350 cells/µL) 
Infants/ 
Children 
ART 
coverage 
NI* 15%  28% 51% 
CD4 
treatment 
threshold  
Infants: 
CD4<20% 
Children: 
CD4<15% 
Infants: 
CD4<25% 
Children: 
CD4<20% 
Infants & children 
<2yrs: treat in 
first year 
irrespective 
Children (>2 yrs): 
CD4<25% 
(>5yrs) CD4<350 
cells/μL  
Start ART 
regardless of 
CD4 count 
(priority given to 
those with CD4 
<350 cells/µL) 
*Not included in the report;  
Table 1.1.3 shows the change in coverage in sub-Saharan Africa from 2002-2016. The 
estimated 11.7 million [10.3 million-12.1 million] people on ART in the region in 2016 
represented an almost threefold increase over 2010 numbers. Sustained progress is needed to 
ensure that 81% of all people living with HIV in the region are accessing treatment by 2020 (the 
second part of the 90-90-90 target). In 2016, the gap to fully achieving this second 90 from the 
90-90-90 target was starting an additional 4.1 million people on antiretroviral therapy. In 2016, 
worldwide, 54% of adults and 43% of children living with HIV were currently receiving lifelong 
antiretroviral therapy [11]. Global ART coverage for pregnant and breastfeeding women living 
with HIV was high at 76%.  
One major change that has aided the increase in people needing ART being able to receive it is 
reductions in the cost of the drugs. Generic drugs have been produced which are identical to 
the ‘branded’ drugs, but costing a fraction of what they did before. In 1996 when ART first 
became available it cost $10,000-15,000 per patient per year. But by 2001 drugs were costing 
DART trial 
started 
ARROW trial 
started 
DART/ARROW 
ended 
My MPhil 
started 
2016 
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as little as $295 per person per year [43]. In PEPFAR programmes (one of the major US 
donors), about 30 to 40 percent of the costs related to treatment are drug-related costs, and the 
other 60 to 70 percent are systems and delivery costs [44], with 34% ARVs and 4% buffer stock 
[45] (Figure 1.1.5).  
 
Figure 1.1.5 Costs of ART provision, by major cost component (reproduced from [45]) 
 
1.1.9. Practical Challenges of treatment 
Effective triple-drug ART has resulted in a major reduction in mortality and morbidity in HIV-
infected adults and children in high-income countries and LMIC but there have been many 
barriers to ART in LMIC. The increase in the number of people needing treatment since the 90-
90-90 targets have been introduced has resulted in an increased burden on the already limited 
resources in LMIC.  
In order for the scale up of ART in sub-Saharan Africa to take place, health care systems need 
to be strengthened. There have been several barriers to scale up that have been cited in the 
literature recently, including inadequate supply and poor retention of health professionals [46, 
47]. In 2008 WHO defined task shifting as a necessary condition for scaling up ART in sub-
Saharan Africa [48]. Task shifting is the process by which specific tasks are moved, where 
appropriate, to less specialised healthcare workers. It has been split into 4 types; Type I – shift 
from medical doctor to non-physician; Type II – shift from non-physician to nurse; Type III – shift 
to lay community providers and counsellors; Type IV – shift to people living with HIV 
themselves. By using lower level health care workers at smaller healthcare facilities, access to 
HIV care could be easier and will hopefully also reduce the cost of travelling to clinic. By sharing 
medical tasks with lower level health care workers, the strain on the already overburdened 
health care staff is reduced and by involving people who have HIV, practical skills needed to 
manage having HIV can be directly passed on to those people who need it [47]. It has been 
shown that when full care and patient self-management fail, patients discontinue treatment, and 
are at risk of drug resistance and treatment failure [49]. 
 
28 
 
The HIV epidemic affects populations in many ways, not just medically but socially and 
psychologically. An ART programme needs to be well integrated into the public healthcare 
system and be comprehensive in addressing the social, psychological and economic needs of 
HIV care, for example social support, socioeconomic status and education. If this can happen 
then HIV could become more widely accepted like other chronic conditions such as diabetes. In 
the early 2000s there was limited integration of ART services into the public system [47]. More 
and more people are now recognising that integration is essential. The main concerns about 
this are that it may take resources away from other vital health services, leading to general 
health care suffering.  
Loss to follow-up is a major challenge in ART programmes [50], since failure to attend inevitably 
means running out of drugs, leading to treatment failure or other poor clinical outcome. Recent 
studies have shown that psychosocial support and regular home visits from community health 
workers and peer adherence counsellors has increased patient retention [51]. Tracing 
defaulters has also been highlighted by several studies as one of the standard tasks of 
community support providers; for example Kabore et al [51] reported that defaulter tracing by 
community healthcare workers was associated with better ART outcomes in Malawi.  
Other challenges are the cost of treatment (although, as described above, this has come down 
in recent years) and the supply chain, including not only drugs but laboratory supplies and 
testing kits. Ensuring there are no interruptions in treatment requires a guaranteed supply of 
ART. This needs careful planning: accurate forecasting is necessary to reduce over-purchasing 
and therefore extra strain on money and storage space. However, the converse is that stock-
outs are common as sites try not to over purchase drugs [52]. As well as the practical 
challenges to treatment, a number of clinical challenges exist. In particular, there is the 
challenge of monitoring patients for toxicity and treatment response during time on ART [46], a 
topic the DART and ARROW trials addressed. 
1.2  Data available 
1.2.1. The DART Trial 
The major driver behind increasing rollout of ART in LMIC was reductions in the cost of drugs. 
However, the cost and infrastructure required for monitoring patients taking ART, as carried out 
in high-income countries, was and still is extremely high. In order to carry out toxicity and CD4 
monitoring (or now VL monitoring) sites need to buy and maintain machines, purchase reagents 
and employ suitably trained staff. At the time the DART trial was being designed, in 2002, in 
Africa patients were already receiving ART without routine laboratory monitoring but no one had 
formally investigated the effects of this and whether this could be done safely, and there were 
still concerns regarding the lack of infrastructure to administer ART and to sustain adherence 
and monitor toxicity in LMIC [53]. Laboratory tests are done 3-monthly in high-income countries 
because they are available and are de facto the standard of care. Due to the potential barriers 
in LMIC (as discussed above) there was a need to explore the question of the necessity of 
these laboratory tests with the introduction of ART in Africa. In 2003 the Medical Research 
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Council Clinical Trials Unit, in partnership with Imperial College London and three African 
research groups in Uganda/Zimbabwe, started the large African DART (Development of 
AntiRetroviral Therapy in Africa) trial [54] to evaluate the need for laboratory tests required for 
monitoring toxicity and efficacy of ART. At this time there had been no clinical trials evaluating 
such questions. The other major question addressed by DART was regarding structured 
treatment interruptions (STI), whereby periods on ART are followed by periods off treatment. At 
the time the trial was being designed there was some evidence to suggest that STIs were safe 
and could reduce toxicity and costs, and improve adherence while maintaining clinical and 
immunological well-being.  
The DART trial was an open-label non-inferiority randomised trial evaluating two strategic 
approaches to the management of ART in symptomatic HIV infected adults in Africa. The first 
strategy compared clinically driven monitoring (CDM) with laboratory plus clinical monitoring 
(LCM). The second approach compared structured treatment interruptions, 12 weeks on, 12 
weeks off with continuous ART (CT) in patients who achieved CD4 cell counts of ≥350 cells/μL 
after 48/72 weeks on continuous ART. Patients were randomised at three sites in Uganda and 
one in Zimbabwe to receive either CDM or LCM and a second randomisation took place after 52 
weeks (or 76 weeks, depending on CD4 counts measured at 48 or 72 weeks) to either 
structured treatment interruptions (STI) or continuous therapy (CT). 
The hypotheses for the DART trial were that CDM would result in a similar outcome to LCM and 
that ART administered as structured intermittent therapy would result in similar outcomes to 
continuous ART. The primary efficacy endpoint was progression of clinical HIV disease (as 
indicated by a new non-recurrent WHO 4 stage HIV event) and/or death and the primary safety 
endpoint was Serious Adverse Events (SAEs). Routine full blood tests were carried out at 
screening, weeks 4 and 12 and then 12 weekly thereafter. All results were returned to clinicians 
in the LCM arm but in the CDM arm results were only returned if requested for valid clinical 
reasons or if there was a grade 4 laboratory toxicity (protocol safety criteria). No total 
lymphocyte counts (TLC) or CD4-cell counts were ever returned for CDM participants. All 
participants received ART and were reviewed by a nurse every 4 weeks. Any decision to switch 
to second-line ART was based on clinical criteria (new or recurrent WHO 4 event; or WHO 3 
event at clinician discretion) in both groups or laboratory criteria (CD4 <100 cells/μL [<50 
cells/μL before July 2006]) in the LCM group. Switching before 48 weeks was discouraged 
following the 2006 WHO guidelines [33]. 
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Table 1.2.1 DART Baseline characteristics and follow-up 
DART LCM n (%) CDM n (%) Total n (%) 
Baseline 1656 1660 3316 
Women 1092 (66%) 1064 (64%) 2156 (65%) 
Age (years) 
 Median (IQR) 
 
36 (18-67) 
 
36 (18-73) 
 
36 (18-73) 
CD4 cell count at ART initiation (cells/μL) 
 Median (IQR) 
 
86 (0-199) 
 
86 (1-199) 
 
86 (0-199) 
WHO stage 
 2 
 3 
 4 
 
363 (22%) 
916 (55%) 
377 (23%) 
 
310 (9%) 
948 (57%) 
402 (24%) 
 
673 (20%) 
1864 (56%) 
779 (24%) 
First-line treatment received: ZDV+3TC plus 
 TDF 
 ABC 
 NVP   
 
1232 (74%) 
150 (9%) 
150 (9%)  
 
1237 (75%) 
150 (9%) 
150 (9%) 
 
2469 (74%) 
300 (9%) 
300 (9%) 
Follow-up    
Lost to follow-up 112 (7%) 122 (7%) 234 (7%) 
Treatment status at end of trial  
 Still on first-line treatment 
 Drug substitution in first-line 
 Switched to second-line 
 
1295 (78%) 
281 (17%) 
361 (22%) 
 
1346 (81%) 
288 (17%) 
314 (19%) 
 
2641 (80%) 
569 (17%) 
675 (20%) 
Self-reported adherence across all visits 
 Missed any pills in last 4 days 
 Missed any pills in last 28 days 
 
3.3% 
7.8% 
 
3.5% 
8.5% 
 
3.4% 
8.2% 
Median follow-up (IQR) [years] 4.9 (4.4-5.3) 4.9 (4.4-5.3) 4.9 (4.4-5.3) 
Adverse events: patients with any 
 Serious 
 ART modifying 
 Grade 4 
 Grade 3/4 
 
260 (16%) 
416 (25%) 
643 (39%) 
1151 (70%) 
 
283 (17%) 
422 (25%) 
683 (41%) 
1168 (70%) 
 
543 (16%) 
838 (25%) 
1326 (40%) 
1319 (40%) 
New WHO 4 event/death 356 (21%) 459 (28%) 815 (25%) 
New WHO4/event-free survival at 5 years  
% (95%CI) 
 
78% (76-80) 
 
76% (70-74) 
 
77% (70-80) 
Death 164 (10%) 218 (13%) 382 (12%) 
Overall survival at 5 years % (95%CI) 90% (88-91) 87% (85-88) 88% (85-91) 
Comparison of CDM vs. LCM [HR (95%CI)] p-value 
Adverse events 
 Serious 
 ART modifying 
 Grade 4 
 Grade 3/4 
 
1.12 (0.94-1.32) 
1.01 (0.88-1.16) 
1.07 (0.96-1.20) 
1.03 (0.95-1.11) 
 
p=0.19 
p=0.86 
p=0.19 
p=0.51 
Events 
 Death 
 New WHO 4 event/death 
 
1.35 (1.10-1.65) 
1.31 (1.14-1.51) 
 
p=0.004 
p=0.0001 
Table 1.2.1 shows baseline characteristics, treatment received and follow-up data for the main 
trial for LCM and CDM comparison. 3316 patients aged ≥18 years with CD4 cell count <200 
cells/μL, who were ART naïve and had no clinical or laboratory abnormalities were randomised 
between January 2003 and October 2004, and followed until December 2008. There was a 
median of 4.9 years of follow-up (14937 person years). As the upper 95% confidence limit for 
the new WHO 4 event/death outcome lies above the pre-specified non-inferiority margin of 1.18 
the team were unable to conclude that in terms of efficacy CDM is not inferior to LCM (that is, 
non-inferiority was not demonstrated). However, in terms of toxicity there was no difference 
found between CDM and LCM (HR 1.12 (96%CI 0.94-1.32) p=0.19 for serious adverse events)  
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suggesting that ART can be delivered safely without routine laboratory monitoring for side-
effects. All trial results can be found in DART main publication [54]. 
These results had major implications for ART programmes in Africa at a time when there was 
uncertainty about long-term funding and sustainability and when >40% people in need could still 
not access treatment. The trial showed that routine laboratory monitoring for toxicity had no 
benefit and ART could be safely delivered with good quality clinical care [54], although small 
(~3% in absolute terms), real improvements could be gained if routine CD4 monitoring was also 
used. 
In March 2006 the second randomisation between STI and CT was terminated by the 
Independent Data Monitoring Committee and the Trial Steering Committee after harms 
associated with STIs emerged in the SMART trial [55]; all patients were moved back to CT. The 
results were published with a median follow-up of 51 weeks after randomisation to STI vs. CT 
[56]. Table 1.2.2 outlines the baseline characteristics for the STI/CT comparison along with the 
results reported.  
Table 1.2.2 STI substudy, baseline characteristics and follow-up 
DART STI  
n (%) 
CT 
 n (%) 
Total  
n (%) 
Baseline 408 405 813 
Women 296 (73%) 299 (74%) 595 (73%) 
WHO stage at ART initiation 
 2 
 3 
 4 
 
103 (25%) 
219 (54%) 
86 (21%) 
 
93 (23%) 
238 (59%) 
74 (18%) 
 
196 (24%) 
457 (56%) 
160 (20%) 
Age at STI/CT randomisation (years) 
 Median (IQR) 
 
37 (32-42) 
 
37 (32-43) 
 
37 (32-43) 
CD4 cell count at STI/CT randomisation 
(cells/μL) 
 Median (IQR) 
 
 
357 (324-428) 
 
 
359 (328-415) 
 
 
358 (325-419) 
ART at STI/CT randomisation:ZDV+3TC plus 
 TDF 
 ABC 
 NVP  
 
271 (66%) 
35 (9%) 
102 (25%) 
 
276 (68%) 
47 (12%) 
82 (20%) 
 
547 (67%) 
82 (10%) 
184 (23%) 
Follow-up    
Median follow-up (weeks) 51 (37-65) 51 (37-64) 51 (37-65) 
Adverse events 
 Serious 
 ART modifying 
 Grade 4 
 Grade 3/4 
 
9 (2%) 
2 (<1%) 
23 (6%) 
80 (20%) 
 
10 (2%) 
10 (2%) 
26 (6%) 
80 (20%) 
 
19 (2%) 
12 (1%) 
49 (6%) 
160 (20%) 
New WHO 4 event/death 24 (6%) 9 (2%) 33 (4%) 
Death 5 (1%) 4 (<1%) 9 (1%) 
Comparison STI vs. CT [HR (95%CI)] p-value 
Adverse events 
 Serious 
 ART modifying 
 Grade 4 
 Grade 3/4 
 
0.88 (0.36-2.17) 
0.20 (0.04-0.92) 
0.81 (0.46-1.43) 
0.98 (0.72-1.34) 
 
p=0.78 
p=0.02 
p=0.47 
p=0.90 
New WHO 4 event/death 2.73 (1.27-5.88) p=0.007 
Death 1.30 (0.35-4.83) p=0.70 
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Between July 2004 and March 2006, 813 patients were randomised to receive either CT or STI. 
Nine patients died and 4 were lost to follow-up. Although absolute event rates were low, the 
incidence of new WHO 4 events/death was increased more than two fold in the STI arm. 
Interrupting ART also resulted in rapid and significant declines in CD4 cell count. These results 
meant the trial team were unable to recommend 12 week STIs initiated at a CD4 cell count ≥300 
cells/μL. 
1.2.2. The ARROW trial 
As with adults there is a high level of infrastructure required to carry out routine laboratory 
monitoring in children. Even though the adult DART trial was well underway there had been no 
trials to investigate the need for routine laboratory monitoring in HIV infected children on 
treatment. There were good reasons to believe that the results in children could be different to 
adults, and that adult results may not be generalisable, because of differences in frequency of 
ART toxicity, predictive value of CD4s and the clinical spectrum of paediatric HIV and its co-
morbidities, particularly in Africa [57]. There was also the urgent need to develop better 
treatment strategies for children in LMIC, since lower rates of virological suppression had been 
reported in children compared with adults in the same calendar periods in high-income settings. 
In particular, it was hypothesised that a 4-drug induction strategy might increase efficacy and 
durability of first-line treatment. Some small observational studies and one larger national UK 
study had noted better virological response with 4 drugs compared to 3 [37]. But there had been 
no randomised trials comparing 4 vs. 3 drugs in children. 
The ARROW trial (AntiRetroviral Research fOr Watoto) [57] was an open-label parallel group 
randomised trial designed to investigate the role of routine laboratory monitoring by comparing 
efficacy and toxicity in children and adolescents receiving standard ART with clinically driven 
monitoring (CDM) versus laboratory and clinical monitoring (LCM), similar to DART. The trial 
included a second factorial randomisation, at ART initiation. It compared a continuous first-line 
ART three-drug two-class regimen, comprising 2NRTIs+NNRTI with an induction with four drugs 
(two classes, 3NRTI+NNRTI) followed by maintenance with three drugs. Children were 
randomised 1:1 to receive either CDM or LCM. In addition children were randomised 1:1:1 in a 
factorial manner to lamivudine + abacavir + NNRTI continuously; induction maintenance with 4 
drug lamivudine + abacavir + NNRTI + zidovudine for 36 weeks, then lamivudine + abacavir + 
NNRTI; or lamivudine + abacavir + NNRTI + zidovudine for 36 weeks, then lamivudine + 
abacavir + zidovudine. 
Routine blood tests were carried out at screening, randomisation to the trial, weeks 4, 8, 12, and 
then 12 weekly. As in DART, results for LCM participants were returned to clinicians but not for 
the CDM participants; haematology/biochemistry test results could be requested for a valid 
clinical reason (CD4/TLC were never returned). All children received ART as syrups or tablets 
dosed according to the WHO weight-band tables. Children were reviewed 4-6 weekly by a 
nurse using a standard symptom checklist. Switch to second-line ART was based on clinical 
criteria in all participants (new/recurrent WHO4 event, or WHO3 events at clinical discretion,  
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particularly if recurrent/persistent) and laboratory criteria for patient on LCM (confirmed on ART 
CD4<15% 1-2 years, <10% 3-4 years and <100 cells/μL ≥5 years). Primary endpoints for the 
monitoring comparison were progression to a new non-recurrent WHO 4 event/death (efficacy) 
and grade 3/4 AEs not solely HIV related (safety). For the ART strategy comparison primary 
endpoints were change in CD4 percentage from randomisation to 72 and to 144 weeks 
(efficacy) and grade 3/4 AEs (safety). Secondary endpoints for both comparisons included 
mortality, new WHO4 event/death, new WHO 3/4 event/death and grade 3/4 AEs (for further 
information see Kekitiinwa et al. 2013) [58]. 
Table 1.2.3 ARROW Baseline characteristics and follow-up (monitoring strategy) 
ARROW LCM n (%) CDM n (%) Total n (%) 
Baseline 600 606 1206 
Female 302 (50%) 308 (51%) 610 (51%) 
Age (years) 
 Median (IQR) 
 
6 (3-9) 
 
6 (2-9) 
 
6 (2-9) 
CD4 at ART initiation  
 Cells/μL median (IQR) if >5 yrs 
 CD4%, median (IQR) 
 
237 (94-366) 
12 (7-17) 
 
244 (114-369) 
13 (8-17) 
 
243 (104-366) 
12 (7-17) 
WHO stage 
 1 
 2 
 3 
 4 
 
7 (1%) 
174 (29%) 
337 (56%) 
82 (14%) 
 
13 (2%) 
160 (27%) 
346 (57%) 
87 (14%) 
 
20 (2%) 
334 (28%) 
683 (57%) 
169 (14%) 
First-line treatment received (ABC+ 
lamivudine) plus 
 NVP 
 EFV 
 ZDV + NVP 
 ZDV + EFV  
 
 
125 (21%) 
72 (12%) 
248 (41%) 
155 (26%) 
 
 
129 (21%) 
71 (12%) 
256 (42%) 
150 (25%) 
 
 
254 (21%) 
143 (12%) 
504 (42%) 
305 (25%) 
Follow-up    
Lost to follow-up 13 (2%) 20 (3%) 33 (3%) 
Treatment status at end of trial  
Still on first-line treatment 
Switched to second-line 
 
565 (94%) 
35 (6%) 
 
577 (95%) 
28 (5%) 
 
1142 (95%) 
63 (5%) 
Median follow-up (years) 4.0 (3.7-4.4) 4.0 (3.7-4.4) 4.0 (3.7-4.4) 
New WHO 4 event/death 39 (7%) 47 (8%) 86 (7%) 
Death 29 (5%) 25 (4%) 54 (4%) 
Comparison CDM vs. LCM [HR (95%CI)] 
New WHO 4 event/death  
Death 
1.13 (0.73-1.73) 
0.80 (0.49-1.44) 
p=0.59 
p=0.45 
This cohort consists of 1206 HIV infected children from three centres in Uganda and one in 
Zimbabwe. Median follow-up was 4 years (total 4685 children-years (CYs)). For new WHO4 
events/death the upper 95% confidence interval for the absolute difference (+0.32/100CY 
[95%CI -0.47,1.12]) lay below the pre-specified non-inferiority margin of +1.6 suggesting that 
overall non-inferiority has been demonstrated. However, from the second year, there were small 
but significant clinical event excesses in CDM, with CD4 monitoring providing clinical benefit; 
nevertheless, the 95% CI for the difference in event rates after one year still lay just within the 
non-inferiority margin, still demonstrating non-inferiority (+0.99 (95% CI 0.37-1.60)). Event rates 
were very low (substantially lower than in DART) and long-term survival high, suggesting ART 
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roll-out should take priority over laboratory monitoring. All trial results can be found in the 
ARROW trial publication [58]. 
Table 1.2.4 ARROW Baseline characteristics and follow-up (first-line ART strategy) 
ARROW Arm A Arm B Arm C 
Baseline 397 404 405 
Female 204 (51%) 197 (49%) 209 (52%) 
Age (years) 
 Median (IQR) 
 
6 (2-9) 
 
6 (3-9) 
 
6 (2-9) 
CD4 at ART initiation  
 Cells/μL median (IQR) 
 CD4%, median (IQR) 
 
221 (87-341) 
12 (7-18) 
 
242 (108,369) 
12 (7-17) 
 
262 (114, 373) 
12 (8-17) 
WHO stage 
 1 
 2 
 3 
 4 
 
4 (1%) 
119 (30%) 
217 (55%) 
57 (14%) 
 
7 (2%) 
116 (29%) 
228 (56%) 
53 (13%) 
 
9 (2%) 
99 (24%) 
238 (59%) 
59 (15%) 
First-line treatment received 
(ABC+ lamivudine) plus 
 NVP 
 EFV 
 ZDV + NVP 
 ZDV + EFV  
 
 
253 (64%) 
143 (36%) 
0 (0%) 
1 (<1%) 
 
 
1 (<1%) 
0 (0%) 
154 (38%) 
249 (62%) 
 
 
0 (0%) 
0 (0%) 
151 (37%) 
254 (63%) 
There was no significant difference between the three first-line strategy arms for mean CD4 
percentage change at week 72 (p=0.33) or 144 (p=0.69). However, at week 36 (when all 
children moved to 3-drugs), CD4% responses were significantly greater in the 4-drug induction 
arms (p<0.0001). 
1.3. Aims of the thesis  
The main aim of this thesis was to address some of the outstanding questions in the treatment 
of HIV-infected adults and children in LMIC. The DART and ARROW trials as described in 
sections 1.2.1 and 1.2.2 had just under 15000 person years and 5000 children years of follow-
up on individuals starting ART in Africa respectively. Apart from the randomised comparisons in 
these trials, the epidemiological potential of these datasets is immense given the substantial 
resources that were employed to ensure high completeness of visits and extensive data 
collection. Some work has already been done on the DART dataset in particular, however many 
important clinical and epidemiological questions still remain. I aim to address the following 
questions in this thesis. 
1.3.1. Modelling causes of death 
The aim is to investigate further the patterns of on-ART mortality in the DART and ARROW 
trials, overall and by specific causes of death in relation to time on ART; both across and within 
each of the CD4 monitoring groups separately. Using different modelling techniques I aim to 
assess the change in hazard of death over time on ART for specific causes of death. Whilst 
patterns of mortality in the first year after initiating ART and early causes of death have been 
previously described in both of these cohorts [38], no analyses of long-term mortality have been  
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carried out to date. As patients survive longer on ART and the number of patients on ART 
increases, understanding causes of long-term mortality may provide indications of further 
interventions that could be used to prevent these deaths in patients receiving ART. Full analysis 
results can be found in Chapter 2. 
1.3.2. Structured and unstructured treatment interruptions 
Preliminary simple analysis comparing the DART STI/CT randomised groups long-term 
suggests that the STI group is likely to remain at increased risk of death many years after 
undertaking STIs as a consequence of persistent deficits in long-term CD4. I aim to assess the 
effects of planned and unplanned treatment interruptions on clinical and immunological 
outcomes using the DART and ARROW data sets. This is relevant for current patients in ART 
programmes where stockouts are common. Full analysis results can be found in Chapter 3. 
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Chapter 2: Cause-Specific Mortality in DART and ARROW 
(Work for this Chapter was done, and this Chapter was mainly written in 2012-2013. Based on 
comments I received during my upgrade, the literature search was updated in 2014.) 
2.1. Introduction 
2.1.1. Background 
HIV-related illness is currently the leading cause of death in sub-Saharan Africa [59, 60]. In 
2013 there were an estimated 1.2 million AIDS related deaths among adults and children in 
sub-Saharan Africa [61]. Antiretroviral therapy (ART) has been shown to improve immune 
function and decrease the risk of opportunistic infections (OI) and death [62, 63] and mortality 
rates have declined significantly over the last decade as the number of people on ART in sub-
Saharan Africa has increased from 50,000 in 2001 to ~1.2 million in 2006 and to ~7.0 million in 
2012 [64]. In low/middle-income countries mortality after starting ART is high. Between 8 and 
26% of patients receiving ART in sub-Saharan Africa die within the first year of treatment with 
most deaths occurring in the first few months [65]. Similarly to adults, high early mortality has 
also been reported in children [66-69]. 
2.1.2. Literature search  
A search of the literature was carried out in Medline for articles published between January 
2002 (when ART rollout to low/middle-income countries started) and July 2014. The aim of this 
literature search was to find articles reporting on the cause of death by time on ART in 
low/middle-income countries. Keywords used for the search included “mortality”, “treatment 
outcomes”, “AIDS related opportunistic infections”, “HIV infections”, “cause of death”, “HAART”, 
“highly active”, “antiretroviral therapy”, “anti-HIV agents” and “antiretroviral agents”. A total of 
4177 potentially relevant citations were identified. Titles and abstracts were screened to capture 
potentially relevant studies (Figure 2.1.1). Studies were selected for full text review if they met 
the following criteria:  
i) included data from low/middle-income countries (including this in the search strategy 
was too restrictive on the search excluding many relevant papers);  
ii) mentioned individual causes of death in the abstract and not just overall mortality.  
Fifty studies received full text review, of which 30 met my inclusion criteria (10 included cause of 
death only (2 paediatric); 3 included change in mortality over time only (1 paediatric) and 17 
included both causes of death and change in mortality over time (1 paediatric)) (Figure 2.1.1). 
Of the 30 articles included, 86% were from sub-Saharan Africa, 10% were multi-regional and 
4% were from the Americas (South and Central America).  
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Figure 2.1.1 Flow diagram of inclusion and exclusion for literature search 
 
 
Literature search result
“mortality”, “treatment outcomes”, 
“AIDS related opportunistic infections”, 
“HIV infections”, “cause of death”, “HAART”, 
“highly active”, “antiretroviral therapy”, 
“anti-HIV agents” and “antiretroviral agents”
N=4177
Title screening
Records excluded 
(n=3927) 
(includes 9 that were 
unobtainable)
Records eligible 
for abstract review 
(n=250) Abstract ScreeningArticles excluded, with reasons (n=200)
Methodology only 2
Investigates biomarkers 
as predictors of mortality 14
High income countries 70
Overall mortality only, with no relevant methods 
to assess early vs. late differences 114
Included 
n=30
Records eligible 
for full text review 
(n=50)
Causes of 
death 
n=10
(2 children)
Change in 
mortality 
risk over 
time on 
ART n=3
(1 children)
n=17
(1 children)
Full Text Review
Articles excluded, with reasons (n=20)
Overall mortality only, with no relevant methods 
to assess early vs. late differences 9
Did not assess mortality or causes of death 4
Investigates biomarkers 
as predictors of mortality 2
High income countries 4
Looked at TB only 1
Change in mortality risk over time 
on ART for specific causes of death 
n=1
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Below I summarise the findings of the 30 papers included from my search. I start with those 
studies describing both causes of death and change in mortality over time (n=17).  
Amuron et al. [70] investigated mortality in 1453 patients initiating ART in an AIDS support clinic 
in Uganda. Overall there were 197 deaths and follow-up was for 42 months. They reported 
higher mortality rates in the first year (12/100 person-years (PYs)) compared to thereafter 
(2/100PYs) (154 patients (78% of all deaths) died in the first year). Low CD4 at baseline, being 
male, WHO stage 3/4 disease, lower weight and not taking cotrimoxazole prophylaxis were all 
independently associated with increased mortality and the most common causes of death were 
tuberculosis (TB), diarrhoea and cryptococcal meningitis. They concluded that earlier ART 
initiation is required to prevent these early deaths that occur in the first year of ART.  
Etard et al. [71] evaluated survival and investigated causes of death among 404 HIV infected 
adults in Senegal. Overall there were 93 deaths and median follow-up time was 46 months. 
Overall incidence of death was 6/100PYs with a slightly higher mortality rate in the first year of 
7/100PYs (47 patients (51% of all deaths) died in the first year), decreasing over time. BMI, 
haemoglobin level and CD4 at baseline were predictors of survival with the most common 
cause of death being mycobacterial infections, neurological disorders and septicaemia. Like 
Amuron et al. they conclude that earlier initiation of ART could reduce early mortality.  
Grinsztejn et al. [72] analysed a cohort of data from 915 patients in Brazil (Rio de Janeiro) and 
859 patients in the US and made a comparison between the two. Outcome was early mortality 
(death occurring during the first year after initiating HAART). Mortality rates and causes of death 
were investigated according to specific periods (first 30 days, 31-90 days, 91-180 days, 181-360 
days) and the effect of CD4 count on the risk and cause of death was assessed in a Cox 
proportional hazards model. They did however only assess the first year. They found higher 
mortality rates (14/100PYs) in the first 30 days on ART in Rio de Janeiro with decreasing 
mortality rate up to the end of the first year (64% of deaths occurred in the first 90 days of 
HAART initiation). This decreasing trend was not seen in the US where rates were low 
throughout (47% of deaths were from days 180-365 in the US). The most common causes of 
death in Rio de Janeiro were AIDS-defining illnesses, TB, cryptococcus and Kaposi’s sarcoma 
(KS). In the US the most common cause of death was non-AIDS defining illnesses; there were 
no deaths from TB in the US. They concluded that in both countries there is a need for earlier 
initiation of ART to reduce early mortality.  
Karstaedt et al. [73] described causes of death in 2943 patients in a single-centre cohort in 
Soweto, South Africa. Causes of death were described according to time on ART and in 
particular, for deaths beyond the first year. The most common causes of death were acute 
sepsis, TB and Mycobaterium avium complex (MAC) bacteraemia. Overall there were 305 
deaths. Median follow-up was 2.7 years. They showed that the percentage of deaths decreased 
over time from 165/305 (54%) in the first 3 months on ART to only 6/305 (2%) after 3 years on 
ART. They found the same causes of death to be common in the first twelve months and 
thereafter.  
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Kouanda et al. [74] investigated causes of death and factors associated with mortality in a 
cohort of 5508 patients in Burkina Faso initiating HAART. They used Kaplan-Meier methods to 
explore potential predictors of death and two Cox models to estimate hazard ratios (HRs) for 
death (one for baseline and one for time-dependent covariates). Median duration of follow-up 
was 23 months and by the end of follow-up 690 (13% of all patients) had died. Overall incidence 
of death was 6/100PYs which reduced over time with the highest rate reported at 6 months of 
18/100PYs. Median time to death was 2.8 months and the most common causes of death were 
wasting, TB and anaemia.  
In 2005, Lawn et al. [62] described rates, risk factors and causes of death among 712 patients 
accessing community based ART in Cape Town, South Africa. There were 68 deaths during 
563 PYs of follow-up and 44 deaths (65% of all deaths) in the first 90 days of ART initiation. 
They showed decreasing mortality rates over time with a rate of 18/100PYs in the first month 
after ART initiation decreasing to just 3/100PYs at 6-9 months after ART initiation. Causes of 
death were wasting, TB, acute bacterial infections, malignancy and immune constitution 
disease. Similarly to previous studies they concluded that treatment should be started earlier 
and certainly for patients with WHO stage 3/4 disease.  
In 2009, Lawn et al. [75] described mortality rates in the first 4 years of ART in 2423 patients 
accessing community based ART in Cape Town, South Africa. There were 197 deaths over 
3155 PYs of follow-up. Mortality was highest in the first month on ART (27 deaths/100PYs). 
They also showed that risk was high for months 0-4 (16/100PYs) but then rapidly decreased 
after that to just 4/100PYs for months 8-12. Death rates were as little as 0.4/100PYs in the 4th 
year of ART. They also assessed the association between CD4 cell count and mortality and 
showed decreasing mortality rate with higher current CD4 count. The most common causes of 
death were TB, acute sepsis and cryptococcal meningitis.  
MacPherson et al. [76] considered a retrospective cohort of 1353 patients initiating HAART in a 
region of South Africa and assessed mortality rates and potential predictors of death. There was 
966PYs of follow-up and at 24 months 124 (9% of all patients) had died. Median time to death 
was 57 days in those who died. The overall mortality rate was 13/100PYs. The mortality rate up 
to 6 months was 20/100PYs declining to just 3/100PYs between 12 and 24 months. The most 
common causes of death were TB and diarrhoea. 
Marazzi et al. [77] assessed excessive early mortality in the first year of ART in 3456 patients 
initiating ART in centres in Mozambique, Tanzania and Malawi. Two hundred and sixty deaths 
were recorded in the first year of initiating ART and the overall mortality rate for the first year of 
ART was 10/100PYs. The highest mortality rate was seen in the first 3 months of treatment at 
16/100PYs (137 (53% of all deaths) occurred in the first 3 months) and the mortality rate 
declined to just 1/100PYs from 9-12 months. BMI, haemoglobin levels and viral load (VL) were 
independent predictors of mortality. The main causes of death were malaria, anaemia and TB.  
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Moh et al. [78] assessed the incidence and determinants of mortality following early ART in 792 
patients in West Africa. Median follow-up was 8 months and 9 (1%) patients were lost to follow-
up. There were a total of 18 (2%) deaths. The most common cause of death was TB, followed 
by cerebral toxoplasmosis, KS, bacteraemia, malaria, cardiac insufficiency and trauma. They 
found the incidence of mortality was greatest in those patient with pre ART CD4<200 cells/μL 
and found no deaths in those with pre-ART CD4≥350 cells/μL. They suggested their data 
supported the need for ART to be started before a patients CD4 drops to below 350 cells/µL. 
Patients with severe morbidity had a higher risk of death with the most frequent morbidity being 
TB.  
Moore et al. [79] examined data from 1132 patients initiating ART in an AIDS care project in 
Uganda to describe mortality over time and determine clinical predictors of death. Overall there 
were 112 deaths over a median of 3 years of ART. Mortality was 16/100PYs in the first 3 
months after ART initiation and decreased over time to just 0.3/100PYs after 24 months. They 
reported TB to be the most common cause of death followed by candida disease. They found 
an association between deaths in the first 3 months and WHO 3/4 disease stage, TB at 
baseline, BMI and non-TB opportunistic infection (OI); after 3 months there were associations 
with time-updated CD4<200 cells/μL, adherence <95%, non-TB OI and low time-updated 
haemoglobin. Early treatment was considered the key to survival along with good adherence.  
Mzileni et al. [80] described mortality trends and causes of death among 2605 HIV-infected 
patients in the HAART era in South Africa between July 2004 and December 2006. They found 
mortality to be higher in males as well as for those with CD4<200 cells/μL at baseline. Mortality 
rate was highest in those with CD4<50 cells/μL. There were a total of 205 deaths, 95% of which 
occurred in the first year of ART. Mortality rates significantly decreased over time to just 2% 
between 19-30 months. The main causes of death were TB, diarrhoea, cryptococcus meningitis 
and pneumonia.  
Woradria et al. [81] looked at TB-HIV coinfection and its effects on mortality in 302 TB-HIV co-
infected patients enrolled in ART programs in Uganda. Total study follow-up was 331PYs. 
There were 53 deaths in total. Thirty-six (68% of all deaths) were in the first 6 months of ART 
initiation, 23 (43%) in the first 3 months (of which 12/23 (52%) died before being able to start 
ART). Overall mortality was 16/100PYs. During the first 3 months the mortality rate was 
34/100PYs, reducing to just 6/100PYs after 9 months on ART. The most common causes of 
death were gastroenteritis, severe anaemia and KS.  
Wamalwa et al. [69] conducted a study investigating both causes of death and mortality rates 
over time in 135 children in Kenya. Median follow-up was 21 months and 11 (8%) children were 
lost to follow-up. There were a total of 20 deaths, 18 (90%) occurring in the first 4 months after 
ART initiation. Overall mortality was 8/100 child years (CYs). In the first 4 months the rate was 
46/100CYs and dropped to just 1/100CYs from 4 months to two years. Low haemoglobin was 
an independent risk factor for mortality. The most common cause of death was pneumonia, 
along with TB, diarrhoea, non-Hodgkin’s lymphoma and anaemia. They suggested that children 
who present with severe wasting and anaemia should be prioritised for ART treatment.  
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Zachariah et al. [82] assessed risk factors for high early mortality in 1507 patients initiating ART 
in Malawi. There were a total of 190 deaths on ART. Sixty-one percent (n=116) of deaths 
occurred in the first 3 months of ART initiation and 79% (n=150) during the first 6 months. They 
found significant risk factors for mortality to be stage WHO 3/4 disease, pre-ART CD4<50 
cells/μL and increasing grades of malnutrition. They concluded that BMI and clinical staging 
were important in highlighting who are still at very high risk despite ART. The most common 
causes of death were oral recurrent candida, KS, bacterial pneumonia and TB.  
In addition Kowalska et al. [83] assessed changing mortality overtime for specific causes of 
death in middle-income countries in Europe, Israel and Argentina. They analysed a cohort of 
12,069 patients and looked at the crude incidence rate of death due to specific causes. A total 
of 1297 patients died during a median follow-up time of 5.4 years. They assessed all cause, 
AIDS-related (884, 68%) and non-AIDS related deaths (413, 32%) by time on ART (<2, 2-3.99, 
≥4 years). They also assessed changing mortality over time for the following more specific 
categories of causes of death: non-AIDS related infection (12, 9%), liver related (LR) (182, 
14%), non-AIDS defining malignancies (125, 10%), cardiovascular disease (CVD) (122, 9%) 
and deaths due to violence (90, 7%). The overall mortality rate was 2/100PYs. They found that 
the incidence rate of death was highest in the first year on ART (3/100PYs) and decreased with 
more time on ART for all cause (~1/100PYs) and AIDS related deaths, non-AIDS related 
infection deaths, LR deaths and violent deaths, however, the rates of non-AIDS related deaths, 
deaths from non-AIDS defining malignancies and cardiovascular deaths remained fairly 
constant over time on ART. 
The following ten studies described causes of death only, without considering time on ART. 
Barlow et al [66] assessed the effectiveness of generic adult fixed-dose combination ART 
(tablet) on 104 children affected with HIV in Uganda. Median follow-up was 96 weeks and no 
children were lost to follow-up. There were a total of 6/104 (6%) deaths, of which 4/6 (67%) 
were in the first 4 months of initiating ART. The other two deaths occurred at 44 and 56 weeks 
respectively. Causes of death included toxoplasmosis, malaria, pneumonia, renal failure and 
severe diarrhoea with dehydration. 
Bourgeois et al. [84] assessed the effectiveness of generic antiretroviral drugs in 109 adult 
patients from Cameroon. They assessed survival and virological and immunological response 
and also assessed causes of death. The median follow-up was 16 months; there were 3 
patients lost to follow-up and a total of 9 deaths, four (44%) of which occurred in the first 6 
months of ART initiation. They found that the most common cause of death was HIV disease 
followed by TB with other deaths being due to poor general health, hepatitis and pancreatic 
disease.  
Bussmann et al. [85] assessed the long term clinical outcomes of 633 patients receiving ART in 
Botswana. The median follow-up was 42 months and 126 (20%) patients died. The most 
common causes of death were wasting syndrome, TB and advanced AIDS.  
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Chihana et al. [86] assessed mortality and causes of death in 17,373 patients in rural northern 
Malawi. From September 2004 to August 2009 there were 905 deaths. The most common 
cause of death was AIDS/HIV, followed by gastrointestinal, cardiovascular disease and cancer.  
Coetzee et al. [87] assessed outcomes in 287 patients up to 2 years after ART initiation in 
Khayelitsha, South Africa. One patient was excluded and one was lost to follow-up. Median 
follow-up was 14 months and 6 had stopped ART. There were a total of 38 deaths and the most 
common cause of death was TB followed by KS.  
Cox et al. [88] carried out an autopsy study describing causes of death in 46 patients in 
Uganda. They made comparisons between 35 HIV positive (10 of whom were on ART) and 11 
HIV negative patients and found the causes of death to be different; in HIV positive patients the 
main cause of death was TB and the leading cause of death in HIV negative patients was non-
infectious disease which included liver failure, cardiac failure and pulmonary thromboembolism.  
Fassinoua et al. [67] assessed the effect of ART in 78 children in the Côte d’Ivoire. Total follow-
up for the 78 children was 1927 children-months. There were only 9 deaths (5 (56%) of which 
occurred in the first 3 months of ART initiation). The most common cause of death was lower 
respiratory infections.  
Karcher et al. [89] evaluated risk factors for treatment denial and loss to follow-up in 159 
patients in western Kenya. Median time on treatment was 9 months. They considered death to 
be a reason for loss to follow-up and reported causes of death in 11 of the total 15 deaths. TB 
was the most common cause of death followed by cryptococcal meningitis and pneumonia. 
They reported an overall mortality rate of 19/100PYs. 
Laurent et al. [90] compared the tolerability and effectiveness of two major first-line ART 
regimens in 169 HIV-1 infected patients in Cameroon. Follow-up was for around 24 months. 
They reported an overall mortality rate of 11/100PYs and there were 19 (11%) deaths. Cause of 
death was mainly attributed to advanced HIV, followed by poor general health, TB and wasting.  
Wester et al. [91] assessed the initial response in 153 ART naïve patients initiating HAART in 
Botswana. Median follow-up was 96 weeks and there were 24 (16%) deaths. The most common 
causes of death were advanced HIV and TB, followed by KS, liver disease, wasting and 
cryptococcal meningitis. 
The following three studies assessed change in mortality over time only. Bong et al [68] 
assessed risk factors for early mortality in 439 children in a hospital in Malawi. There were a 
total of 49 (11%) deaths. They found that 71% (35/49) of deaths occurred in the first 3 months 
and 89% (44/49) in the first 6 months of ART. 38 children were lost to follow-up. Children who 
were stage WHO 3/4 at baseline had severe wasting or CD4 cell count below the threshold for 
severe immunodeficiency (CD4<200 cells/μL) had a significantly greater risk of early death at 3 
or 6 months. They recommended scaling up prevention of mother-to-child transmission 
(PMTCT) to prevent children becoming infected with HIV.  
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Braitstein et al. [92] made a comparison between low (N=4810) and high (N=22,217) income 
countries, of mortality in HIV infected patients in the first year of ART. There were cohorts in 
Africa, Asia and South America and Europe and North America. There were lower CD4 counts 
for those starting ART in low-income countries compared to high income countries (N=22217). 
There was 2236PYs and 20,532PYs of follow-up in low and high income countries respectively; 
loss to follow up was 15% and 5%. Mortality was higher in low-income countries compared to 
high income countries, with a total of 124 (3%) and 414 (2%) deaths respectively; 97/124 (78%) 
and 255/414 (62%) deaths occurred in the first 6 months on ART. The difference between high 
and low-income countries in terms of mortality changed over time, with the hazard ratio (HR) of 
low vs. high going from 4.3 (95% CI 1.6-11.8) in the first month to just 1.5 (0.7-3.0) in months 7-
12. They suggested that earlier diagnosis and initiation of treatment in low-income countries 
would help reduce this difference and reduce the high early mortality in both settings.  
Hoffmann et al. [93] assessed data from a cohort study of 16,356 patients taking ART in South 
Africa. They included 15,060 patients with a median follow-up time of 1.8 years. They found that 
mortality was highest early during ART with a mortality rate of 34/100PYs in the first 3 months 
after ART initiation. The mortality rate declined to just 3/100PYs in years 2-4 after ART initiation. 
Gupta et al. [94] carried out a systematic review of observational studies of early mortality post-
ART initiation in low- and middle-income countries in Asia, Africa, and Central and South 
America. This systematic review includes several studies from my search and in total they 
included 50 studies (76% from sub-Saharan Africa) where 14 studies reported cause specific 
mortality. They found the most common causes of death to be TB, wasting, advanced HIV and 
chronic diarrhoea. Median follow-up time ranged from 3-55 months and sub-Saharan Africa had 
the highest probability of 12 month mortality of 0.17. 
In summary, I found no studies looked at changes in individual causes of death over timescales 
covering the first few years on ART in low-income countries. Only one study looked at change 
for specific categories of death (non-AIDS vs AIDS related). Those studies that did investigate 
change in mortality all found a decrease in mortality over time on ART with the highest mortality 
rates being in the first 3-6 months on ART. Common causes of death across these studies were 
TB, other infections (including diarrhoea, gastroenteritis, pneumonia and septicaemia), KS and 
anaemia. 
 
2.1.3. Data available for analysis 
Data are available from the Medical Research Council Clinical Trials Unit (MRC CTU) DART 
trial [54]. In DART patients with CD4 count <200 cells/μL were randomly assigned to either 
laboratory and clinical monitoring (LCM) or clinically driven monitoring (CDM). The aim was to 
investigate whether delivery of ART with or without routine monitoring of CD4 counts led to 
similar outcomes in terms of efficacy and with or without routine haematology/biochemistry tests 
led to similar outcomes in terms of toxicity. In all participants 12 weekly CD4 counts (for 
efficacy) and 12 weekly full blood counts/haematology and biochemistry (for toxicity) were 
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performed. For LCM participants test results were returned to treating clinicians and for CDM 
participants all tests were carried out but were not returned. The DART trial showed that CDM 
was inferior to LCM (HR 1.35 95%CI 1.10-1.65, p=0.004) for mortality, but there was no 
difference between the groups in any adverse event outcome. Because of this, the aim of this 
chapter is to investigate further patterns of mortality overall and by specific causes of death in 
relation to time on ART; both across and within each of the CD4 monitoring groups separately. 
Using different modelling techniques I aim to assess the change in hazard of death over time for 
specific causes of death without having to make any arbitrary classifications of time upfront as 
done in the papers reviewed in section 2.1.2. Whilst patterns of mortality in the first year after 
initiating ART and early causes of death (COD) have been previously described in this cohort 
[95], no analyses of long-term morbidity have been undertaken to date. As patients survive 
longer on ART and the number of patients on ART increases, understanding causes of long-
term mortality may provide indications of further interventions that could be used to prevent 
these early deaths. Therefore in this chapter I investigate the different methods that can be 
used to model this change in mortality risk.  
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2.2. Methods 
2.2.1. Objectives 
The primary outcome of interest in this chapter is mortality, firstly overall mortality, secondly 
cause-specific mortality. I am specifically interested in the effect of time on ART (antiretroviral 
therapy) and the effect of monitoring strategy in the DART trial (LCM: Laboratory and clinical 
monitoring with 12 weekly CD4 counts monitored by physicians, CDM: clinically driven 
monitoring, CD4 counts are performed 12 weekly but not given to the physicians and are 
therefore not used for patient management). Time on ART has been calculated as time from 
randomisation (enrolment and ART initiation) to either death or 31st December 2008 (end of 
follow-up under the randomised strategy) whichever occurred first. Any patients who died after 
31st December 2008 have been censored on this date (i.e. not included as a death). 
Deaths were reported using the death case report form. All deaths were reviewed by an 
Independent Endpoint Review Committee (ERC) to assign cause and relationship to drug. This 
was done on the basis of a structured clinical narrative written by the clinician managing the 
patients. The ERC consisted of an Independent Chair, project leaders from each site and two 
other independent clinicians. No member reviewed deaths (endpoints) from their own site. As 
well as determining the cause, the ERC classified all deaths by whether they were 
definitely/probably related, uncertainly related or unlikely to be related to any drug including 
antiretrovirals and concomitant medications. All reviews were done blind to the CD4 monitoring 
randomisation and CD4 count. Where cause of death was considered to depend on the CD4 
count, the ERC provided two adjudications e.g. “cause=A if CD4<X, otherwise if CD4≥X, cause 
= B”, and the unblinded trial manager administrating the ERC then input the appropriate 
adjudication into the database. 
2.2.2. Methods 
There are several methods that can be used to analyse survival data. Here I will consider just 
three main approaches. They are Poisson Regression, Cox Regression and Flexible Parametric 
Models (FPMs). All of these methods estimate rate or hazard ratios (HRs) to measure how 
much a covariate increases or decreases the mortality risk. These methods are outlined along 
with their regression models, advantages, disadvantages and what they have been used for in 
this chapter in Table 2.2.1.  
  
 47 
 
Table 2.2.1 Different methods proposed for modelling the effect of covariates on time-to-
event data/hazards 
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 Uses a piecewise 
exponential model to split 
time into several intervals 
allowing the hazard to 
change over time, where 
the hazard follows an 
exponential model within 
each time interval 
 Full likelihood is 
decomposed into a term 
containing only functions 
of the baseline hazard 
and a term containing 
only functions of 
covariates Xi and ß. 
 The latter is called the 
partial likelihood and is 
maximised to provide a 
semi-parametric estimate 
of ß 
 Extension of the parametric 
Weibull model in which log 
cumulative hazard increases 
linearly with log time 
 Uses restricted cubic splines 
made up of cubic polynomial 
segments which are joined at 
values known as knots to allow 
non-linear variation in log time 
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  Hazard rate is constant within each chosen time 
interval, jth )(0  
(where j is the interval) 
 Hazard rate is not 
directly estimated but it is 
treated as a sum of 
probability elements at 
the times that events 
have occurred enabling it 
to vary freely with the 
data 
 Hazard varies over time but has 
a parametric form 
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 Allows some flexibility in 
the shape of the baseline 
hazard (e.g. compared to 
simple exponential or 
Weibull) 
 Can be a good 
approximation to the Cox 
model depending on how 
much the hazard is 
changing 
 Allows rates to be 
estimated and easily 
compared over time and 
by covariates 
 Considered standard 
method for analysing 
survival data because it 
does not make any 
assumptions about the 
shape of the underlying 
hazard 
 Does not require the time scale 
to be split a priori in order to 
flexibly model the hazard 
 Introduces flexibility into the 
survival functions in a way that 
can be modelled directly 
(parametric)  
 Interpretation of parameters in a 
proportional hazards FPM is 
exactly that of the Cox model 
(but can also use log normal or 
proportional odds) 
 Enables easier investigation of 
the hazard function over time 
and by covariates 
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 Could miss changes in the 
hazard if split too few 
times. 
 If split too often then there 
would be too many model 
parameters 
 Could be considered 
biologically implausible as 
risk does not change 
abruptly when moving from 
one interval to the next 
 Does not provide 
smoothly varying 
estimate of the hazard 
and so it is difficult to 
visualise exactly how the 
risk is changing 
 Choosing an appropriate degree 
of complexity for the time 
varying model can be arbitrary 
and is not straight forward 
 Unable to fit some models due 
to low event numbers when 
comparing factors* 
 Models may be sensitive to 
exactly when the first events 
occurred* 
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 Compare cause-specific 
mortality rates between 0-
1 and >1 years on ART for 
LCM and CDM 
 Calculate cause-specific 
rates and their 95% CIs 
 Compare cause-specific 
hazard ratios between 
CD4 monitoring vs. no 
CD4 monitoring for 0-≤1 
year and >1 years on 
ART 
 Calculate cause-specific 
hazard ratios and their 
95% CIs 
 Predict hazard functions over 
time for overall mortality and for 
individual causes of death 
 Predict hazard differences 
between CD4 monitoring 
strategies over time 
*Findings discovered whilst using this method with my data 
2.2.3. Comparison of randomised groups using cause-specific Poisson regression 
models 
Using a piecewise exponential or Poisson model, the time at risk can be split into several 
intervals, and the constant underlying baseline hazard ij modelled in each interval: 
)exp()|( βxx ijjiij th   
This model can then be fitted using Poisson regression as follows: 
)(~ ijij Poissond   
βx ijijij y   )ln()ln(  
Where dij is the indicator for whether or not the ith patient has died in interval j and μij is the 
mean of the Poisson distribution. Modelling is now on the log scale so the time at risk for the ith 
subject in interval j, yij is incorporated as an offset )ln( ijy and )ln( jj   . 
Using the Poisson model with split times may be a good approximation to the Cox model, 
depending on how much the hazard is changing. Splitting the time scale into several intervals 
allows some flexibility in the shape of the baseline hazard function, but it is still discontinuous 
and does not vary smoothly. In this analysis I have split time at 1 year, based on the 
observation that approximately half (47%) of the deaths occurred in the first year on ART and 
because this is the time point which WHO use to define failure of first-line treatment [99]. I will 
estimate a constant baseline mortality rate within the first year and a different but constant rate 
thereafter. I can then directly test whether there is a difference in the hazard in the two time 
intervals and whether these differences also vary across the different CD4 monitoring 
strategies. Using the Poisson regression model as above, I fit both CD4 monitoring strategy and 
 49 
 
time period along with their interaction; I am then able to estimate the incidence rate ratio (IRR) 
for early (0-≤1 year) vs. late (>1 years) deaths in the CD4 monitoring group and similarly the 
IRR in the no CD4 monitoring group.  
2.2.4. Flexible parametric models (Royston-Parmar models) 
When using exponential piecewise Poisson regression models, it is required that the data are 
split into time intervals over which the hazard is considered constant. If split too often there 
would be too many parameters in the model; not only can this make analysis time very long, but 
including such a large number of dummy variables results in a noisy estimate of the baseline 
hazard function. If split too few times a change in hazard rate could be missed and therefore a 
model fitted which poorly reflects the data, which may then impact on the estimates of  . 
Further, these splitting times are completely arbitrary, as shown by the different thresholds used 
in the studies identified in my literature review (variably 1 month, 3 months, 6 months or a year). 
For example, in the above, it may be unrealistic to assume the hazard rate changes abruptly at 
1 year. Smooth functions of the hazard using either splines or fractional polynomials (FPs) 
should better model how the hazard is changing over time. But there is still the limitation of 
where to put the knots and how to choose the FPs. 
One spline based method is that of Royston-Parmar, also known as flexible parametric models 
(FPMs) [98, 100]. FPMs are a parametric approach to survival analysis, but they introduce far 
more flexibility into the survival/hazard functions than standard parametric survival models such 
as Weibull or log-normal. The hazard function is not discontinuous at various points in time as in 
the piecewise exponential models, and it is possible to obtain continually varying hazard 
predictions and confidence intervals (CIs); however, one still has to choose specific points in 
time for the spline knots. Below I use the overall survival data from the DART trial to summarise 
the theory behind these models and show how they are simply an extension of the parametric 
Weibull model, which itself is an extension of the exponential model for survival data. 
The cumulative hazard function for the Weibull model is as follows: 
1)( ttH   
for some 01  , where 1  is a shape parameter. The Weibull hazard function:  
1
1
1/)()(  ytdttdHth   
is constant when 1 =1 (simple exponential), monotonic increasing when 1 >1 and monotonic 
decreasing when 1 <1. Effects of co-factors are estimated as )exp( 0 βxii   . 
In DART, for mortality, 1 =0.58 (95% CI 0.52-0.64) suggesting strong evidence that the Weibull 
model may be a better fit than the simple exponential model ( 1 =1). Comparing the Nelson-
Aalen (NA) non-parametric estimator of the cumulative hazard function as in Figure 2.2.1 (left 
panel) and the 95% CI compared with the estimate from the Weibull model over time (red line) 
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and the exponential model (straight blue line), and a similar comparison for the estimates of the 
survival function (right panel) shows that the Weibull model is indeed a better fit than the simple 
exponential model. However, the Weibull parametric model makes very strong assumptions 
about how the hazard is changing over time. Figure 2.2.1 shows that the Weibull model lies just 
on the edge of the 95% CI for the NA estimate during the first 2 years suggesting that it is 
potentially not modelling the early hazard as well as it could. Investigating the hazards for each 
of the models in Figure 2.2.1 confirms that there are quite large differences in the way these 
models estimate the change in hazard over time. In particular, the Weibull model estimates an 
extremely high initial hazard (red line above Nelson-Aalen estimate in Figure 2.2.1 below), 
which then abruptly drops to a much lower and realistic level shortly after ART initiation.  
Figure 2.2.1 Neslon-Aalen estimator of the cumulative hazard function and Kaplan-Meier 
survival function (green) compared with the Weibull (red) and Exponential (blue) model 
estimations 
 
The approach of Royston and Parmar starts with the Weibull model in its logarithmic form, 
excluding covariates 
 tttH lnlnln)(ln 101     (1.0) 
 
This shows that )(ln tH is a sum of two components, a constant and a linear function of log 
time. Figure 2.2.1 shows that this linear form for )(ln tH does not fit the cumulative hazard 
function as well as it could do, therefore a more flexible approach is needed. 
 
0.0
0.1
0.2
0.3
C
um
ul
at
iv
e 
ha
za
rd
 fu
nc
tio
n
0 1 2 3 4 5 6
0.7
0.8
0.9
1.0
S
ur
vi
va
l f
un
ct
io
n
0 1 2 3 4 5 6
Years on ART
 51 
 
Equation (1.0) is extended as follows:  
);(ln)(ln tftH   
where );(ln tf  represents a general family of non-linear functions of time lnt, with a 
parameter vector  , and is monotonic increasing in lnt. A suitable family of such functions is 
cubic splines, these are piecewise cubic polynomials with a separate cubic polynomial that is fit 
in each of a pre-defined number of intervals. The number of intervals is chosen by the user, and 
the split points are known as knots. The spline is cubic between the knots but is only continuous 
in its 2nd derivative at the knots, providing more flexibility than a simple cubic polynomial alone. 
The preferred option here is a restricted cubic spline; this is a special case that forces the 
function to be linear before the first knot and after the last knot (the first and last knots are 
known as boundary knots) i.e. it includes a linear term in the tails (to prevent over fitting and 
model instability) and then additional terms involving the cubic polynomials between the 
boundary knots. Working on the log scale of time (1.0) is generalised using restricted cubic 
spline functions as follows for m interior knots: 
)(ln........)(ln)(lnln);(ln)(ln 1231210 tztztzttstH mm   
where )(ln),(ln,ln 21 tztzt and so on are the pre-defined basis functions of the restricted 
cubic spline, one for each interior knot. When one or more interior knots are specified, the spline 
function includes a constant ( 0 ), a linear function of tln with parameter 1 , and a basis 
function of tln  for each interior knot i, which also has a regression parameter 1i (i=1…m). 
The no interior knot case is the simple Weibull model ( tln10   ) (df=1 for one function of lnt 
)ln( 1 t  in the model). The number of knots to be used has to be pre-specified, or equivalently 
the degrees of freedom (df) for the model. The df are one more than the number of interior 
knots, so a model with df(3) has 2 interior knots and 2 boundary knots and a total of 3 (=df) 
functions of lnt in the model.  
Whilst it is also possible to choose the location of the knots to improve the ‘fit’ of the model, this 
runs the risk of over-fitting to the specific dataset. It is not recommended and therefore is not 
done here. Previous investigation [100] has shown that optimal knot positioning does not 
appear to be critical for a good fit and may even cause problems when the fitted curve follows 
small scale features of the data too closely. Royston & Parmar [98] suggested knot positions 
based on empirical centiles of the distribution of the uncensored log survival times, as given in 
Table 2.2.2, with boundary knots at the smallest and largest uncensored log-survival times. 
These knot positions provide considerable flexibility without over-fitting.  
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Table 2.2.2 Positions of internal knots for modelling the baseline distribution function in 
FPM models. Knots are positions on the distribution of uncensored log-survival times 
Interior Knots df Centiles of the interior knots 
0 1 None (Weibull) 
1 2 50 
2 3 33, 67 
3 4 25, 50, 75 
4 5 20, 40, 60, 80 
5 6 17, 33, 50, 67, 83 
 
In addition, a decision must be made as to which type of model to use, the proportional hazards, 
proportional odds or probit-scaled FPM to give the ‘best’ fit. A proportional hazards FPM models 
log cumulative hazard as a spline in lnt as discussed above; a proportional odds FPM models 
log cumulative odds as a spline in lnt and the probit-scaled FPM models on the normal 
equivalent deviate scale as a spline in lnt. 
The simple log-logistic (proportional odds) model is: 
logit   ix;1 tS  = logit    βxitS  01  
where logit(x)=ln{x/(1-x)} 
As for the Weibull model where flexibility is increased by extending the model term in lnt using 
spline functions, the log-logistic model can be extended in a similar way: 
 xβxβ 




  ):(lnln
)(
)(1ln 10  tsttS
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And similarly for the probit scaled FPM the probit (log normal) model is generalised as follows: 
 
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001
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using natural cubic spline for );(ln ts  
The FPMs described here are the natural cubic spline generalisation of the Weibull, log-logistic 
and lognormal models. In order to choose which model to use and the number of dfs, each 
model is fitted to the data and the AIC (Akaike information criterion) calculated, where
kLAIC 2)ln(2  , k is the number of parameters in the statistical model, and L is the 
maximized value of the likelihood function for the estimated model. The ‘best’ model is the 
model that minimises the AIC, thus trading off improvements in model fit (smaller -2ln(L)) 
against model complexity required to achieve this (number of parameters +2k). 
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Figure 2.2.2 AICs for PH, PO and probit-scaled models with various dfs for overall 
mortality in DART 
 
The model that minimises the AIC is the normal model with df(4) (an extension of the probit 
model) (Figure 2.2.2). However, for df(4) and higher, the difference in AICs between model 
types (i.e. hazard, normal, or odds) is statistically indistinguishable (<3.84, p>0.05 for χ2 on 1 
df). Therefore, instead of the normal model which produces acceleration factors from the log 
normal model for covariate effects that are hard to interpret (particularly for the wider clinical 
audience), I have chosen to use the hazard model, with df(4) (an extension of the Weibull 
model) as this provides standard HRs which are easier to interpret. This choice of model is 
further supported by Figure 2.2.3 where for the DART data the predicted hazard for overall 
mortality is very similar whether I use a proportional hazards (PH), proportional odds or probit-
scaled FPM with 4 df. This figure also demonstrates the poorness of fit for the simple Weibull 
model (df=1) (red dashed line). 
Figure 2.2.3 Predicted hazard rate (per 100 PY) for all-cause mortality 
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Figure 2.2.4 Assessing the fit of PH(4) – all-cause mortality 
 
Figure 2.2.4 shows that a PH(4) FPM (green) is a very good fit to the data and is 
indistinguishable from the Kaplan Meier (blue), in contrast to the Weibull model shown in red 
(AIC 3522.23 vs. 3572.15 for the basic Weibull model). 
2.2.5. Comparing the CD4 monitoring strategies using flexible parametric models 
Covariates can be included in the model either by (i) replacing 0  with βix0  which 
estimates an average (proportional) effect of x on the hazards in the PH model (or equivalent for 
the proportional odds or probit-scaled models) or (ii) by fitting an interaction between covariate 
ix  and one or more of the )ln(t terms (including the spline as defined in section 2.2.4 p49). The 
latter is effectively an interaction model, also equivalent to stratifying the hazard by the covariate 
(fitting a separate hazard over time in each group). For the DART data, I wish to investigate how 
the hazard between the monitoring strategies changes over time, so (ii) is likely to be more 
informative. 
Royston and Parmar [98] discussed how time-dependent effects could be fit by including 
interactions between a covariate and the spline variables in S{ln(t)|y, k0}.  In an old version of 
the STATA command stpm, the dfs for the time-dependent effect had to be the same as for the 
baseline hazard; this tended to lead to over-fitting of the models and certainly of the time-
dependent effects. However, it is now possible with the updated stpm2 command to have a 
different number of df for the baseline hazard and the time-dependent effect (using the dftvc 
option); of note the optimal number of df for the time-dependent effect is, in nearly all situations, 
lower than that for the baseline hazard (dftvc<df). To enable the different number of df for the 
underlying baseline hazard and the time-dependent effect, different sets of spline variables are  
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calculated, one for the baseline hazard rate and one for each of the time-dependent effects 
which tends to produce a smoother model. Default knot locations for time-dependent effects are 
the same as for the baseline hazard knots shown in Table 2.2.2. As before, the model which 
minimises the AIC is preferred. I therefore chose the dftvc for the CD4 monitoring strategy in 
DART and the df for the underlying mortality hazard which jointly minimise the AIC. However, I 
chose to favour parsimony by selecting a less complicated model if the AIC was <3.84 greater 
than the ‘best’ model. I have demonstrated selecting the ‘best’ model when including monitoring 
strategy as a time-dependent effect in Figure 2.2.5 using the PH model. 
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Figure 2.2.5 AICs for the PH model with varying df and dftvc 
a: All df 
 
b: df(4), df(5), df(6) 
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Figure 2.2.5 shows that the model that minimises the AIC has df(5) for the baseline hazard and 
dftvc(5) for the time-dependent effect of monitoring strategy (AIC=3513.787). However, for 
baseline df=4, 5, 6, all but 1 of the different combinations of dftvc are within 3.84 of this 
minimum AIC, meaning that they are statistically similar (Figure 2.2.5b). In addition it has been 
shown previously that, without including monitoring strategy in the model as a covariate, the 
‘best’ df for the baseline hazard is 4df. With 4df, dftvc(0) (i.e. no time-varying effect, proportional 
hazards), dftvc(1), dftvc(2) and dftvc(3) have AIC within 3.84 of the minimum AIC (at 3516.005, 
3516.287, 3517.627 and 3516.693 respectively). Because I want to model the hazards flexibly, 
but not introduce too much noise into estimates I have chosen df(4) with dftvc(3) as this is the 
model with the third lowest AIC for df=4 and is <AIC + 3.84. Although dftvc(0) and dftvc(1) have 
the lowest AICs for df=4, these either assume proportionality or adds an extra linear lnt 
interaction term in the no CD4 monitoring group which are both fairly strong assumptions. The 
closeness of the AIC illustrates the challenges of the FPM model selection. From this model the 
hazard ratio and its 95% CI are calculated for no CD4 vs. CD4 monitoring. Figure 2.2.6 shows 
the difference in hazards between the two monitoring strategies (black line) along with the 95% 
CI, compared to the lowest df=5 AIC model in red.  
Figure 2.2.6 Difference in mortality hazard rate (no CD4 monitoring-CD4 monitoring) per 
100PY 
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2.2.6. Competing risks  
The above sections have focused on a single time to event outcome such as overall mortality. 
However, each cause of death can be considered an outcome in its own right, with a patient 
dying from only one of these causes. Thus each of these causes of death are ‘competing’ to be 
the one cause of death, that is, these causes can therefore be considered as ‘competing risks’ 
in the statistical sense. 
A competing risk is an event that happens prior to the event of interest, and means that one can 
never observe the event of interest. For mortality the different causes of death are the 
competing risks; if a patient died of septicaemia, then they can never die of say TB (or some 
other cause). If T is time to the event and R is the cause of failure, with 1 to K specific causes, 
competing risk analysis is simply finding out about the joint distribution of T and R. There are 
two important measures in competing risks, these are the cause-specific hazard rate and the 
cumulative incidence function (CIF). The cause-specific hazard for cause k, )(thk  gives the 
hazard rate for the immediate risk of death from cause k at time t conditional on not having 
already died of cause k or of any other K-1 causes of death. It is estimated by treating events 
due to competing causes as censored observations. All regression models described in Table 
2.2.1 above can be used to model cause-specific hazards, similarly to overall hazards.  
The CIF is the probability, as a function of time, that a subject dies of that cause in the presence 
of all other possible competing causes. The CIF is defined as: 
 
 



I
i
iik
k
iktSt
kcausefromfailtTPtCIF
1
)()(
|)(

 
where k is the cause, i is the subject, )( ik t  is the cause-specific hazard at the time the ith 
subject died or was censored, )( itS  is the overall probability of survival to time ti and Δik=1 if 
subject i died from cause k. Therefore the CIF is a function of both the cause-specific hazards 
and the overall survival probability. Further, since      iik tt  , the sum of CIFk(t) for 
k=1…..K is the overall survivor function, as estimated from Kaplan-Meier. As t , the 
CIF the probability of observing the event of interest as the first event of all the competing 
risks (e.g. P(die from septicaemia)): as this is <1, the distribution is improper and has a ‘sub-
hazard’. Fine and Gray [101] specify a model for the hazard of the sub-distribution which thinks 
of the hazard as that which generates failure events of interest while keeping individuals who 
experience competing events as “at risk” so that they can be adequately counted as not having 
any chance of failing from this specific cause.  
As an example I have estimated the CIF for TB in the presence of all other causes of death 
using competing risks in Figure 2.2.7. However, as overall mortality and cause-specific death 
rates are low in DART (only 11% died by trial closure), there is relatively little difference 
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between the sub-distribution hazard and the cause-specific hazard in this specific example. 
Whilst this cause-specific hazard can be estimated by artificially censoring deaths/events from 
other causes (as above), one cannot construct a Kaplan-Meier curve as the basis of this cause-
specific hazard [102]. I have chosen to model the cause-specific hazard for each type of death 
separately and all further analyses will be carried out using the cause-specific hazards. 
Figure 2.2.7 Modelling CIF for TB in the presence of other causes 
 
2.2.7. Choosing the best model for the individual causes of death 
The methods described in sections 2.2.4 to 2.2.5 can be applied to a cause-specific hazard 
regression model as well as an overall hazard regression model. As with all-cause mortality I 
could choose the model that minimises the AIC (Table 2.2.3). However, for most individual 
causes there are small numbers of deaths, meaning power to detect important variation in 
hazards is low; that is, even when the fit is very good the AIC may be penalised by the larger 
number of parameters. For causes with ≤13 deaths (and TB) the Weibull (PH model with df=1) 
is the ‘best’ fit to the data according to AIC; however, where there are more events, models with 
greater flexibility are typically chosen, supporting low power being the major determinant behind 
choice of df=1. 
The overall mortality analyses showed that the overall hazard of death is highly non-linear, 
therefore in this chapter where AIC is minimised in the Weibull model I will use instead FPMs 
with either df=3 or df=2 provided the difference in AIC is <3.84 compared with the Weibull model 
(Table 2.2.3).  
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Table 2.2.3 AIC for FPMs (no covariates) for cause-specific mortality with df(1), df(2), df(3) 
and df(4) 
Cause of death Number of deaths 
AIC 
Weibull df=2 df=3 df=4 
All-cause mortality 382 3572.152 3551.908 3528.771 3522.23 
Septicaemia/Neutropenia 44 636.267 618.904 613.992 
Cannot 
compute an 
improvement 
Neurological 38 550.480 538.534 537.826 539.801 
Cryptococcus 32 482.704 477.337 473.033 472.434 
TB 31 443.425 445.205 444.842 445.116 
HIV related malignancy* 26 362.196 361.528 363.385 364.37 
Respiratory event 24 366.136 366.597 365.834 366.579 
GI event 15 235.253 234.719 235.927 
Cannot 
compute an 
improvement 
Trauma/Suicide 13 201.045 202.955 201.602 203.185 
Wasting/diarrhoea 11 186.067 187.032 188.626 188.869 
Renal event 11 168.939 170.137 172.114 174.057 
Cardiovascular disease 10 151.835 153.251 155.098 156.992 
Other† 48 638.531 637.755 639.580 634.032 
Unknown 80 979.391 979.512 979.747 986.758 
*Includes cervical cancer, kaposi’s sarcoma, non-hodgkin’s lymphoma, other B cell lymphoma and central nervous 
(CNS) lymphoma 
†Includes cryptosporidia, liver, anaemia, other cancer, lactic acidosis, herpes simplex virus (HSV) or cytomegalovirus 
(CMV), malaria/cholera, stevens-johnson syndrom (SJS) 
Shading shows models which minimise the AIC: if this is the Weibull model, df=1 (0 knots), second lowest also shaded 
and used in results. 
 
The chosen models are as follows: PH(4) for cryptococcus and other as cause of death (COD); 
PH(3) for septicaemia/neutropenia, neurological, TB, respiratory and trauma/suicide; and PH(2) 
for HIV related malignancy, GI, wasting/diarrhoea, renal and CVD as COD. As with the overall 
mortality I wish to compare the monitoring strategies for each individual COD. I have tried to 
apply the same methods as for the overall mortality, i.e. including monitoring strategy as a time-
dependent covariate, however, due to low event rates in certain causes of death this was not 
possible. For this reason I will return to the Poisson models which still allow some flexibility in 
the model for mortality from individual causes of death to be fitted, but also allow formal 
comparisons between the monitoring strategies to be made, despite the low event rates. 
2.2.8. Additional work on the difference in CD4 monitoring strategies 
In order to estimate how much difference in risk by monitoring strategy could be explained by 
CD4, I have fitted standard time-updated Cox models. I have used Cox rather than FPM to 
avoid problems with instability in the baseline hazards for specific causes. I also used Cox over 
Poisson to allow a more flexible baseline hazard than piecewise exponential and because, 
although CD4 readings were scheduled 12 weekly, small variations in when the CD4 counts 
were taken are easier to accommodate in the Cox model.  
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2.3. Results 
2.3.1. Causes of death in DART 
In the DART trial there were 14,937 person years (PY) of follow-up between January 2003 and 
December 2008 (end of follow-up under CD4 monitoring strategy) with a median of 4.9 years 
follow-up per patient. A total of 382 patients died on or before 31st December 2008. Of these 
303 (79%) had an ascertainable cause of death and 179 (47%) died in the first year on ART. 
Overall mortality was 179/3316 (5%) in the first year on ART and 203/3094 (6%) subsequently. 
This equates to 5.6/100PY in the first year of ART and 1.7/100PY thereafter. So, as might be 
expected, given the severe immunodeficiency at ART initiation in the trial (median CD4 86 
cells/µL), overall mortality was substantially higher in the first year on ART. This was also clear 
in both of the two CD4 monitoring strategies; with 82 deaths (5.2/100PY) in the CD4 monitoring 
group (LCM) and 97 (6.1/100PY) in the no CD4 monitoring group (CDM) in year 1; and 82 
(1.4/100PY) LCM and 121 (2.1/100PY) CDM deaths subsequently (p<0.001 for year 0-≤1 vs. 
year >1 in both LCM and CDM (Table 2.3.1)). 
Table 2.3.1 Deaths by time on ART and monitoring strategy 
  LCM (n=1656) CDM (n=1660) Total 
  0-1 yrs >1 yrs 0-1 yrs >1 yrs LCM CDM 
Total patients  1656 1552 1660 1542 1656 1660 
Deaths All 82 (5%) 82 (5%) 97 (6%) 121 (7%) 164 (10%) 218 (13%) 
Causes        
 HIV 44 39 49 62 83 111 
Drug (not just ART) 7 4 4 6 11 10 
HIV and drug 10 6 14 11 16 25 
Neither HIV or drug 6 15 11 15 21 26 
Unknown relationship 
to HIV/drug 15 18 19 27 33 46 
 
Regardless of time on ART (exact p=0.3) and regardless of CD4 monitoring strategy (exact 
p=0.9), most deaths were judged primarily HIV-related (93/179 (52%) early vs. 101/203 (50%) 
late) or were related to both HIV and drugs (24 (13%) early vs. 17 (8%) late), with few deaths 
judged primarily drug-related (ART/concomitant medication) (11 (6%) early vs. 10 (5%) late). 
Deaths where cause could not be ascertained also occurred similarly in both periods (34 (19%) 
early vs. 45 (22%) late) (Figure 2.3.1). 
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Figure 2.3.1 Deaths by time on ART and monitoring strategy 
 
 
There were a large number of individual causes of death. For patients with more than one 
cause of death, the ERC adjudicated the primary cause (disease/condition directly leading to 
death) separately from the other secondary causes (other disease/conditions leading to the 
primary cause of death). This enabled me to group the deaths into the categories outlined in 
Table 2.3.1. The primary diagnosis was used to determine the cause of death category for 
analysis. Neurological events excluded cryptococcal meningitis as this is presented separately 
under cryptococcal disease. Patients were only classified as dying from 
septicaemia/neutropenia if they had an infection or evidence of a fever in the presence of their 
neutropenia; else they were included with anaemia/thrombocytopenia/pancytopenia/ 
neutropenia. Of note is that most septicaemia/pneumonia/meningitis infections causing death 
had little definitive support for a specific infecting micro-organism (bacteria, virus or fungi) either 
in the text given for the primary cause of death, the structured narrative, any organism data 
associated with concurrent WHO stage 3/4 events or from the microbiology form. This was 
predominantly because microbiological facilities were limited or not available. 
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Table 2.3.2 Detailed cause of death by treatment and time on ART 
Cause of death* LCM  (CD4 monitoring) 
CDM  
(no CD4 monitoring) Total 
 0-≤1 yr >1 yr 0-≤1 yr >1 yr 0-≤1 yr >1 yr 
Septicaemia/Neutropenia 12 (15%) 2 (2%) 20 (21%) 10 (8%) 32 (18%) 12 (6%) 
Neurological event 11 (13%) 6 (7%) 14 (14%) 7 (6%) 25 (14%) 13 (6%) 
Cryptococcus 10 (12%) 3 (4%) 9 (9%) 10 (8%) 19 (11%) 13 (6%) 
Tuberculosis (TB) 4 (5%) 3 (4%) 8 (8%) 16 (13%) 12 (7%) 19 (9%) 
HIV-related malignancy 3 (4%) 16 (20%) 3 (3%) 4 (3%) 6 (3%) 20 (10%) 
Respiratory event 7 (9%) 3 (4%) 6 (6%) 8 (7%) 13 (7%) 11 (5%) 
Gastro-intestinal (GI) event 3 (4%) 5 (6%) 4 (4%) 3 (3%) 7 (4%) 8 (4%) 
Trauma/Suicide 3 (4%) 4 (5%) 2 (2%) 4 (3%) 5 (3%) 8 (4%) 
Wasting/Diarrhoea 2 (2%) 1 (1%) 3 (3%) 5 (4%) 5 (3%) 6 (3%) 
Renal 0 (0%) 2 (2%) 2 (2%) 7 (6%) 2 (1%) 9 (4%) 
Cardio-vascular disease 
(CVD) 0 (0%) 3 (4%) 1 (1%) 6 (5%) 1 (1%) 9 (4%) 
Hepatic 4 (5%) 2 (2%) 0 (0%) 3 (3%) 4 (2%) 5 (3%) 
Cryptosporidia 3 (4%) 1 (1%) 1 (1%) 2 (2%) 3 (2%) 4 (2%) 
Anae/Pan/Thromb/Neut† 2 (2%) 2 (2%) 1 (1%) 2 (2%) 4 (2%) 3 (2%) 
Other cancer 1 (1%) 2 (2%) 1 (1%) 3 (3%) 2 (1%) 5 (3%) 
Lactic acidosis 1 (1%) 3 (4%) 0 (0%) 2 (2%) 1 (1%) 5 (3%) 
HSV/CMV‡ 1 (1%) 0 (0%) 3 (3%) 1 (1%) 4 (2%) 1 (1%) 
Malaria/Cholera 0 (0%) 2 (2%) 2 (2%) 1 (1%) 2 (1%) 3 (2%) 
Stevens-Johnson-Syndrome 
(SJS) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (1%) 
Unknown primary cause 14 (17%) 21 (26%) 17 (18%) 27 (22%) 31 (17%) 48 (24%) 
Total 82 82  97 121 179 203 
*Ordered by total number of deaths 
†Anaemia/Pancytopenia/Thrombocytopenia/Neutropenia with no sign of fever 
‡ Herpes simplex virus (HSV)/Cytomegalovirus (CMV) 
 
Of the 179 deaths in the first year on ART, the most common causes were 
septicaemia/neutropenia 32 (18%), non-cryptococcal neurological events 25 (14%), 
cryptococcus 19 (11%), respiratory events 13 (7%), and TB 12 (7%). Whilst these causes of 
death remained amongst the most common after >1 year on ART, accounting for 12 (6%), 13 
(6%), 13 (6%), 11 (5%) and 19 (9%) deaths respectively; their cause-specific incidence (i.e. 
absolute risk of dying from this specific cause) dropped significantly from 0-≤1 vs. >1 years on 
ART (septicaemia/neutropenia, non-cryptococcal neurological events, cryptococcus all 
p<0.0001; respiratory events p=0.001 and TB p=0.02) (Figure 2.3.2). Mortality also dropped 
significantly for cryptosporidia (p=0.04), GI events and HSV/CMV (both p=0.02). There was 
some evidence to suggest rates of death from wasting/diarrhoea also declined (p=0.06); and for 
hepatic deaths, trauma/suicide and malaria/cholera and anaemia/pancytopenia/ 
thrombocytopenia/neutropenia with no sign of fever there was marginal evidence of a decline 
(p=0.11, p=0.14, p=0.14 and p=0.18 respectively). There was no evidence of a decline in 
cause-specific mortality for lactic acidosis (p=0.79), renal deaths (p=0.80), SJS (p=0.35), CVD 
(p=0.40), and other cancer (p=0.64). Of note, HIV-related malignancy was the most common 
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cause of death after >1 year on ART, responsible for 20 (10%) deaths, and rates were similar 
from 0-≤1 year to >1 year (p=0.9) (Figure 2.3.2). Although 17% of deaths 0-≤1 year and 24% of 
deaths >1 year could not have the primary cause of death assigned, rates of death from an 
unknown primary cause also dropped albeit with only marginal significance (p=0.14). 
Figure 2.3.2 Cause-specific death rates by CD4 monitoring strategy and time on ART 
 
 
Due to there being a large number of causes of death and with some causes only having a few 
events I have selected the causes of death with ≥10 events to investigate further. There were 
just eleven causes included in these further analyses (septicaemia/neutropenia, neurological 
event, cryptococcus, TB, HIV-related malignancy, respiratory event, GI event, trauma/suicide, 
wasting/diarrhoea, renal and CVD). By using Poisson models I have been able to assess the 
change in risk of death from 0-≤1 year to >1 year and to assess whether this differs between 
CD4 monitoring strategies for this subset of causes (Figure 2.3.3). 
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Figure 2.3.3 Risk ratios (RR) for late vs. early deaths by CD4 monitoring strategy 
 
Note: p-values show the heterogeneity tests for whether the change in risk of dying from each specific cause >1 vs. 0-
≤1 on ART is the same (or different) according to CD4 monitoring strategy 
Renal and CVD events are only included for CDM as there were no events in the LCM group for 0-≤1year, so the full 
interaction model cannot be fitted. 
 
There was marginal evidence that the declines in cause-specific death rates from 0-≤1 to >1 
years on ART varied between CD4 vs. no-CD4 monitoring strategies (Figure 2.3.3) for 
cryptococcus (p=0.10), respiratory events (p=0.14), HIV-related-malignancies (p=0.15) and 
septicaemia/neutropenia (p=0.16). For cryptococcus, respiratory events and 
septicaemia/neutropenia, declines in cause-specific mortality appeared greater in those 
receiving CD4 monitoring. 
Of note, the relative risk (RR) of death from HIV-related malignancies was estimated to slightly 
increase after the first year on ART for the CD4 monitoring group, compared to a small 
decrease in the no CD4 monitoring group, although this observed increase in LCM was not 
statistically significant (p=0.57). This trend of a smaller reduction in risk in the CD4 monitoring 
group vs. no CD4 monitoring group was in the opposite direction to that observed for all other 
causes except GI events which also did not reach statistical significance (p=0.46). HIV-related-
malignancies leading to death after 1 year on ART were cervical cancer (n=9), lymphoma (n=5) 
and Kaposi’s sarcoma (n=6) in the CD4 monitoring group; and lymphoma (n=3) and Kaposi’s 
sarcoma (n=3) for the no CD4 monitoring group.  
Most follow-up (11,623PY) was >1 year from ART initiation: given the overall mortality (see 
methods section 2.2.4) and the fact that CD4 monitoring might be expected to have little effect 
during the first year on ART (when WHO guidelines recommend not switching for CD4 failure) I 
66 
 
also compared long-term impact of CD4 vs. no CD4 monitoring restricting to those who survived 
1 year (Figure 2.3.4).  
Figure 2.3.4 Cause-specific RR (+ 95% CI) for no CD4 monitoring vs. CD4 monitoring after 
1 year on ART 
  
There is strong evidence to suggest that after 1 year of ART, CD4 monitoring reduced the risk 
of death for TB (p=0.007), with a pronounced almost 6 fold (RR (95% CI) 5.45 (1.59-18.7)) 
increase in the risk of death from TB for those patients not receiving CD4 monitoring. Overall 
after 1 year on ART there were 3 vs. 16 TB-related deaths in those with CD4 vs. no CD4 
monitoring respectively; and interestingly, after 2 years on ART there were 1 vs. 12 TB-related 
deaths. There is also good evidence that the absolute risk of dying from 
septicaemia/neutropenia was higher in the no CD4 monitoring group than in the CD4 monitoring 
group (p=0.04) after 1 year on ART, and there is a similar but weaker (p=0.06) effect for 
cryptococcus. There was marginal evidence that after 1 year on ART, the risk of death from 
wasting/diarrhoea, respiratory events (both p=0.14) and renal events (p=0.11) was higher in the 
no CD4 monitoring group. However, for HIV related malignancies the no CD4 monitoring group 
had a lower risk of death after 1 year on ART, reflecting the results above (p=0.02). For all other 
events there was no evidence of a difference in risk by CD4 monitoring strategy after 1 year on 
ART.  
2.3.2. Cause-specific hazards of death in DART 
Although simple piecewise exponential (PE) models fitted above give some insight into cause-
specific mortality risks (represented as red lines on Figure 2.3.5), and also by monitoring 
strategy, clearly an abrupt change in risk exactly 1 year after ART initiation is biologically 
implausible.  
The Cox model can only compare CDM vs. LCM, it cannot compare late vs. early hazards 
directly as these are not directly estimated. Therefore cause-specific hazards of death for 
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individual causes with ≥10 deaths have been estimated using flexible parametric models as 
described in section 2.2.4.  
Figure 2.3.5 Cause-specific hazards of death over years on ART (CDM and LCM 
combined) 
 
Most causes of death had their highest hazard of death in the first 12 months after ART initiation 
except CVD (ignoring the implausible early time given that the first death was at 75d) and renal 
events (Figure 2.3.5). For septicaemia/neutropenia, neurological, cryptococcal and respiratory 
causes, cause-specific hazards increased from 0 at time t=0 to a maximum at days 25-37, 
probably because acutely sick patients were ineligible and all enrolled participants had to give 
consent at day 0 (i.e. could not be moribund). For HIV related malignancies the hazard 
increased more gradually from 0 at t=0 to a maximum hazard at 11 months, similarly for GI 
events at 5 months and for trauma/suicide at 6 months. In contrast the risk of dying from TB or 
wasting/diarrhoea was greatest at ART initiation. These initial changes in hazard appear to be 
very influenced by the timing of early events (the times of the first 3 events are displayed on 
Figure 2.3.5). Looking at the most common causes of death, those with earlier deaths (e.g. 
septicaemia/neutropenia at 9 days) show an increase in hazard from t=0 – whereas only slightly 
later deaths lead to a hazard greatest at t=0 then declining. 
The risk of death from these causes with the highest early risks then declined rapidly to 1 year 
and stayed low. In contrast, the hazard of death from HIV-related malignancies and GI events 
declined more steadily out to 6 years. Trauma/suicide had a decline in hazard to 2 years, but 
then there was a steady increase in hazard which appeared to still be increasing at 6 years.  
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The risk of dying from renal events increased steadily for the first year on ART and continued to 
increase until 18 months when it then remained approximately constant. The risk of dying from 
CVD was very low during the first year and then appeared to increase throughout follow-up; 
although as seen in Figure 2.3.2 the cause-specific event rate for CVD deaths was very low.  
I investigated the individual cause-specific hazards by monitoring strategy (Figure 2.3.6) but 
estimates were unreliable due to small numbers, particularly with respect to initial hazard 
trajectories, which appear to depend strongly on timing of first events as above. 
 
Figure 2.3.6 Cause-specific hazards of death during time on ART by CD4 monitoring strategy 
 
In general the trajectories are similar between CD4 and no CD4 monitoring strategies for all 
causes of death with a higher hazard in the first year than subsequently (apart from CVD and 
renal). Because of the nature of the interventions I should note that any estimated early 
differences in cause-specific hazards are unlikely to reflect true differences between the arms; 
there was no difference in CD4 monitoring received before 12 weeks, and the main purpose of 
CD4 monitoring is to identify first-line failure and trigger a switch to second-line, which is not 
recommended by WHO until after 1 year on ART. Thus instability in the hazard estimates close 
to ART initiation is very likely due to the small number of events and their timing. 
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Results broadly followed the crude piecewise exponential analysis shown in Figures 2.3.3 and 
2.3.4. The hazard of death from septicaemia/neutropenia, cryptococcus and TB appeared to be 
higher after 1 year on ART for the no CD4 monitoring group, but absolute differences were 
small. The hazard of death from HIV-related malignancy also appeared greater in the CD4 
monitoring group throughout, although absolute differences were small (Figure 2.3.2). The 
hazard of death from CVD appeared to be greater early on in the no CD4 monitoring group, but 
as with the overall hazard this may be dependent on the very early death seen in this group and 
the very late deaths seen in the CD4 monitoring group. Trauma/suicide, CVD and renal events 
were the only causes where the hazard increased in one or both of the groups. In order to 
assess long term differences formally I tried to fit FPMs for after 1 year on ART, but there were 
too few events for models to converge. I successfully investigated the same model for all deaths 
to increase the number of events. The model that minimised the AIC for overall deaths after 1 
year on ART had df(3) and dftvc(4) (Figure 2.3.7), but the hazards showed substantial instability 
and over-fitting. As above, any early differences appear to be due to the models being very 
sensitive to when the first event occurred, even after 1 year on ART.  
Figure 2.3.7 Hazard of death 1 year after ART initiation, LCM vs. CDM for all deaths 
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Figure 2.3.8 Difference in hazard rate (CDM-LCM) per 100 PY for overall mortality from 1 
year after ART initiation 
 
This model (Figures 2.3.7 and 2.3.8) suggests that the two monitoring strategies appear to be 
converging as time approaches 6 years, i.e. that there might be no long term difference in 
mortality under the different CD4 monitoring strategies.  
As outlined in section 2.2.5 of the methods, any difference in hazards between the monitoring 
strategies has been assessed using a FPM for overall mortality including year one. I have re-
displayed the difference in the overall mortality hazard rates (CDM-LCM) per 100 PY (including 
year one) along with the 95% confidence intervals in Figure 2.3.9. As I have seen in some of the 
individual causes of death, whilst there is a small difference very early on after ART initiation 
this is not statistically significant and the CIs are very wide. A significant excess in mortality rate 
in the no CD4 monitoring group appeared from 18-24 months and increased until around 3 
years when the excess in mortality rate for the no CD4 monitoring group was between 0.87 and 
0.95 deaths per 100PY compared to the CD4 monitoring group. This then appears to remain 
constant throughout longer term follow-up, in contrast to Figure 2.3.8 above. 
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Figure 2.3.9 Difference in hazard rate (CDM-LCM) per 100PY overall mortality 
 
The difference in conclusions drawn about long term effects of CD4 monitoring in Figures 2.3.8 
and 2.3.9 is therefore a consequence of the choice of model. In Figure 2.2.6 in methods, df(5) 
dftvc(5) for overall mortality suggested smaller differences long term than df(4) dftvc(3) in Figure 
2.3.9. Thus numbers are too small to reliably refute or support long-term differences; what is 
clear is that any differences that exist are small. 
2.3.3. Role of CD4 count in explaining mortality differences between CD4 monitoring 
groups 
CD4 count is one of the major determinants of mortality risk. In high-income countries, the 
association between the risk of specific COD and CD4 varies [103, 104], but to date this has not 
been described in low-income countries. I therefore investigated first whether there was any 
variation in CD4 count at death by cause and second whether there was any relationship 
between time-updated CD4 count and mortality (overall and by cause). 
Firstly I looked at the latest CD4 count near to the time of death; the median CD4 counts for the 
11 individual causes of death can be seen in Figure 2.3.10. Overall, CD4 counts were taken a 
median of 48 (IQR 26-58, range 0-1085) days before death. There were 70 deaths where the 
CD4 count was >6 months prior to death and these have been excluded from below. 
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Figure 2.3.10 Median latest CD4 count at the time of death by cause 
 
Overall, CD4 at death was higher for late vs. early deaths (136 cells/μL, IQR 36-293 vs. 66 
cells/μL IQR 19-128, p<0.001). This pattern is the same for many of the individual causes but 
the power is too low to detect reliably (p≥0.1 in most cases).  
Median CD4 count (cells/µL) was particularly low with very little difference between early vs. late 
mortality at deaths from septicaemia/neutropenia (0-≤1 years 54; >1 year 85, p=0.39), 
cryptococcus (0-≤1 year 33; >1 year 26, p=0.94) and wasting/diarrhoea (0-≤1 year 19; >1 year 
51, p=0.36). Low CD4 at early deaths for these causes of death might be expected as these are 
the causes with the earliest peak in cause-specific hazard, so deaths are closer to ART 
initiation, before CD4 could rise and when patients who are sickest may be overrepresented. 
However the low median CD4 counts for both early vs. late deaths suggests it is sick and/or 
failing first-line treatment patients who are dying all the way through the trial and not just at ART 
initiation. There was also little difference between early vs. late in terms of CD4 count at deaths 
from TB, HIV-related malignancy and renal events (all p>0.2); however, CD4 counts were 
slightly higher at HIV-related malignancy deaths than for other causes. 
There may be some difference in CD4 counts at deaths from trauma/suicide with a relatively 
high CD4 count after >1 year on ART. However, this difference is also not significant (p=0.24), 
possibly due to low numbers of events. For CVD there is a high CD4 count at the time of death 
for those patients dying >1 year after ART initiation (median 367, IQR 280-380), suggesting this 
is perhaps not related to immunodeficiency but perhaps a long term effect of ART. As in Table 
2.3.2 there is only one death from CVD 0-≤1 years after ART initiation; this patient had a CD4 
count of 6 cells/µL at ART initiation and no post baseline counts, so it is difficult to compare the 
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two treatment periods. Deaths from trauma/suicide and GI events both have median CD4>200 
cells/L >1 year after ART initiation, perhaps suggesting a less strong association with 
immunodeficiency.  
Thus there is some evidence of variation across the different causes in CD4 counts at death. 
However, this has not assessed the effect of CD4 on those at risk who could, in theory, have 
had even lower CD4s. To do this I have fitted time-dependent Cox models with interactions 
between CD4 monitoring group and log2(CD4). The log transformation has been chosen based 
on a standard fractional polynomial. 
 
Figure 2.3.11 Cause-specific HRs and 95%CIs for the relationship between specific 
causes of death and latest CD4 
 
For nearly all causes of death there is a significant decrease in the hazard of death with an 
increase in CD4 count. Figure 2.3.11 shows that for all-cause mortality a doubling of CD4 count 
decreases the hazard of death by 51% in the LCM group and 44% in the CDM group. There is 
strong evidence of an interaction between CD4 and monitoring strategy (p=0.001) in all-cause 
mortality with slightly more benefit seen from higher CD4 counts in the LCM group. A similar 
effect was seen for TB where there was good evidence (p=0.025) of an interaction between 
CD4 and monitoring strategy with greater benefit seen from higher CD4 counts in the LCM 
group than the CDM group.  
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As the CD4 monitoring group is the group whose CD4 counts are monitored by the clinicians, 
this is probably because clinicians modified management to reduce mortality risk on the basis of 
CD4 counts e.g. by switching to second-line treatment at low CD4 or remaining on first-line at 
high CD4. This greater benefit of increasing CD4 count in the CD4 vs. no CD4 monitoring group 
is seen in nearly all other causes of death (other than CVD and trauma/suicide), however due to 
the small numbers of events in the individual causes of death these differences do not reach 
statistical significance. There is no evidence of an effect of CD4 on CVD in the LCM group, 
probably attributed to the fact that there is only 1 death in this group that happens very early on 
after ART initiation; this is represented by the wide confidence interval.  
2.3.4. Time dependent effect of CD4 counts after >1 year on ART in DART 
Again as there is no real difference in management between the monitoring strategies up to 1 
year after ART initiation, I have looked at the impact of time-dependent CD4 on mortality from 1 
year after ART initiation onwards. log2CD4 has been chosen as the transformation to model as 
it is a better fit than the linear CD4 model based on AIC. Figure 2.3.12 shows the HRs 
comparing LCM vs. CDM for first the main effect (as in Figure 2.3.4), then adding CD4 as a 
time-dependent effect and then finally a transformation of CD4 as time-dependent effect.  
Figure 2.3.12 Time-dependent effect of CD4 on CDM vs. LCM from 1 year after ART 
initiation 
 
After 1 year on ART there is a significant benefit in the LCM group in terms of all-cause mortality 
(HR (95%CI)=1.50 (1.14-2.00), p=0.004). Adjusting for time-dependent CD4 (using a log2 
transformation) completely removes the treatment effect, HR 0.97 (0.72-1.31). This therefore 
suggests that the long term differences overall between LCM and CDM are completely 
explained by differences in the CD4 count. In fact for all causes of death there is a reduction in 
the benefit of LCM when adjusting for log2CD4; however for individual causes, these reductions  
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are small and do not explain much of the overall difference by CD4 monitoring strategies.  
2.3.5. ARROW causes of death 
Similar analyses have been carried out in the ARROW trial [58]; however due to the low number 
of deaths seen in the ARROW trial I have only been able to investigate all deaths and not 
individual causes. 
In the ARROW trial there were 4685 child years (CY) of follow-up between 15th March 2007 and 
16th March 2012 (planned trial closure) with a median follow-up of 4 years. A total of 54 patients 
died on or before 16th March 2012. Overall mortality was 40/1206 (3%) in the first year on ART 
and 14/1157 (1%) subsequently. This equates to 3.4/100CY in the first year of ART and 
0.4/100CY thereafter, that is, substantially higher overall mortality in the first year on ART as 
seen in the DART trial. This was also clear in both the monitoring strategies; with 27 deaths 
(4.7/100CY) in the CD4 monitoring group (LCM) and 13 (2.2/100CY) in the no CD4 monitoring 
group (CDM) in year 1; and 2 (0.1/100CY) LCM and 12 (0.7/100CY) CDM deaths subsequently 
(for year 0-≤1 vs. year>1 p=0.002 in LCM and p=0.003 in CDM respectively) (Table 2.3.3). 
Table 2.3.3 Deaths by time on ART and monitoring strategy (ARROW) 
  LCM (n=600) CDM (n=606) Total 
  0-1 yrs >1 yrs 0-1 yrs >1 yrs LCM CDM 
Total patients  600 569 606 588 1206 1157 
Deaths All 27 (5%) 2 (<1%) 13 (2%) 12 (2%) 29 (2%) 25 (2%) 
Cause        
 HIV 22 1 9 10 23 19 
Drug (not just ART) 1 0 1 0 1 1 
 HIV and drug 2 0 0 0 2 0 
Neither HIV or drug 1 0 1 0 1 1 
Unknown relationship to 
HIV/drug 1 1 2 2 2 4 
 
As in DART, regardless of time on ART (exact p=0.5) and regardless of CD4 monitoring 
strategy (p=0.7), the majority of deaths were judged primarily HIV related (31/40 (78%) early vs. 
11/14 (79%) late). Very few deaths were judged primarily related to drug (2 early vs. 0 late). 
There were only 6 deaths where cause of death could not be ascertained (Figure 2.3.13).  
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Figure 2.3.13 Deaths by time on ART and monitoring strategy in ARROW 
 
Due to the low numbers of deaths in the trial overall I have simply looked at the individual 
causes of death in an exploratory manner. The individual causes of death are outlined in Table 
2.3.4. Of the 40 deaths that occurred in the first year the most common cause of death was 
septicaemia/neutropenia (13 (33%) deaths) followed by respiratory events (11 (28%) deaths). 
This is slightly different to that of the DART trial where respiratory events were a less common 
cause at only 7% in the first year, but likely reflects the importance of pneumonia as a key 
infection in childhood. In ARROW respiratory events became the major cause of death after 1 
year on ART (5 deaths, 36%); however wasting/diarrhoea was a more common cause of death 
than septicaemia/neutropenia after 1 year on ART (3, 21% vs. 1, 7% deaths respectively).  
Table 2.3.4 Detailed cause of death by monitoring strategy and time on ART (ARROW) 
 CDM LCM Total 
Cause of death * 0-≤1 yrs >1 yrs 0-≤1 yrs >1 yrs 0-≤1 yrs >1 yrs 
Respiratory event 4 (31%) 3 (25%) 7 (26%) 2 (100%) 11 (28%) 5 (36%) 
Septicaemia/Neutropenia 4 (31%) 1 (8%) 9 (33%) 0 (0%) 13 (33%) 1 (7%) 
Wasting/Diarrhoea 0 (0%) 3 (25%) 3 (11%) 0 (0%) 3 (8%) 3 (21%) 
Neurological event 2 (15%) 0 (0) 3 (11%) 0 (0%) 5 (13%) 0 (0%) 
Unknown 2 (15%) 1 (8%) 2 (7%) 0 (0%) 4 (10%) 1 (7%) 
Tuberculosis (TB) 0 (0%) 2 (17%) 0 (0) 0 (0%) 0 (0%) 2 (14%) 
Cardio-vascular disease 
(CVD) 0 (0%) 1 (8%) 1 (4%) 0 (0%) 1 (3%) 1 (7%) 
Anae/Pan/Thromb/Neut† 0 (0%) 0 (0) 1 (4%) 0 (0%) 1 (3%) 0 (0%) 
HIV-related malignancy 0 (0%) 1 (8%) 0 (0) 0 (0%) 0 (0%) 1 (7%) 
Trauma/Suicide 1 (8%) 0 (0) 0 (0%) 0 (0%) 1 (3%) 0 (0%) 
Malaria/Cholera 0 (0%) 0 (0) 1 (4%) 0 (0%) 1 (3%) 0 (0%) 
Total 13 12 27 2 40 14 
*Ordered by total number of deaths 
†Anaemia/Pancytopenia/Thrombocytopenia/Neutropenia with no sign of fever 
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2.3.6. Modelling the hazard of death in ARROW 
As in the DART trial, I used flexible parametric models to estimate the overall mortality risk in 
the ARROW trial. I have used the same methods as outlined in section 2.2.4 and have started 
by assessing which model will be the ‘best’ fit to the data. Figure 2.3.14 shows the AICs for all 
the different models that could be used. 
Figure 2.3.14 AICs for PH, proportional odds and probit-scaled models with various dfs 
for overall mortality 
 
 
This shows that the best fit to the data (the model that minimises AIC) is the probit scaled model 
with 5 df; however as in DART I have chosen the hazard model for ease of understanding for 
clinicians. Selecting the most parsimonious PH model, within 3.84 units of the lowest AIC, the 
chosen model is therefore the hazard model with 3 df (PH(3)). However, this overall model 
ignores a major imbalance in year 1 deaths (27 LCM vs. 13 CDM) which can only be due to 
chance as management was essentially the same during the first year. In contrast, post-one-
year there were 12 deaths in CDM vs. 2 deaths in LCM, i.e. substantial crossing of hazards, and 
so a simple model including only a proportionate effect of CDM vs. LCM in ARROW will average 
out these two effects and not be meaningful.  
As in DART I therefore need to use the model where I can give a different number of degrees of 
freedom for the baseline hazard and a time-dependent effect of monitoring strategy. I assessed 
the best model to fit for the time-dependent effect using stpm2 and have fitted different dftvcs 
and assessed the fit using the AIC. Figure 2.3.15 shows the AICs for the different models when 
including monitoring strategy as a time-dependent effect using the PH model.  
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Figure 2.3.15 AICs for the PH model with varying df and dftvc (ARROW) 
a: All df 
 
 
b:df(3), df(4), df(5) 
 
The model that minimises the AIC is with df(3) for the baseline hazard and dftvc(1) for the time-
dependent effect of monitoring strategy (AIC=612.5839) and I have chosen to use this model. 
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Figure 2.3.16 Predicted hazard rate (per 100PY) for all-cause mortality in ARROW by 
monitoring strategy 
 
As seen in the DART trial, there is a peak in hazard during the first few months of time on ART. 
As in DART it is likely that the timing of this specific peak is due to the sensitivity of the models 
to when the first deaths occurred, but that it genuinely reflects initial higher mortality risks shortly 
after starting ART. This model also shows that this peak in hazard is in fact greater in the LCM 
arm early on but that the longer term hazard is reduced for LCM. As in DART there is no 
difference in the monitoring strategies between LCM and CDM before 12 weeks and little 
difference over the first 12 months as switch to second-line was discouraged before then: 
therefore this early difference seen in Figure 2.3.16 is likely to be by chance. 
Figure 2.3.17 Difference in hazard rate (CDM-LCM) per 100PY for overall mortality in 
ARROW 
 
The conclusion here is similar to that in DART. Any long term effects of CD4 monitoring that 
exist are small (estimated difference in hazard rate per 100PY at 5 years in ARROW is 0.35 
(95% CI 0.04-0.66) compared to 0.94 (95% CI 0.35-1.53) in DART). 
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2.4 Discussion 
In this analysis I have assessed how the overall hazard of death and the hazard of death for 
specific causes changes over time from ART initiation. The work in this chapter extends the 
understanding of changes in mortality risk on ART in low/middle-income countries. A meta-
analysis by Gupta et al. [94] found 14 studies (11 in low-income countries which are included in 
my review above [71, 76, 77, 80, 82, 84, 85, 87, 89-91] and 3 in high-income countries [105-
107]) that reported cause-specific mortality up to one year after ART. They found that TB (5-
44%), wasting (5-53%), advanced HIV (20-37%) and chronic diarrhoea (10-25%) were the most 
common causes of death with sub-Saharan Africa reporting the highest all-cause mortality at 12 
months. However, this meta-analysis did not look at deaths beyond one year so did not look for 
changes in mortality risk over time. Similar to the studies in this meta-analysis, I also found TB 
to be one of the most common causes of death in the first year after initiating ART, however 
wasting and diarrhoea were not so common causes of death in DART. In contrast to this, 
Grinsztejn et al. [72] found that in Baltimore (a high income country) the most common causes 
of death were non-AIDS defining illnesses and no death occurred because of TB.  
Most studies that have investigated rates of death over time have looked in specific time 
intervals, using Poisson regression [83, 104] and have not considered causes of death. A few 
studies have investigated the change in hazard over time in overall mortality using smoothing 
non-parametric hazard estimates from Cox regression [71, 72, 74, 93, 94] or Weibull piecewise 
models [79, 92, 108]. In contrast to the relatively strong assumptions of e.g. parametric Weibull 
models, the method I have used here, FPMs, is a much more flexible approach which allows for 
the continuous changing hazard without over fitting change points to the specific data. 
Mortality rates 
I started by looking at the simple distribution of deaths over time on ART and from different 
causes. In DART about half (47%) of the deaths occurred in the first year after ART initiation 
similar to the studies identified in my literature review. For example, Etard et al. [71] showed that 
51% of all deaths occurred in the first 12 months after ART initiation in a Senegalese cohort. 
Mzileni et al. [80] reported that 95% of deaths occurred in the first year which is considerably 
higher than that seen in DART or by Etard et al. This could be attributed to the fact that 91% of 
patients in this study had a CD4 count <200 cells/μL at baseline: but then so did DART (all were 
<200 cells/µL) and the median CD4 at baseline for Etard was 128 cells/µL. This difference is 
more likely because the follow-up for the Mzileni study was only 30 months, therefore 
proportionately more deaths will be in the first year. Most of the studies in my literature search 
reported the percentage of deaths in the first 3 months rather than the first year, all of which 
were higher than DART at around 65-80% of deaths occurring in the first 3 months. It is difficult 
to compare proportions of deaths which occurred in different time intervals since these will 
depend on the duration of follow-up which varied considerably across studies.  
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As outlined in the introduction to this chapter, Braitstein et al. [92] showed that mortality rates 
within the first months following ART initiation were higher in sub-Saharan Africa than in 
industrialised countries (6.4% vs. 1.8% at year 1). As seen in DART they also showed that the 
mortality rates in low-income countries fell within the first few months and also found that by 
around 4-6 months, mortality rates approached those seen in high income countries. They 
suggested that despite the more advanced immunodeficiency seen in low-income countries, the 
immunological response to ART is similar in both low and high income countries. Grinsztejn et 
al. [72] compared the early mortality pattern and causes of death among patients starting 
HAART in Brazil and the US; they showed that the decreasing trend in mortality rates that 
occurs in low-income countries was not present to the same degree in high-income countries, 
although there was still a decrease in mortality. It is likely that the lower mortality rates seen in 
higher income countries are due to the higher baseline CD4 counts and how accessible 
antiretroviral treatment is. Any lower mortality rates seen in low-income countries are likely due 
to those low-income countries that take part in trials (where treatment and care are more 
accessible), as generally, lower income countries have higher mortality rates, as noted by Moh 
et al. [78].  
Figure 2.4.1 shows that overall mortality changes in DART were consistent with 7 studies of a 
similar sample size identified by my literature search. Long term rates differed across all studies 
although they were still declining over time and were lower after 1 year of ART as in DART. 
Early and long term rates were highest in Hoffman [93], but early (0-3 month) mortality rates 
were high and relatively similar for all other studies (Amuron [70], MacPherson [76], Kouanda 
[74], Moore [79], Lawn [75] and Marazzi [77]). Rates were lower for DART (11.0/100PYs) which 
may be due to the trial setting. In Uganda, Amuron et al. had baseline CD4 counts of 108 
cells/µL and in South Africa MacPherson had baseline CD4 counts more similar to that in DART 
of just 93 cells/µL so I would expect mortality rates to be similar to those in DART if not better. 
In Burkina Faso, Kouanda et al had a median baseline CD4 of 124 cells/µL which is higher than 
in DART, as are the baseline CD4 counts in South Africa for Hoffman et al. who had a median 
baseline CD4 of 127 cells/µL. You might expect mortality rates to be lower in DART than in 
these examples because of the lower baseline CD4 counts in DART, however I think due to the 
trial setting this is not the case. 
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Figure 2.4.1 Changing mortality rates per 100PY during time on ART in low/middle-
income limited countries (including DART for comparison)*  
                    
*Example of 7 studies shown for illustration and DART for comparison. These studies were chosen as they gave actual 
details of individual rates over time and had a similar sample size to that of the DART trial. 
 
Mortality rates in Amuron et al. [70] and MacPherson et al. [76] may be higher than some of the 
other studies as there was active tracing of those lost to follow-up in these studies resulting in 
better ascertainment of deaths. Similarly, in Hoffman et al [93], the higher rates might be due to 
better ascertainment of deaths through the linkage to the vital statistics registry. However in 
DART, mortality ascertainment was near complete so this seems unlikely to explain their higher 
death rates compared to DART despite similar or higher pre-ART CD4s. Loss to follow-up 
without confirming death could inflate survival estimates, and reduce mortality estimates in 
cohorts compared to a trial, the opposite effect to that seen here. Assuming all those lost to 
follow-up were deaths could potentially make mortality look higher than it actually is. However, 
this approach puts a maximum band on the greatest possible mortality.  
 
 
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60
Time from ART initiation (months)
Amuron et al. [70]
N=1453
Kouanda et al. [74]
N=5608
Hoffmann et al. [93]
N=16356
Moore et al. [79]
N=1132
Lawn et al. [75]
N=2423
Marazzi et al. [77]
N=3456
DART Trial [54]
N=3316
MacPherson et al. [76]
N=1353
1.7
5.6
16.4
2.7 1.6 1.3
16.3
4.4
2.6
0.7 0.4N
ot
 r
ep
or
te
d
15.9
6.3
3.4 2.5 1.2 0.3
34.0
12.0
6.3
3.9 3.3
19.5
7.5
2.9
18.0
11.5 9.0 8.0
16.5
6.7
3.0 1.3 2.4
 83 
 
Differences in monitoring could be another explanation for differences in absolute mortality rates 
between these studies; however, in most studies, monitoring seemed to be regular and included 
CD4 and viral loads rather than just clinical monitoring so this is an unlikely reason for higher 
mortality rates compared to DART. One possible question is whether the monitoring was regular 
enough? Hoffman et al [93] monitored patients using CD4 and HIV RNA at baseline, after 6 
weeks on ART and then 6 monthly thereafter. In DART patients were monitored every 12 weeks 
and were also reviewed by a nurse every 4 weeks – this more regular clinical monitoring might 
have reduced the mortality rate in the trial. In DART clinical monitoring without CD4s was 
inferior to CD4 monitoring in terms of mortality so less regular monitoring could potentially 
increase mortality rates, although this would be expected to have a greater impact after 1 year 
on ART, not early after starting treatment. Some recent work by the DART team [109] suggests 
that 12-weekly and 24-weekly CD4 monitoring have similar mortality outcomes, so probably the 
different frequency of measurement is also not a major driver for mortality differences between 
these other studies and DART. 
In contrast other studies such as Moh et al [78] had very low mortality rates likely due to the 
higher baseline CD4 counts of 252 cells/µL, and may have underestimated mortality due to 
there being no active search for patients lost to follow-up. However, their long term rates are 
very similar to those in DART. 
Another question is whether baseline factors other than CD4 differed enough to lead to 
differences in mortality between DART and these other studies. Hoffman et al. showed 
associations between pre-ART characteristics and long-term mortality for higher WHO stage, 
lower CD4 count, higher HIV RNA and TB symptoms. However, baseline characteristics would 
be expected to provide less information the further from baseline deaths occur. Supporting this 
lesser impact of baseline cofactors on long-term risk, in rural Uganda Moore et al. [79] found 
that baseline CD4 cell counts and WHO clinical staging were less predictive of late mortality 
adjusting for time-updated CD4. 
One other important aspect may be that diagnostic tests, second-line ART, hospitalisations and 
concomitant medications were all available and provided free of charge in DART, whereas 
patients typically bear the cost of these themselves in other studies. Free access may therefore 
have lowered mortality rates in DART compared to other studies. 
Mortality rates in children appear to be similar to those in adults with there being high early 
mortality in ARROW, which has also been seen in paediatric studies that took place in hospitals 
in Malawi [68] and Nairobi [69]. As in adults the highest mortality was seen in the first 0-4 
months and is likely due to the low CD4 counts at ART initiation. The key interest in paediatrics 
is preventing these early deaths and making sure children get the treatment they need as soon 
as possible, and preventing children getting HIV in the first place by increasing access to 
antiretroviral therapy to prevent mother to child transmission. 
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Modelling the changing hazards 
Figure 2.4.1 also illustrates the arbitrary timepoints considered in mortality analyses to date. 
Whilst all these studies show that risk is changing mostly in the first year after ART initiation, 
there is considerable variation in estimates of when this is happening, because of different 
categorisations used which assume that there is an abrupt change in the hazard of death at 
specific timepoints which does not make sense clinically. Etard and Hoffman [71, 93] also 
presented smoothed estimates of instantaneous hazard of death from time on ART; this 
appears to show change points in hazard of death at 9 months in Etard and in Hoffman at 9 
months and 3 years (not stated explicitly: estimated from curve). Using a different method of 
piecewise exponential modelling, Moore et al. found evidence for two change points in mortality 
risk, one at 3 months and one at 10 months. In addition to the DART results shown in Figure 
2.4.1, using the flexible parametric modelling I have shown that there is a very rapid decline in 
hazard around 30-60 days which was not apparent from previous categorisations. The varying 
estimates found by Etard and Hoffmann show that any modelling strategy that fixes change 
points on the basis of observed data runs the risk of over fitting, as it does not seem plausible 
that genuine changes in risk occur at different times in different studies. The different change-
points also make comparing results from different studies more difficult. However, even though 
the FPMs are able to model the hazard continuously and they do not abruptly cut the data they 
are not without their limitations. As I found when modelling the individual causes of death, the 
models appeared to be very sensitive to when the first event occurred and the timing of 
subsequent events. I tried to overcome this by modelling from 1 year after ART initiation; 
however I still found instability in the boundaries of the models even after 1 year of ART.  
Causes of death 
Deaths in DART were reasonably consistent with that of the 30 studies in my literature search 
which found the most common causes of death to be TB, KS and anaemia. Only one study 
looked at causes of death in the first year separately and they found there to be no difference in 
the causes of death in the first 12 months compared to thereafter, supporting on-ART deaths 
being primarily due to HIV from failure of treatment. Of the deaths that occurred during the first 
year after ART initiation in DART, 52% were considered primarily to be HIV-related, 5% were 
related primarily to drug and 12% were neither related to drug or HIV (remainder being 
unknown). By specific cause: septicaemia/neutropenia (18%), neurological events (14%), 
cryptococcus (11%), TB (7%) and respiratory events (7%) were the most common causes in 
year one. These results are further supported by data from a prospective cohort study in 
Uganda which showed TB, cryptococcus and diarrhoea to be the most common causes of 
death [70]. In the meta-analysis by Gupta et al. [94] it is likely that TB and other opportunistic 
infections contributed to the substantial proportion of deaths due to wasting.  
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Over a median 4.9 years follow-up in DART 51% of deaths were primarily HIV-related. Over 
total follow-up I found that septicaemia/neutropenia was the most common cause of death 
(12%) followed by neurological events (10%), cryptococcus (8%) and then TB (8%), HIV related 
malignancy (7%) and respiratory disease (6%). I thus found a higher proportion of HIV-related 
deaths than the 32% AIDS-related deaths reported for the EUROSIDA cohort by Kowalska et al. 
[83] over 0-10 years on ART. However, this cohort is from high-middle income countries rather 
than low-income countries as in DART; and some deaths judged primarily HIV-related in DART 
were not from AIDS. Further, Kowalska et al. [83] showed that the 68% of all deaths that were 
non-AIDS-related, were non-AIDS-related infection in 9% (counted as HIV-related in my 
analysis), liver malignancy 14%, non-AIDS-defining malignancies 10%, CVD 9%, violent death 
(trauma/suicide) 7% and other 7%, with 12% of all deaths of unknown cause. They also found 
no increase in the risk of non-AIDS deaths with prolonged exposure to ART. These non-AIDS 
causes of death occurred rarely in DART, suggesting that long-term outcomes in low/middle-
income countries might be quite different. Moore et al. found that in Uganda TB was the most 
common clinical condition associated with death, followed by candida disease, cryptococcal 
disease, pneumonia and Kaposi’s sarcoma. Zachariah et al. [82] also reported candida to be a 
common cause of death. Kouanda [74] and Macpherson [76] also found TB to be the most 
common cause of death. Grinsztejn [14] found that in Brazil AIDS defining illness (62%) was the 
most common cause of death, then TB 32%, cryptococcus 12%, Kaposi’s sarcoma 12%, and 
HIV related malignancies 18%. The fact that candida was also among the most commonly 
reported causes of death suggests there may have been issues with ascertainment, since 
candida is typically non-fatal unless it is an extremely rare bloodstream fungal infection. 
Ascertainment of death in DART, in theory, is better, as it was a randomised controlled trial with 
an independent Endpoint Review Committee; however there was still a high proportion of 
unknown deaths illustrating the challenges of reporting causes of death amongst HIV individuals 
in low/middle-income countries. 
It is difficult to compare results across studies due to different ways of classifying deaths. 
Differing CD4 at ART initiation may explain some differences but there are other possible 
explanations. For example patients in Kowalska et al. were from Europe, Israel and Argentina 
with access to VL monitoring and many more drugs than are available in Africa. As a 
consequence they would likely switch earlier for failure, possibly repeatedly, and therefore might 
be more at risk from “serious non-AIDS” type causes of death such as ageing and long-term 
inflammation-related effects of HIV. In contrast, in low/middle-income countries, switch for first-
line failure is typically later, based on immunological/clinical criteria as there are only two 
regimens available. Thus more deaths may be HIV-related, even in the long term, if patients die 
on first-line before they are able to switch – or die shortly after switch as a consequence of 
acute severe illness around switch. 
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In the DART trial, looking overall and at individual causes of death I have been able to confirm 
the prolonged benefit of ART with the majority of the most frequent causes showing a significant 
decline during time on ART. Assessing the causes with lower event rates could lead to definitive 
conclusions which the data may not really be able to support and so I have not assessed any 
causes with less than 10 deaths overall. It is however, important to bear in mind the low event 
rates for some causes within the subgroups for monitoring strategy or years on ART. Two 
causes of death showed somewhat different patterns and are discussed in more detail here. 
First, trauma/suicide had a peak in hazard of death at around 6 months after ART initiation and 
like some of the other causes declined rapidly to around 2 years. However, in contrast it then 
started to increase steadily, possibly stabilising at 6 years. Evidence suggests that risk for 
suicidal behaviour increases during the initial weeks following a diagnosis of HIV and then 
declines as patients adjust to their HIV status. However, as patients’ health and quality of life 
decline, risk of suicide may again increase [110] particularly among middle-aged and older 
patients, who frequently experience poorer health-related quality of life with disease progression 
off ART. However, whether this would be the same on longer-term ART is unclear, although 
given the low rates of mortality might not be expected. These results may suggest the need for 
long-term psychological support in patients on ART. However, an alternative explanation is that 
with improving health, patients on long-term ART return to work and experience higher levels of 
road traffic accidents, falls or other unintentional injuries; in particular road traffic accidents are 
the 13th most common cause of death in the African region (WHO cause-specific mortality 
2008, update from 2011) [64, 111]. 
I found there to be no overall change in the risk of death from HIV-related malignancies, 
meaning that post 1 year it was the most common cause of death. Given the timescales these 
deaths are most likely due to pre-cancerous events that occurred prior to ART initiation. Cervical 
cancer was the main HIV related malignancy but only led to death (n=8 deaths) in the CD4 
monitoring group. Cervical cancer can take a long time to develop. It is a result of a viral 
infection, human papillomavirus (HPV), which is actually very common in all women and is a 
virus that most women can get rid of. However, in those with immunodeficiency (e.g. patients in 
DART) this is not always the case. The risk of malignancy will increase as patients live longer 
without ART, which is why cervical cancer is an AIDS-defining illness according to the Centre 
for Disease Control (CDC) definitions. How incidence changes with increasing time on ART is 
unclear, but it is possible that risks could remain high for first few years on ART if pre-cancerous 
changes have already occurred before ART initiation. Kaposi’s sarcoma (KS) is similarly caused 
by the human herpes virus 8. Again people with a weak immune system cannot fight this virus 
and therefore KS is more likely to develop in those off ART; it is a very common malignancy in 
those with HIV. In DART 5 LCM vs. 1 CDM deaths were from KS. It seems unlikely that these 
were caused by the CD4 monitoring strategy, but instead are plausibly due to the fact that 
DART patients had very low CD4 counts pre-ART and were therefore more vulnerable towards 
these virus-driven cancers which had probably started to manifest within the first few months of 
treatment before CD4 reconstitution could occur. 
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The most common causes of death in ARROW were septicaemia/neutropenia in the first year 
after initiation of ART; thereafter respiratory events became the major cause of death which is 
consistent with Fassinou et al [67] who also found respiratory events to be the most common 
cause of death in three out of nine children who died. 
CD4 count 
The vast majority of studies have shown associations between CD4 count and mortality, with 
both baseline (pre-ART) and time-updated CD4. However, some studies in low/middle-income 
countries such as Moore et al. [79] and Hoffman et al. [93] have found weaker associations 
between pre-ART CD4 and early mortality, and instead stronger associations with WHO clinical 
stage. As pre-ART CD4 is highly associated with WHO stage, this may reflect confounding and 
over fitting to some specific aspects of these datasets, or to unreliably measured (i.e. 
inaccurate) CD4 counts.  
In high-income countries Achhra et al. [112] found that time-dependent CD4 independently 
predicted all-cause mortality and non-AIDS deaths in the SMART trial; but not fatal or non-fatal 
cardiovascular events. The CASCADE collaboration [103] also found an association between 
cause of death and time-dependent CD4 for all causes except unintentional deaths. In addition 
data from the D:A:D cohort [104] showed that higher CD4 cell counts have a strong association 
with a lower risk of mortality from all causes, except, like Achhra, for deaths from CVD which 
had a marginal association. Marin et al [113] also showed there to be no association between 
CD4 and CVD deaths. Despite these findings being from high-income countries, they are similar 
to my results from DART, suggesting the impact of CD4 counts is the same wherever you are if 
you have HIV and are on ART. These results are further supported by Lawn et al. [75] who 
showed in 2423 patients on ART in South Africa that the relationship between time-updated 
CD4 cell counts and mortality rates was extremely strong and that the absolute CD4 cell count 
at any given time point was the key determinant of mortality risk. My question was slightly 
different, namely whether the strength of this relationship varied by different causes of death 
and CD4 monitoring strategy. In DART I have shown that for all-cause mortality and major 
individual causes of death, including those that are not traditionally thought of as 
immunodeficiency-related (with the possible exception of CVD deaths), the hazard of death 
declines similarly and significantly with increasing CD4 count. I have also shown that the 
associations between CD4 and mortality are similar whether patients were monitored with or 
without CD4 counts, apart from TB where in the CD4 monitoring group there was a stronger 
association between cause of death and CD4 than in the no CD4 monitoring group. After 
assessing the change in risk of TB death as CD4 increases, there was a quicker decline in the 
risk of TB death in the CD4 monitoring group as CD4 increases above ~50 cells/µL. This could 
be due to one of two reasons – first clinicians may keep patients in the CD4 monitoring group 
with TB and with higher CD4s on failing first-line regimen while they treat TB, as this has fewer 
drug-drug interactions and may allow more successful TB treatment. Second, in the no CD4 
monitoring group they do not know the CD4 so may assume it is low and switch the patient to 
second-line treatment which makes the treatment of TB more complicated.  
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Strengths and limitations  
Most studies I have found have been electronic databases of ART programmes whereas the 
DART study has the advantage of being a randomised controlled trial with more consistent and 
complete data collection, particularly regarding death ascertainment and adjudication of cause 
of death. With over 3000 patients randomised, DART is the largest treatment randomised 
controlled trial in Sub-Saharan Africa. In addition to this trials tend to have a more consistent 
drug supply (i.e. no stockouts), they have access to information on concomitant medication and 
diagnostics and therefore have good ‘on ART’ estimates of mortality. The DART trial had a loss 
to follow-up (LTFU) of just 7% whereas Hoffman et al. reported a LTFU of 23% during 
observation of patients over approximately two years; this was more than 3 times that of the 
DART trial over 5 years. Moore et al. [79] did not report any LTFU so I am unable to make any 
comparison between DART and another trial but they did have fewer patients than in DART. 
With this low LTFU in DART I can be reasonably confident that mortality was ascertained well 
which is a strength for the study. The presence of an endpoint review committee (ERC) allowed 
independent assignment of COD, which was also independent of CD4 in DART, this allowed 
consistent review of deaths across all centres.  
One limitation of the work carried out here is that I have not looked at the changing effect of 
baseline predictors over time which may have given more insight into the changing hazard over 
time. The other major limitation was the relatively low numbers of deaths from each specific 
cause of death, despite the size of the DART trial, and even fewer in children in the ARROW 
trial. 
2.5 Conclusions 
Deaths were most commonly related to HIV disease both during the first year after ART 
initiation and subsequently, probably due to advanced immunodeficiency at ART initiation and 
as a consequence of fairly late detection of failure of first-line therapy respectively. A recent 
paper from the IeDEA and ART-CC collaborations [114] suggests that ongoing presentation 
with low CD4 will mean these patients will continue to be a substantial proportion (~25%) of 
those initiating ART over the next decade. HIV-related deaths after 1 year on ART were also the 
main driver of long-term differences between CD4 vs. no-CD4 monitoring strategies. The 
contribution of HIV-related-malignancies, likely triggered by pre-cancerous events occurring 
before ART initiation to longer-term ART mortality highlights the importance of earlier HIV 
diagnosis and access to care. Low but increasing risks of deaths from trauma/suicide in adults 
highlight the importance of long-term psychosocial support and empowering patients to manage 
their own treatment, as highlighted in Chapter 1.  
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Chapter 3: Effect of Treatment Interruptions in DART and ARROW 
3.1. Introduction 
3.1.1. Background 
Antiretroviral therapy (ART) has been widely available in low/middle income countries (LMIC) for 
several years [115] and adherence to treatment in sub-Saharan Africa, as reported by patients, 
pharmacies, medical records and Medication Event Monitoring, is relatively high compared to 
high-income countries [116]. However, structural factors such as supply chain interruptions or 
stockouts, employment migration and conflicts can disrupt adherence in these settings [117, 
118] even if the individual has personal intention to adhere. The unstructured nature of such 
interruptions can make assessing their impact difficult. Several studies have shown that 
unplanned interruptions like these are common; studies in LMIC [119, 120] and high-income 
countries [121-125] have shown they contribute to worsening patient outcomes, but most have 
looked at relatively short-term effects (average follow-up 24 months for references cited).  
In the early 2000s structured treatment interruptions (STIs) were widely investigated as a 
mechanism to reduce toxicity and ART costs. Several randomised trials demonstrated 
conclusively that such STIs significantly increase the risk of HIV-related events and serious non-
AIDS events not traditionally thought to be HIV-related, and they are no longer recommended 
[126-128]. Long-term follow-up of these randomised trials provides an unbiased mechanism of 
assessing longer-term effects of treatment interruptions since randomisation ensures balance 
across different groups, in contrast to possible difficulties with time-dependent confounding in 
assessing the effect of unplanned treatment interruptions. For example, the SMART trial [129] 
investigated stopping ART if CD4 was >350 cells/μL and restarting if <250 cells/μL. It showed 
that mortality risks associated with treatment interruptions reduced after returning to continuous 
therapy, but still remained elevated 18 months later, compared to those never interrupting. It 
also showed that despite a hazard ratio of 1.5 for major clinical events, meaning a substantially 
increased relative risk associated with interruption, the absolute risk between interruption and 
continuous treatment for major clinical events was small at <2%.  
The DART STI sub-study [128], conducted in LMIC, investigated a fixed period 12 weeks on/12 
weeks off strategy for patients with CD4 cell count ≥300 cells/μL. Despite absolute rates of 
WHO stage 4 events/death being low, STIs resulted in a greater than twofold increased relative 
rate of disease progression compared with continuous therapy (CT) over a median follow-up of 
51 weeks. The team therefore concluded that STIs could not be recommended and any further 
randomisation to the STI arm was terminated. All patients on the STI arm restarted ART with 
continuous therapy. 
The TRIVICAN trial [127], which is the only other trial in sub-Saharan Africa (Côte d’Ivoire) to 
assess STIs, reported an increase in morbidity both in the CD4 cell count guided arm with 
interruption and reintroduction thresholds at 350 cells/μL and 250 cells/μL respectively, and the 
fixed period strategy arm of two months off, four months on. The CD4 guided arm stopped early 
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due to inferiority compared to the CT arm; patients on the CD4 guided treatment arm had 
severe morbidity 2.5 fold higher than those on CT, very similar to the results from the DART STI 
sub-study. The predefined criteria for non-inferiority of -5/100PYs with CD4 <350 cells/μL at 24 
months was met by the fixed period strategy with a difference between the arms of -
0.87/100PYs. However, the percentage of patients with CD4 <350 cells/μL in the CT arm was 
lower than anticipated, which made the clinical significance of this non-inferiority uncertain 
[130].  
Other trials in LMIC showed similar results with similar strategies; however all had the same 
conclusion that STIs could not be recommended in clinical practice. The STACATTO trial [131] 
investigated a CD4 guided treatment interruption strategy of stopping ART if CD4>350 cells/μL 
and then restarting CT for at least 12 weeks if two consecutive CD4 counts were <350 cells/μL 
(higher threshold than in the TRIVICAN and START trials). This trial showed no difference in the 
primary endpoint of the proportion of patients with viral load (VL)<50 copies/mL. This suggests 
that using strategies with higher thresholds (and therefore less continuous time off treatment) 
may minimise the harm associated with STIs. 
A review of trials and studies that have investigated STIs, including both CD4 count guided or 
fixed period interruptions [132], concluded that interrupting treatment results in a variable 
degree of harm. It concluded that some strategies are less harmful than others, and that 
interrupting and restarting treatment at higher intervals for CD4 guided treatment, and reducing 
the time off treatment in each interval could reduce the risks. It also concluded that the benefits 
of a short period of time off treatment may potentially outweigh the risks. The effect of total 
duration of time off treatment is something that I will assess in this chapter. 
As in adults the introduction of ART has reduced AIDS related mortality and morbidity in 
children. However, complete HIV suppression requires a high level of adherence to ART to be 
sustained over a lifetime. There have been 6 randomised trials of various sample sizes 
assessing the effects of treatment interruptions in children/adolescents, only one of which was 
in LMIC and 3 of which assessed the effects of planned interruptions. The first was a small pilot 
trial in South Africa [133] enrolling 30 ART naïve children and randomising them to continuous 
or intermittent therapy. Children randomised to the STI arm were monitored weekly using VL 
and CD4 counts. ART was restarted if VL increased by 1 log10 copies/mL. Viral rebounds 
occurred rapidly within a week of stopping treatment but equally re-suppressed on re-
commencing ART. In contrast to adults in the DART STI sub-study, they found that CD4% 
remained elevated during an interruption and sometimes continued to increase. There have 
been three randomised controlled trials of planned, CD4 marker-driven, treatment interruption in 
children with chronic HIV infection. In the PENTA 11 trial [134] HIV-infected children were 
randomised to CD4-guided STIs or CT. The primary outcome was a composite of a CD4%/cell 
count outcome (CD4% <15 [age 2-6 years] or CD4% <15 and CD4 cell count<200 cells/μL [7-15 
years]) or new CDC stage C diagnosis (i.e. new AIDS) or death. One hundred and nine children 
were randomised (56 CT and 53 STI); only 1 CT and 4 STI reached a CD4%/cell count 
outcome. No child died or had a new CDC stage C diagnosis. The CHER trial [135] found that 
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early limited ART (criteria for re-initiating ART after interruption was CD4%<25% or CD4 count 
<1000 cells/μL) was superior to deferred ART but did not have a continuous treatment arm for 
comparison. The other randomised trial based in Botswana, the BANA II study, aimed to 
evaluate whether structured treatment interruptions could contribute to better long-term 
treatment outcomes in HIV-infected children [136], results of which are yet to be published.  
Short-cycle therapy (5 days on/2 days off) has been evaluated in a number of small studies in 
adults and young people [137-141] and shows promise; however the concept is somewhat 
different to the treatment interruption trials since participants have mostly been on efavirenz-
based ART (which has a long half-life, 40-55 hours) and the rationale is that there is sufficient 
drug in the patient’s system to continue to suppress the virus for the short treatment break.    
Whilst STIs are no longer recommended, unplanned treatment interruptions (UPTIs) are 
common in both LMIC and high-income countries, but their impact is harder to assess because 
of confounding. Further research into the role of planned/structured interruptions of ART in both 
adults and children in low/middle income countries would be useful to estimate short and long 
term risks of UPTIs, particularly because most trials and studies assessing the effect of 
treatment interruptions have been based in high-income countries. The populations and patients 
treated vary greatly between the two settings meaning the results from high-income countries 
are not necessarily generalisable to LMIC. The work in this chapter assesses the effects of both 
planned and unplanned treatment interruptions in low/middle-income countries using data from 
two trials. 
3.1.2. Data available for analysis 
Data for this chapter are available from the MRC CTU DART and ARROW trials as described in 
Chapter 2. In particular, data are available from the structured treatment interruption (STI) sub-
study within DART. Within the DART trial patients with CD4 cell counts ≥300 cells/μL at 48 or 72 
weeks after ART initiation were randomised between either continuous treatment (CT) or a 12 
week on/12 week off treatment strategy in order to assess the effect of STIs. Following a review 
by the Data Monitoring Committee on 16th March 2006 the STI sub-study was terminated due to 
an increase in the relative rate of disease progression in the STI arm compared to the CT arm. 
Patients who were in the STI arm of DART when the sub-study was terminated were moved 
back on to CT. I am therefore able to assess whether or not there is an effect of these STIs on 
long term outcomes even after returning to CT. In addition data on unplanned treatment 
interruptions (UPTIs) and reasons for these are available in both DART and the paediatric 
ARROW trials; there were no STIs by design in ARROW. 
The aim of this chapter is to investigate the long-term effects of STIs after patients have 
returned to continuous therapy using data from the randomised STI sub-study within the main 
DART trial [128, 142]. I also aim to compare reasons for and outcomes following unplanned 
treatment interruptions in this and the parallel paediatric trial, ARROW [143] conducted in the 
same centres in Uganda and Zimbabwe. 
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3.2. Methods 
3.2.1. Introduction 
In the DART STI sub-study [128], following a pilot study in 100 patients, patients with CD4 
counts ≥300 cells/µL at week 48 or 72 were randomised at either 52 or 76 weeks respectively 
post ART initiation (if not already randomised) to receive either structured treatment 
interruptions (STI) or continuous treatment (CT). Patients randomised to the STI group stopped 
ART immediately; 12 weeks later the same ART was restarted for 12 weeks and the on/off 12 
week cycles continued until trial termination or one of the following: a WHO stage 3/4 event or 
CD4 cell count <50 cells/µL (LCM only) any time after STI randomisation. Either of these events 
occurring on ART was also considered clinical/immunological failure on first-line ART. Those 
patients who were taking nevirapine (NVP) had a 2 week staggered stop of NRTIs (NRTIs were 
continued for 14 days after stopping NVP). CD4 cell counts were recorded at trial enrolment 
(ART initiation) and then 12 weekly thereafter. Treatment interruptions (TIs) were timed so that 
the scheduled 12 weekly laboratory tests fell 8 weeks into the STI cycle and 8 weeks after 
restarting ART. The next STI cycle could be deferred if the patient had received <12 weeks of 
continuous ART, CD4 cell count was ≤200 cells/µL 4 weeks before the scheduled STI start 
(LCM only) or the patient was pregnant or breastfeeding.  
 
3.2.2. Objectives 
The primary outcomes of interest in this chapter are change in CD4 count, clinical event rates 
(new WHO3/4 event/death, WHO4 event/death and mortality), switch to second-line treatment 
and immunological ART failure from 48 weeks after ART initiation (defined in section 3.2.6). I 
am specifically interested in the effect of STIs on CD4 count over the longer term, the effect of 
total time off treatment (planned or unplanned) on CD4 count 4 years after ART initiation and 
the effect of cumulative time off treatment on the above clinical event outcomes.  
The main exposure for adults in the DART trial is the number of STI cycles in those randomised 
to the STI group, which I have considered to be planned interruptions. In addition to these 
planned interruptions, unplanned interruptions (UPTIs) are also assessed as exposures in both 
adults and children. An unplanned treatment interruption is defined as stopping all three 
antiretroviral drugs for ≥4 days, with a reason other than on STI in DART (and not part of the 
STI pilot) and for any reason in ARROW. The reason for the 4 day threshold is because CRFs 
prompted clinicians to only record interruptions ≥4 days. I can therefore not be confident that all 
shorter interruptions were correctly ascertained. In adults I have assessed the effect of the 
number of STI cycles and the effect of total time off treatment for both planned (STI) and 
unplanned treatment interruptions (UPTI); in children I have only assessed the effect of UPTIs 
as there were no STIs by design in ARROW. 
Deaths (reporting of which is described in Chapter 2) have been used to calculate overall 
survival which is defined in adults as time from randomisation into the main DART trial to death 
and in children as time from randomisation into the ARROW trial to death. As in Chapter 2 for 
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adults (DART) any patients who died after 31st December 2008 have been censored (i.e. not 
included as a death). For children (ARROW) this censoring date is 16th March 2012.  
For the STI sub-study baseline CD4 values were those nearest to but before and within 120 
days of STI/CT randomisation. Subsequent CD4 counts were 8 weeks after starting STI then 12 
weekly thereafter. A 6 week window of time either side of each CD4 count was used (apart from 
at baseline as described above); counts that fell exactly 6 weeks between 2 scheduled 
timepoints fell in the window of the next time point (e.g. a CD4 count recorded at 26 weeks 
would be considered a 32 week CD4 count and not a 20 week count). Post STI termination (16th 
March 2006) baseline values were the closest CD4 count recorded within 6 weeks prior to 16th 
March 2006 (treating this as the baseline date for the post-STI trial follow-up). Subsequently the 
closest CD4 count within a window of 6 weeks every 12 weeks was used. 
3.2.3. Change in CD4 counts 
I first investigated the change in CD4 count after the termination of the STI sub-study when all 
patients were receiving CT (Figure 3.2.1). By assessing the difference between those patients 
who were originally randomised to STI and those who always had CT I can assess the long 
term effects of these STIs. I have not included any data in Figure 3.2.1 past 144 weeks (~3 
years) post 16th March 2006 as <100 patients per arm were at risk after these timepoints. These 
timepoints are however included in the models used later. 
 
Figure 3.2.1 Absolute CD4 count during and after the STI sub-study 
 
Figure 3.2.1 shows an unexpected rapid increase in CD4 count from 96-108 weeks after 16th 
March 2006 (overall p<0.001). I first investigated whether this was associated with the 
randomisation between CD4 (LCM) vs. no CD4 monitoring (CDM) (Figure 3.2.2). 
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Figure 3.2.2 Absolute CD4 count during and after the STI sub-study by monitoring 
strategy 
 
Two points are clear from this plot: Firstly, the mean CD4 count at 80 weeks post randomisation 
for CT/LCM is larger than might be expected. Investigating this further shows there were 2 
outliers with CD4 cell count ≥650 cells/µL at this timepoint and the numbers in this subgroup are 
small (N=8), so these outliers have a large influence on the mean and its standard error. 
Secondly, the increase from 96-108 weeks post 16th March 2006 is happening across the board 
whether STI or CT and whether LCM or CDM (all p<0.001). I therefore next looked at results by 
centre to see if this could be caused by an external factor such as a machine change. 
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Figure 3.2.3 Entebbe centre (MRC/UVRI) 
 
In the Entebbe centre there is a significant increase (p<0.001) in CD4 in both the CT and STI 
arms (both p<0.001) from 96-108 weeks preceded by a decrease from 72-84 weeks (Figure 
3.2.3). All other centres showed no significant variation between these timepoints (JCRC 
p=0.41, Harare p=0.32, AA p=0.75) (Figure 3.2.4). 
Figure 3.2.4 Absolute CD4 counts at JCRC, HAR and AA centres 
  
The dates that fall around 96 weeks in Entebbe are 6th December 2007 – 27th February 2008, 
during which time the ARROW trial team (but not the DART team) were informed of a 
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biochemistry machine change (but not a CD4 machine change). Even though machines are 
different, it is possible that some change in laboratory practice might be the reason for the 
change in CD4 counts in the Entebbe centre in DART. Figure 3.2.5 shows absolute CD4 counts 
in all the Entebbe patients (not just STI/CT patients) by week from 16th March 2006. 
Figure 3.2.5 Absolute CD4 counts between 78 and 102 weeks in all Entebbe patients not 
just the STI sub-study patients 
 
CD4 counts are generally lower between 88-96 weeks [median (IQR) 238 (166-321) cells/µL; in 
contrast to 78-87 weeks 321 (210-438) and 97-102 weeks 365 (247-474) respectively] and at 93 
weeks there are no CD4 counts at all. In fact there were no CD4 counts taken between 21st 
December 2007 and 2nd January 2008; it is very likely that this is due to the Christmas and New 
Year period.  
Due to the lower CD4 counts at the Entebbe centre from weeks 88-96, from now on I have set 
all CD4 counts from Entebbe patients between week 88 and week 96 to missing (there is still 
80% of all usable data included in the analysis during these timepoints from other centres).  
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Figure 3.2.6 Absolute CD4 count during and after the STI sub-study by CT/STI 
randomisation – excluding Entebbe CD4 counts between 19th November 2007 and 11th 
January 2008 
 
Figure 3.2.6 shows that there is still a slightly larger than expected increase in mean CD4 
between 96 and 108 weeks in STI; however this is much less pronounced. 
Of note, the problem with the Entebbe CD4 counts had not been identified in the main trial 
analysis, probably because the specific period of time occurred at very many different 
timepoints from ART initiation (time zero for the main randomisation). 
3.2.4. Mixed modelling for long term trends in CD4 counts 
Figure 3.2.6 shows that even up to 2-3 years after returning to CT those patients who received 
STIs have lower CD4 counts than those on CT. The CD4 count increases more rapidly at re-
initiation of ART but from the data, CD4 counts in STI patients never recover to that of the CD4 
counts in CT patients (at 144 weeks post 16th March 2006; mean CD4 is 485 cells/µL for CT 
patients vs. 444 cells/µL for STI patients, p=0.002). One question based on these data, is given 
more time, would these CD4 counts have recovered?  
 
In DART I assessed the long-term trends in CD4 counts in CT and STI when back on long-term 
ART using mixed models including fixed and random effects (unstructured covariance matrix) 
for initial value at 16th March 2006 and a long term slope with heteroskedastic errors depending 
on STI/CT [144]. Extrapolating using these mixed or random effects models (denoted RE 
models from now on) allows me to assess whether the CD4 counts for patients in the STI group 
would ever recover to the same levels as in the CT group even after returning to CT at the end 
of the STI sub-study (16th March 2006). The reason for using RE models over the standard 
linear regression is that they are suitable for longitudinal or repeated measures data. Standard 
linear regression assumes that each observation is independent; using this I would only be able 
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to assess CD4 as an outcome at a particular point because repeated measurements from one 
individual are likely to be related to each other. RE models enable me to fit different (random) 
slopes and intercepts specific to each patient (and depending on the group they were in) during 
the STI sub-study. Given these individual slopes and intercepts, assuming that the residual 
error is independent (and normally distributed) is reasonable. 
The most basic fixed effects model is 
 ijijij weekcd  4   (3.1) 
where i is the patient and j is the week (representing the number of weeks from termination of 
the STI sub-study on 16th March 2006) and ij are the heteroskedastic error terms depending on 
STI/CT, i.e.  2,0~ kij N   where k indexes STI or CT group membership. 
This fits a simple linear regression model to all patients, an intercept () followed by a 
(constant) slope (β) over time (here weeks from termination of the STI trial on 16th March 2006).  
The next step is to allow for different intercepts (baseline CD4) and slopes (change in CD4 over 
time) for each patient (for now ignoring any STI/CT randomisation group effect). These are the 
random effects. 
ijijiiijij weekweekcd  4  
which can also be written as 
     ijijiiij weekcd  4   (3.2)  
Where i represents how much an individual patient’s intercept varies from the overall 
population mean intercept, and βi represents how much an individual patient’s slope varies from 
the overall population mean slope, with  0~, MVN . If I do not specify a covariance 
structure for the random effects (i and βi) then the following default independent structure is 
used: 
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Instead I have used an unstructured matrix (shown below) which allows the covariance between 
i and βi to be correlated which is more plausible and supported by a likelihood ratio test 
(p=0.005).  
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Figure 3.2.6 shows that there are different overall intercepts and slopes depending on which 
STI/CT group a patient is in. In order to include this treatment effect I have fitted: 
ijijiiiijijiij weekrxstiweekweekrxsticd   ''4  
or  
 ijijiiiiij weekrxstirxsticd   )'()'(4  (3.3) 
Where rxsti is the randomised group allocation variable, ’ is the difference in mean baseline 
CD4 (intercept) between the STI group and the CT group and β’ is the corresponding difference 
in change in CD4 over time (slope).  
Given the substantial differences in CD4 between on/off ART STI cycles shown in Figure 3.2.6, 
it is plausible that the CD4 counts in those patients off ART at the time the trial was terminated, 
i.e. who were in the middle of an STI cycle, may increase differently to those patients who were 
on ART at the time the sub-study was stopped. Allowing different CD4 counts for patients in the 
CT group, STI patients on ART at the time the sub-study was stopped (STI-on) and STI patients 
off ART at the time the sub-study was stopped (STI-off) (new variable newsti) I found that this is 
indeed the case and the change in CD4 for STI patients off ART at the time the sub-study was 
stopped is more rapid (until around 12 weeks) than for those STI patients on ART when the 
sub-study was stopped (Figure 3.2.7). This suggests I cannot fit a linear slope across the whole 
follow-up period for patients who are in the STI-off group. 
Figure 3.2.7 Change in CD4 count before and after sub-study closure (CT vs. STI-on vs. 
STI-off) 
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I wish to model this different rate of increase in the initial 12 weeks for STI-off patients. In order 
to do this I have used piecewise linear functions. I first created a new variable for the first 12 
weeks after 16th March 2006 (initial_week), this variable will be equal to the week variable until 
12 weeks and will then be equal to 12 thereafter. I can then include this variable in the model to 
allow for the different increase in slope for the STI-off patients. With this new variable my model 
becomes as follows: 
ijijiiijiiiiij weekinitialnewstiIweeknewstinewsticd   _))(2()'()'(4  
(3.4) 
where CT, STI-on and STI-off are defined as newsti=0, 1, 2 respectively. The variable 
initial_week only contributes to the model when newsti=2 (STI-off) as I only want to include it for 
those patients who are off ART when the sub-study was stopped. I define initial_week as 0 for 
all other groups apart from STI-off. 
Figure 3.2.8 shows some individual fits for random STI-on and STI-off patients. 
Figure 3.2.8 Including the different slope for STI-off patients (individual fits) 
 
I have used model 3.4 to predict whether or not the CD4 counts for the patients in the STI group 
will ever reach the CD4 counts in the CT group.  
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3.2.5. Modelling the effect of number of STI cycles on CD4 counts 132 weeks after the 
sub-study closure 
Now I have modelled the effect of STIs on the changing CD4 count over time it is also useful to 
assess the effect of STIs at a particular timepoint. I have chosen 132 weeks post termination of 
the STI sub-study because 96% of those randomised to the STI sub-study were still in follow-up 
and 95% of those had CD4 available at 132 weeks. At 144 weeks this was less; despite 95% of 
patients still being in FU only 89% had data on CD4.  
The effect of number of STI cycles received on the single CD4 count 132 weeks post sub-study 
closure was assessed using normal linear regression, adjusting for age at ART initiation, sex, 
centre, randomised monitoring strategy (LCM/CDM), weeks on ART at STI randomisation and 
CD4 pre-ART and pre STI/CT randomisation.  
Linear regression assumes that outcome data are normally distributed and if they are not then 
the parameter estimates could be misleading. Figure 3.2.9 shows the distribution of CD4 counts 
at 132 weeks post sub-study closure (note that CD4 count has been truncated at the 99th 
percentile; 1036 cells/µL, to reduce the impact of outliers on the distribution). 
Figure 3.2.9 Distribution of CD4 at 132 weeks post sub-study closure 
 
Figure 3.2.9 shows the CD4 counts at 132 weeks post sub-study closure may be slightly 
skewed. To confirm whether or not this is the case I fitted a Box-Cox regression model to find 
the maximum likelihood estimates of the parameters of the Box-Cox transform (3.5), that makes 
these data closest to normality [145-147]. 
 transformation,


 1)(  yy  (3.5) 
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Here y is CD4 at 132 weeks post sub-study closure. The power transform  has been estimated 
to be 0.85 (95% CI 0.71-1.00). As the confidence interval just includes 1, this suggests that 
there the CD4 count at 132 weeks can be modelled in its absolute form, and that departures 
from normality are not large enough to materially affect results. 
3.2.6. Effect of STIs before and after sub-study closure on clinical events 
Given the relatively low numbers of events, comparisons between STI and CT in terms of 
clinical event rates and switch to second-line were made using Poisson regression as described 
in Chapter 2; section 2.2.3. Clinical events of interest were new WHO 3/4 event/death, WHO 4 
event/death and mortality. In addition I assessed the effect of STIs on rates of switch to second-
line ART and immunological failure from 48 weeks after ART initiation. The reason for 
considering immunological failure separately from switch to second-line was because those 
patients in the LCM group would have been assessed for first-line failure and switch to second-
line based on their CD4 counts. But in those patients in the CDM group the CD4 counts would 
not have been known and so the switch to second-line treatment would have been based on 
clinical failure alone. Therefore, by following the protocol, switch to second-line was based on 
different criteria in those monitored with vs. without CD4s. Definitions of immunological failure 
followed broadly the trial protocols for those monitored with CD4 as follows - adults and children 
aged ≥5 years: confirmed CD4 50-99 cells/µL or single CD4 <50 cells/µL; children only: aged 3-
<5 years confirmed CD4%<10% and aged 1-<3 years confirmed CD4%<15%. As in section 
3.2.5, I have adjusted Poisson models for age at ART initiation, sex, centre, randomised 
monitoring strategy (LCM/CDM), weeks on ART at STI randomisation and CD4 pre-ART and 
pre STI/CT randomisation. 
3.2.7. Effect of total duration off treatment on longer-term CD4 in all trial participants 
The analyses above only included participants randomised in the STI sub-study. In both 
ARROW and DART I investigated the longer-term impact of total time off treatment (planned 
and unplanned) by modelling CD4% 3 years after ART initiation in all children (ARROW) and 
absolute CD4 4 years after ART initiation in all adults (DART). I chose these timepoints as the 
median follow-up in ARROW was 4 years and in DART 5 years and so the majority of all those 
randomised were still alive and in follow-up one year previously. In both cases I took the closest 
value within ±12 weeks. I used CD4% rather than absolute CD4 count in children as it varies 
less with age in uninfected children and is generally preferred when monitoring immune status 
in children infected with HIV [148]. Models were adjusted for the effect of sex, pre-ART CD4 
(CD4% in ARROW), age at randomisation, centre, LCM/CDM and randomised first-line 
treatment strategy in ARROW. I initially used multivariable fractional polynomials (MFPs) [149] 
to allow for any non-linearity in the effect of continuous factors.  
Planned treatment interruptions (STIs) as described in section 3.2.1 are those interruptions that 
have come from the STI sub-study (DART only) and unplanned treatment interruptions (UPTIs) 
have come from those interruptions that were not part of the STI sub-study (DART and 
ARROW). By design there were no STIs in ARROW and so there are only UPTIs. UPTIs were 
defined as stopping all 3 antiretroviral drugs for ≥4 days (with a reason other than an STI in 
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DART). As above, I have chosen the cut off of 4 days because the case report forms (CRFs) 
explicitly asked clinicians not to log treatment interruptions of less than this. While there are 
some patients who reported a treatment interruption of <4 days, because of the CRF 
instructions, this will have substantial ascertainment bias and so I have excluded any such 
interruptions.  
a. DART: Finding the best way to model CD4 at 4 years post ART initiation 
Before carrying out the analysis described above I investigated how best to model the CD4 
count 4 years after ART initiation in the same way as I assessed the best way to model CD4 at 
132 weeks after cessation of the STI sub-study in section 3.2.5.  
Figure 3.2.10 Distribution of CD4 at 4 years before and after transformation 
 
Plotting the distribution of CD4 counts (Figure 3.2.10 left panel) shows that the data are slightly 
skewed (left panel). Using a Box-Cox transform as described in section 3.2.5 gave ˆ =0.66 
(95% CI 0.62-0.71). As the 95% confidence interval excludes both 1 (linear/no transformation) 
and 0.5 (square root) there is no intuitively obvious transform to use. Figure 3.2.10 (right panel) 
shows the square root transformation and the data are only moderately less skewed than the 
untransformed data. I have therefore decided to model the CD4 at 4 years on the absolute 
scale, which is easier for interpreting effect estimates. Of note however, I have also truncated 
the CD4 at 4 years at the 99th percentile (850 cells/µL) to avoid the few outliers potentially 
influencing the modelling. 
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b. ARROW: Finding the best way to model CD4% at 3 years post ART initiation 
I have also carried out the same check for the CD4% at 3 years after ART initiation in ARROW. 
Plotting the distribution of CD4% (Figure 3.2.11) shows that the data are slightly skewed, 
however using a Box-Cox transform as described in section 3.2.5 gave a ˆ =1.34 (1.21-1.46). 
The 95% CI does not contain 1 but the lower confidence limit is reasonably close to 1 and as 
the data are not highly skewed, for ease of interpretation and consistency with DART I have 
decided to model the CD4% at 3 years on the linear scale.  
Figure 3.2.11 Distribution of CD4% 3 years post ART randomisation 
 
 
c. DART & ARROW: Finding the best way to model total duration off treatment 
The key exposure is the total duration off treatment. Any time off ART that occurred after 4 
years (DART) or 3 years (ARROW) has been excluded as occurring before the outcome. 
Because of the difference in the mean changes in CD4 count shown in Figure 3.2.6 for the STI 
and CT arms, I have also included a variable to assess the effect of ever/never interrupting 
ART. Figure 3.2.12 shows the distribution of time off treatment (STIs and UPTIs) in DART to 4 
years (excluding those who have not had any time off treatment). 
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Figure 3.2.12 Distribution of total time off treatment (DART) 
 
Figure 3.2.12 shows that the distribution of time off treatment is very skewed with almost all 
patients having a total time off treatment less than 250 days (6 months) with very few patients 
being off treatment for more than 2 years in total.  
I first modelled the effect of total duration off treatment on CD4 at 4 years by using a simple 
linear regression model. 
Figure 3.2.13 Modelling effect of total duration off treatment on CD4 at 4 years using 
simple linear regression (before and after truncating) 
 
Several outliers appear to have a large influence on the model (Figure 3.2.13 – left panel). As 
with the CD4 at 4 years (outcome) I have therefore truncated the total time off treatment 
(exposure) at the 99th percentile (365 days). Further investigation into the distribution of total 
time off ART, looking at STIs and UPTIs separately, indicates that some very long interruptions 
were counted as very long STI cycles despite the fact that cycles should only be 12 weeks (84 
days) in length (underlined in Table 3.2.1).  
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Table 3.2.1 Total duration off treatment for STIs by number of STIs 
Maximum 
number of STI 
cycles 
N Total duration off treatment 
Median (IQR) 
Days off treatment 
(Min, Max) 
0 409 0 (0-0) (0, 7) 
1 85 84 (75, 84) (17, 262) 
2 149 168 (140, 168) (83, 411) 
3 139 247 (212, 252) (147, 336) 
4 31 308 (278, 330) (254, 342) 
This appears to occur where a patient starts an STI as planned, but then fails to re-attend clinic 
at the end of an STI, leading to a long interruption which was initially for STI but then for failure 
to attend. Because of this I have capped STI cycles to 91 days (84+7 days); any patient who 
has had a cycle of STI lasting more than 91 days has the extra time off for that cycle considered 
as part of a UPTI and added on to the total duration off treatment for any UPTIs for that patient. 
For example if a patient has a total of 270 days off treatment for just one cycle I have 
considered this as 91 STI days and 179 UPTI days.  
A separate question is whether the linear model is a good representation of the relationship 
between time off ART and CD4 response (Figure 3.2.13 – right panel). One method to model 
non-linearity in the relationship between time off ART and CD4 response is to use multivariable 
fractional polynomials (MFPs) and I have first modelled total duration off treatment using an 
MFP as described in section 3.2.8 [149]. I have adjusted for pre-ART CD4 (CD4% in ARROW), 
sex, centre, randomised monitoring strategy and age at ART randomisation. In addition I have 
adjusted for randomised first-line strategy in ARROW. 
3.2.8. Multivariable Fractional Polynomials 
Fractional polynomials (FPs) can be used to allow for non-linearity in the effect of a continuous 
factor in a structured way. The most common FPs are FP1 where the number suffix denotes the 
degree of FP. FP1 are monotonic [have positive or negative slope], and those with power p<0 
have an asymptote as x. FP2 may be monotonic or unimodal [have a maximum or a 
minimum for some value x]; when p1 and p2<0 then they have an asymptote as x. First I 
distinguish between an FP transformation and an FP function or model. An FP1 transformation 
of a positive argument x>0 with power p is defined as xp, where p is from S={-2, -1, -0.5, 0, 0.5, 
1, 2, 3} (where 0 refers to the natural log of x and not x0=1). An FP1 function or model is defined 
as φ1*(x;p)=β0+β1xp. An FP2 transformation of x with powers p=(p1,p2), or for p1=p2 (p1, p2), is 
the vector xp with 

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ppxxx
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ppp  
An FP2 function (or model) with parameter vector β=( β1, β2)T and powers p is φ2*(x;p)= β0+ 
β1xp1+ β2xp2.  
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a. Building an MFP model 
The selection between an FP2 vs. FP1 vs. linear model uses a systematic search for possible 
non-linearity, provided by a function selection procedure which is added to backwards 
elimination. When selecting a model there are two significance levels that are needed, 1 for 
selecting variables with backwards elimination and 2 for comparing the fit of the functions 
within the function selection procedure. Model selection is as follows: 
1. Choose 1 and 2. Here I have chosen 1=2=0.05. Setting 1=1 forces no variable 
selection and 2 =1 forces no FP selection. 
2. Choose maximum permitted degrees of freedom for the FP functions (4df=FP2; 
2df=FP1 and 1df=linear function – default is 4df which I have used here for continuous 
factors, if a binary factor then df=1). 
3. The function selection procedure is then as follows: 
i. Inclusion: Test the best FP2 model for x (here x is the total time off treatment) at 
the 1 level against the null model using 4 df. If x is significant then continue, if 
not then drop from the model.  
ii. Non-linearity: Test FP2 for x against a straight line at the 2 level on 3 df. If 
significant, continue; otherwise, stop, with the chosen model for x being a straight 
line (linear). 
iii. Simplification: Test the best FP2 for x against the best FP1 at the 2 level using 
2df. If significant then the final model is FP2, if not then FP1. 
 
When modelling these data using MFPs I have restricted the powers to the set S={-2, -1, -0.5, 0, 
0.5, 1, 2} to avoid any over fitting of variables that can sometimes occur when using cubic 
functions. When fitting the model there are several variables that I wish to adjust for regardless 
of significance and therefore the backwards elimination part of the model selection is not carried 
out and a full model approach has been used. 
Fitting a model as above to my data (i.e. adjusting for pre-ART CD4 (CD4% in ARROW), sex, 
centre, randomised monitoring strategy and age at ART randomisation and allowing non-linear 
effects of all covariates), and including the ever/never off treatment variable as described in 
section 3.2.7c, suggests an FP1 with (1) (i.e. linear) is the best fit to the data (Figure 3.2.14).  
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Figure 3.2.14 Assessing the fit of an FP1(1) for total duration off treatment 
 
 
3.2.9. Assessing the effect of cumulative time off treatment on clinical outcomes 
Time-dependent Cox regression was used to assess the effect of cumulative time off treatment 
on clinical outcomes (mortality, WHO4 event/death, WHO3/4 event/death, switch to second-line 
and immunological failure as defined in 3.2.6) in both DART and ARROW. These models were 
used because an individual’s risk of an event at a particular time depends on their total time off 
treatment at this timepoint: i.e. depends on a factor which varies across time in each risk set. I 
therefore expanded my dataset to one record for every risk set a person contributed to and 
calculated time off ART to each of those timepoints. Given the results from the CD4 outcome 
analysis (see below), I also assessed the effect of cumulative time off treatment from STIs and 
UPTIs separately. I used MFP to assess non-linearity in these key exposures. 
For most outcomes, there were many events in the first year on ART when risk of events is 
likely to be high because they have only just started treatment (i.e. not related to interruptions), I 
therefore also investigated heterogeneity in the effect of time off treatment dividing time on ART 
at <1 vs. ≥1 years by splitting my data at 1 year as described in section 2.2.3.  
Using the MFP approach I have adjusted for sex, pre-ART CD4, centre, age at ART 
randomisation and ever/never off treatment. In addition I have adjusted for randomised first-line 
strategy in ARROW. The MFP model suggests an FP(1) model would be suitable to model the 
cumulative time off treatment.  
The same method has been applied in children using the ARROW data for consistency with the 
addition of adjusting for the randomised first-line strategy. 
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3.3. Results 
In DART there were 813 participants randomised into the STI sub-study between July 2004 and 
March 2006 (405 to CT and 408 to STI). A total of 404 participants had at least 1 STI cycle (85, 
149, 139 and 31 patients had 1, 2, 3 and 4 STI cycles respectively). There were 4 patients who 
despite being randomised to the STI arm never actually interrupted ART. Reasons for stopping 
STIs were sub-study closure (as described in section 3.2.1) in 302 (75%) and clinical/patient 
reasons in 102 (25%) (Figure 3.3.1). Clinical reasons were mostly due to low CD4 or WHO 3/4 
events (64/102, 63%), followed by illness (not WHO 3/4) (12/102, 12%) including malaria, 
cellulitis, facial palsy and pelvic inflammatory disease, then clinic error (11/102, 11%) including 
clinician oversight. Patient reasons were mostly due to pregnancy (12/102, 12%) and patient 
decision (3/102, 3%). As expected those who stopped STIs due to clinical/patient reasons had 
fewer STIs; 44, 37, 21 and 0 patients stopping STIs for clinical/patient reasons had 1, 2, 3 and 4 
STI cycles respectively (p<0.001) (Figure 3.3.1).  
Figure 3.3.1 Reasons for stopping STIs and cycles received 
 
Another way to assess this is to look at the reasons for stopping STIs by the number of STIs a 
patient could have received before sub-study closure rather than did receive. These results are 
displayed in Figure 3.3.2. 
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Figure 3.3.2 Reasons for stopping STIs and cycles a patient could have received 
 
Figure 3.3.2 shows that 100%, 87%, 73% and 52% of patients who could have received 1, 2, 3 
or 4 STI cycles before sub-study closure actually received all the cycles they could have done 
(p<0.001). This suggests the more cycles a patient could have received the more likely they 
were to not receive all their cycles. It also demonstrates that the chance of a patient receiving all 
4 cycles they could have received was much lower than receiving all 3, 2 or 1 cycles that they 
could have received i.e. the population of patients receiving 4 cycles is more highly selected 
than those receiving fewer cycles. In contrast Figure 3.3.1 shows that of those who only 
received 1 cycle of STI, sub-study closure accounted for only around 50% of the reasons for 
stopping, but it does not tell us whether they could have received more. Of those patients who 
received fewer cycles than they could have done, this was mostly due to low CD4 or a WHO 3/4 
event.  
3.3.1. Change in CD4 count 
Figure 3.3.3 shows the mean CD4 counts during the STI sub-study by sub-study arm (STI/CT); 
interrupting ART resulted in a rapid and significant drop in CD4 count 8 weeks after each STI 
and a rapid increase in CD4 count 8 weeks after each restart of ART. It also shows the mean 
CD4 counts for those in the STI arm who had stopped STIs. What is interesting is that even 
towards the end of the trial and 8 weeks after the final planned restart of ART (week 68 as 
highlighted) there was still a net decrease in CD4 compared to at randomisation for those 
patients on the STI arm; mean change in CD4 for those in the STI arm from STI randomisation 
to week 68 was -63 (SD 103) cells/μL; in those who had stopped STIs -51 (102) cells/μL and 
those who were still having STIs -75 (102) cell/μL. In contrast, in the CT arm (as would be 
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expected) there is generally a steady increase during the course of the STI sub-study (mean 
change from STI randomisation to week 68 was +40 (SD 121) cell/μL).  
Figure 3.3.3 Absolute CD4 count change over STI study 
 
After the sub-study closed on 16th March 2006, STI patients returned to CT and follow up on 
these patients continued as part of the main DART trial. This allowed me to assess the effects 
of these STIs on long term CD4 counts. Figure 3.3.4 shows mean CD4 counts before and after 
sub-study closure in those randomised to CT and STI separately; also split by those who were 
off ART at the time the trial was terminated (STI-off) and those who were on ART at the time the 
trial was terminated (STI-on), as described in section 3.2.4. 
Figure 3.3.4 Absolute CD4 count during and after the STI sub-study by CT/STI-on/STI-off 
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STI/CT patients were followed for a median (IQR) 1.9 (1.6-2.2) years post sub-study closure 
within the DART trial. From the mixed model, patients randomised to CT had a mean CD4 of 
402 cells/µL (95% CI 389-414) at sub-study closure and as expected patients randomised to 
STI had a CD4 that was 93 cells/µL (74-112) lower in those on ART and 169 cells/µL (142-197) 
lower in those off ART at sub-study closure (both p<0.001). Subsequently CD4 counts in both 
the STI and CT patients increased. However, CD4 counts in those who had had STIs remained 
lower than those in the CT group even after 2 years back on CT. I also observed that CD4 
increased more rapidly during the first 12 weeks back on CT for those who were off ART at sub-
study closure compared to those who were on ART (STI-on or CT) (Figure 3.3.4). From the 
mixed model, those off ART gained 83 cells/µL (57-108) during the first 12 weeks back on ART, 
significantly more than those on ART at sub-study closure (p<0.001), who gained on average 9 
cells/µL (8-10) during the first 12 weeks (STI-on +11 cells/µL (10-13); CT +7 cells/µL (6-8)). 
Subsequently both STI groups gained CD4 at similar rates of 48 (41-54) and 49 (40-59) 
cells/µL/year respectively (heterogeneity p=0.78), significantly faster than the 31 (25-36) 
cells/µL/year in CT (p<0.001) (Table 3.3.1). 
Table 3.3.1 Modelling the effect of STIs on long term CD4 counts 
Variable Estimate and 95%CI p-value 
Fixed effects 
CD4 at sub-study closure (cells/L) 
CT 402 (389, 414) - 
STI-on ART -93 (-112, -74) <0.001 
STI-off ART -169 (-197, -142) <0.001 
Change in CD4 after sub-study closure (cells/L/week) 
CT 0.59 (0.49, 0.69) <0.001 
STI-on ART 0.92 (0.79, 1.04) <0.001 
STI-off ART 0.95 (0.76, 1.14) <0.001 
Change in CD4 after sub-study closure (cells/L/week) – initial 12 weeks 
CT omitted  
STI-on ART omitted  
STI-off ART 7 (5, 9) <0.001 
Random effects 
sd(CT) 117 (108, 127)  
sd(CTXweek) 0.9 (0.8, 1.0)  
corr(CT, CTXweek) -0.2 (-0.3, -0.1)  
sd(STI-on) 114 (103, 125)  
sd(STI-onXweek) 0.9 (0.8, 1.0)  
corr(STI-on, STI-onXweek) -0.2 (-0.4, -0.1)  
sd(STI-off) 88 (71, 110)  
sd(STI-offXweek) 0.9 (0.7, 1.0)  
corr(STI-off, STI-offXweek) -0.1 (-0.3, 0.2)  
sd(initial_week) 6 (4, 8)  
sd(residual error): 
 CT 
STI-on 
STI-off 
 
85 (83-87) 
80 (78-82) 
79 (76-83) 
 
Number of observations=9867 
Number of groups = 798 
Observations per group: Minimum = 1; Average =12.4; Maximum = 19 
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As the CD4 counts increased at a slower rate for CT and a quicker rate for STI, I asked the 
question - will these CD4 counts ever recover and be the same as in the CT group? Using the 
mixed model methods as outlined in section 3.2.4 and assuming our model extrapolates 
another 1-2 years, by extrapolating from my model the mean CD4 in STI patients on ART at 
sub-study closure would equal that in CT 5.4 years (95% CI 4.1-7.1 years) after sub-study 
closure and in STI patients off ART at sub-study closure the mean CD4 would equal that in CT 
4.6 (1.5-9.8) years after sub-study closure. As expected from the mean increases shown in 
Table 3.3.1 above, there is no real difference between STI-on and STI-off in terms of the 
recovery time of the CD4 counts reflected in the overlapping confidence intervals. For this 
reason I have also fitted a model with a common STI slope past 12 weeks. Using this updated 
mixed model the mean CD4 in the STI-on group would equal that in the CT group 5.3 years 
(95%CI 4.2-6.4 years) after sub-study closure and the STI-off group the mean CD4 would equal 
that in the CT group 4.9 (1.8-8.0) years after sub-study closure.   
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3.3.2. Long term effects of STIs 
Table 3.3.2 shows results from a multivariable linear regression model investigating the effects 
of 1, 2, 3 or 4 STI cycles on a patient’s CD4 132 weeks after sub-study closure. At 132 weeks 
post sub-study closure there were 741 (91%) patients with CD4 available; 23 (3%) had died 
prior to 132 weeks post sub-study closure, 28 (3%) were lost to follow-up and 21 (3%) had no 
CD4 recorded at 132 weeks.  
Table 3.3.2 Long term effects of STIs on CD4 count at 132 weeks post sub-study closure 
 N  
or 
median 
(IQR) 
CD4 count at 132 weeks  
post sub-study closure 
Univariable Multivariable 
Variable  Estimate  
(95% CI) 
p-value Estimate  
(95% CI) 
p-value 
Number of STIs:  0 (CT) 
   1 
   2 
   3 
  4 
375 
71 
137 
127 
31 
0 
-57 (-101, -15) 
-54 (-87, -20) 
-33 (-67, 0.76) 
-5 (-67-57) 
- 
0.009 
0.002 
0.06 
0.87 
0 
-58 (-99, -17) 
-53 (-84, -22) 
-43 (-76, -11) 
-14 (-73, 45) 
- 
0.006 
0.001 
0.009 
0.64 
Pre ART CD4 (per 50 cells/mm3 
higher) [Median (IQR)] 
133  
(83-168) 
 
18 (7, 29) 
 
0.001 
 
10 (-0.6, 21) 
 
0.06 
Pre STI/CT CD4 (per 50 
cells/mm3higher) [Median (IQR) 
358  
(325-419) 
 
30 (23, 37) 
 
<0.001 
 
29 (22, 35) 
 
<0.001 
Age at ART initiation (per 10 years 
older) [Median (IQR)] 
36  
(31-42) 
 
0.20 (-15, 16) 
 
0.98 
 
12 (-3, 27) 
 
0.10 
Sex: Male 
 Female 
191 
500 
0 
74 (46-101) 
 
<0.001 
0 
66 (39, 93) 
- 
<0.001 
Centre:  
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 IDI*, Mulago 
 
302 
156 
237 
46 
 
0 
-10 (-43, 23) 
-16 (-45, 13) 
-46 (-99, 7) 
 
- 
0.55 
0.29 
0.09 
 
0 
11 (-21, 42) 
2 (-25 29) 
-27 (-77, 23) 
 
- 
0.51 
0.88 
0.28 
Monitoring strategy:  
 LCM (CD4 monitoring)  
 CDM (no CD4 monitoring) 
 
380 
361 
 
0 
6 (-19, 31) 
 
- 
0.63 
 
0 
7 (-16, 30) 
 
- 
0.55 
Weeks on ART at STI 
randomisation: 
 52 weeks 
 76 weeks 
 
454 
287 
 
0 
-34 (-59, -9) 
 
- 
0.008 
 
0 
-16 (-41, 9) 
 
- 
0.20 
Mean CD4 in reference category - - - 439  
(406, 472) 
<0.001 
*Infectious Disease Institute 
†Reference category: pre ART CD4 =100; pre STI/CT CD4 = 400; Age = 40 years (approximate medians) 
 
Estimated reductions in CD4 132 weeks post sub-study closure associated with one, two, three 
or 4 cycles of STIs were 58, 53, 43 and 14 cells/µL compared to CT. Overall CD4, 132 weeks 
after sub-study closure was 51 cells/µL lower in STI vs. CT (95% CI 28-74, adjusted p<0.001) 
with no evidence of significant variation across number of cycles (heterogeneity p=0.61). Figure 
3.3.2 suggests that one reason the point estimate for 4 cycles may be closer to 0 is that the 
group of patients who undertook 4 cycles is more highly selected (only 52% of those who could 
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have theoretically had 4 cycles of STIs). As expected there was an effect of earlier CD4 counts 
on CD4 132 weeks after sub-study closure; with CD4 132 weeks after sub-study closure being 
marginally higher in those with higher pre-ART CD4 (increase of 10 cells/µL for every 50 
cells/µL higher at ART initiation (randomisation into the main trial), p=0.06) and significantly 
higher in those with higher CD4 at STI/CT randomisation (increase of 29 cells/µL for every 50 
cells/µL higher at CT/STI randomisation, p<0.001). I also found a gender effect with females 
having a higher CD4 at 132 weeks than males (p<0.001). Patient’s age at ART initiation had no 
significant effect, nor did monitoring strategy or weeks on ART at STI randomisation (all p>0.1). 
There was no evidence that the effect of the number of STI cycles or having undergone any 
STIs varied by whether patients were monitored using CD4 or not (interaction p=0.19, p=0.42 
respectively).  
Although patients who stopped STIs for clinical/patient reasons might have been expected to 
have lower CD4 132 weeks after sub-study closure than those stopping STIs specifically 
because of sub-study closure, reductions in CD4 were in fact similar in those who stopped their 
STIs due to clinical/patient reasons, compared with those who stopped due to sub-study closure 
(heterogeneity p=0.67) (Figure 3.3.5).  
Figure 3.3.5 Impact of number of STI cycles and reason for stopping STIs on CD4 132 
weeks after sub-study closure (adjusted for other the factors in Table 3.3.2) 
 
Because sub-study closure happened at a fixed date, some patients were restarted on ART in 
the middle of an STI. Therefore, even though the number of STIs is the same, the actual 
amount of time off ART varies somewhat. I have therefore also looked at the effect of STIs by 
considering the effect of total duration off treatment for STIs; results from this analysis support 
the results above with no evidence of an increasing detrimental effect for longer periods off 
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(ever/never off ART: CD4 77 cells/µL lower [95%CI -133, -22] at 132 weeks post sub-study 
closure, p=0.01, and 1.00 cells/µL higher [-0.90, 2.91] per week off treatment at 132 weeks post 
sub-study closure, p=0.30; methods as described in section 3.2.10 adjusted for the other factors 
in Table 3.3.2). 
3.3.3. Clinical Outcomes 
During the randomised phase there were 773 person years (PYs) at risk and there were 788 
PYs at risk subsequently (i.e. after 16th March 2006). During the randomised phase there were 
higher rates of both new WHO 4 events/death (p=0.008) and new WHO3/4 events/death 
(p<0.001) in STI vs. CT (Table 3.3.3 & Figure 3.3.6). After sub-study closure, rates of new WHO 
4 events/death and WHO 3/4 events/death declined in both groups but remained higher in those 
having previous STIs. In particular, interaction tests investigating heterogeneity in STI vs. CT 
effects before and after sub-study closure supported excess risk associated with randomisation 
to STI persisting post sub-study closure (p>0.7 i.e. no evidence that the STI-associated excess 
changed). However power was too low to detect any genuine differences between STI and CT 
in mortality post sub-study closure (Table 3.3.3). After sub-study closure, rates of switch to 
second-line were greater than during the randomised phase in both groups with a trend towards 
greater rates in STI vs. CT (p=0.08): there were no switches to second-line in the CT group 
during the study so I cannot estimate this rate. Rates of immunological failure (CD4<100 
cells/µL) were greater after sub-study closure with a significantly higher rate in the STI group 
(p=0.04) during this period, although there was no evidence of heterogeneity between time 
periods overall (p=0.21).  
Table 3.3.3 Effect of STIs before and after sub-study closure on clinical events, switch to 
second-line and immunological ART failure 
 
 
Before 16th March 2006 
Randomised phase 
After 16th March 2006 
All patients on continuous 
therapy 
 STI vs. CT STI vs. CT 
Total PYs at risk 773 788 
Deaths 5 vs. 4 
1.3 vs. 1.0/100PYs 
RR=1.24 (0.33-4.62), p=0.32 
3 vs. 1 
0.8 vs. 0.3/100PYs  
RR=3.02 (0.31-29.0), p=0.34 
New WHO4 event/death 24 vs. 9 
6.4 vs. 2.4/100PYs 
RR=2.65 (1.23-5.69) p=0.008 
4 vs. 2 
1.1 vs. 0.5/100PYs 
RR=2.08 (0.38-11.38) p=0.40 
New WHO3/4 event/death 52 vs. 23 
14.4 vs. 6.1/100PYs 
RR=2.24 (1.37-3.67) p<0.001 
11 vs. 6 
3.4 vs. 1.7/100PYs 
RR=1.98 (0.73-5.37) p=0.18 
Switch to second-line 3 vs. 0 
 
40 vs. 26 
10.0 vs. 6.7/100PYs 
RR=1.55 (0.95-2.55) p=0.08 
CD4<100 cells/µL 3 vs. 4 
0.8 vs. 1.0/100PYs 
RR=0.74 (0.17-3.32) p=0.70 
25 vs. 12 
2.3 vs 1.1/100PYs 
RR=2.08 (1.04-4.14) p=0.04 
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Figure 3.3.6 Effect of STIs on clinical events, switch to second-line and immunological 
ART failure before and after sub-study closure 
 
3.3.4. Unplanned Treatment interruptions (UPTIs) in DART and ARROW 
Planned treatment interruptions (STIs) occurred as a result of the DART STI sub-study. But in 
addition to these planned interruptions there were patients who had had unplanned treatment 
interruptions (UPTIs). 
In addition to the 404 patients in the DART trial who were part of the STI sub-study and had at 
least 1 STI cycle, 1055 of 3316 (32%) adults in DART had at least one UPTI lasting ≥4 days 
recorded on their CRFs; median total UPTI duration per patient was 18 days (IQR 7-49). There 
were a total of 1955 UPTIs lasting a median of 9 days (IQR 6-24) (Table 3.3.4). Overall 1434 
(43%) adults had at least one TI (STI or UPTI) lasting ≥4 days, 1253 (38%) and 1006 (30%) with 
a TI lasting >7 or >14 days respectively with median total time off treatment of 56 days (IQR 13-
163). A similar proportion of patients had UPTIs in both the CD4 and no CD4 monitoring groups 
(chi-squared p=0.81), therefore I have grouped the two monitoring strategies together below. In 
DART, of the 1055 patients who had at least 1 unplanned treatment interruption, 90% (n=957) 
had 3 or fewer interruptions with <1% (n=9) of patients having ≥10 interruptions.  
 
  
1.00.2 0.5 1.5 2.0 5.0 10.0
Death
New WHO4 
event/death
New WHO 3/4 
event/death
Switch to 
Outcome
Before
After
Before
After
Before
After
Before or after 
sub-study closure
Before
After
Rate per 100PYs 
(# events)
0.008
<0.001
0.04
0.41
Pooled p-value
STI vs. CT
Interaction
p-value*
Before vs. after 
Sub-study closure
0.51
0.78
0.78
CD4< 100 Before
After
1.3 (5)
0.8 (3)
6.4 (24)
1.1 (4)
14.4 (52)
3.4 (11)
0.8 (3)
10.0 (40)
STI
0.8 (3)
2.3 (25)
0.08 0.21
CT worse STI worse
1.0 (4)
0.3 (1)
2.4 (9)
0.5 (2)
6.1 (23)
1.7 (6)
0 (0)
6.7 (26)
CT
1.0 (4)
1.1 (12)
Not 
applicable
Not applicable
second-line
cells/mm3
*Test whether the difference between STI vs. CT varies during randmonised phase and post sub-study closure (16th March 2006)
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Table 3.3.4 DART Treatment interruptions (planned and unplanned) 
Treatment interruptions Unplanned Any 
Patients with at least one interruption 1055/3316 (32%) 1434/3316 (43%) 
Patients with at least one interruption that lasted 
 >7days 
 >14 days 
 
842/3316 (25%) 
539/3316 (16%) 
 
1253/3316 (38%) 
1006/3316 (30%) 
Median length of all time off treatment  
(IQR) 
[range] 
18  
(7-49) 
[4-957] 
56  
(13-163) 
[4-1272] 
Total number of TIs per patient* 
 0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 ≥10 
 
2261 
626 (59%) 
243 (23%) 
88 (8%) 
37 (4%) 
24 (2%) 
12 (1%) 
8 (<1%) 
5 (<1%) 
3 (<1%) 
9 (<1%) 
 
1882 
618 (43%) 
369 (26%) 
212 (15%) 
125 (9%) 
52 (4%) 
24 (2%) 
15 (1%) 
6 (<1%) 
3 (<1%) 
10 (<1%) 
Total number of interruptions 1955 3205 
Median length of an interruption  
(IQR) 
[range] 
9  
(6-24) 
[4-957] 
21  
(7-83) 
[4-1104] 
* Percentages are of patients with any interruption 
There were no planned treatment interruptions by design in ARROW, but as adults did in DART, 
children too had unplanned treatment interruptions. 285 of 1206 (24%) children in ARROW had 
at least one UPTI lasting ≥4 days, with a median total UPTI duration per patient of 13 days (IQR 
7-34) (Table 3.3.5), significantly fewer individuals than in DART (32% vs. 24%, p<0.001). In 
ARROW there were a total of 546 UPTIs lasting a median of 7 days (IQR 6-14). There were 211 
(17%) and 115 (10%) UPTIs lasting >7 days and >14 days respectively. Of the 285 children 
who had at least 1 UPTI, a similar proportion as DART had 3 or fewer interruptions; 252 (88%), 
with <1% (n=11) having ≥6 UPTIs. 
Table 3.3.5 ARROW Treatment interruptions (unplanned) 
Treatment interruptions LCM n=600 
CDM 
n=606 
Total 
N=1206 
Patients with at least one interruption 141 (24%) 144 (24%) 285 (24%) 
Patients with at least one interruption that lasted
 >7days 
 >14days 
 
108 (18%) 
63 (11%) 
 
103 (17%) 
52 (9%) 
 
211 (17%) 
115 (10%) 
Median length of all time off treatment  
(IQR) 
[range] 
16  
(7-36)  
[4-169] 
12  
(7-32)  
[4-248] 
13  
(7-34)  
[4-248] 
Total  number of TIs per patient* 
 0 
 1 
 2 
 3 
 4 
 5 
 ≥6 
 
459 
77 (55%)* 
31 (22%) 
14 (10%) 
5 (4%) 
7(5%) 
7(5%) 
 
462 
88 (61%) 
30 (21%) 
12 (8%) 
6 (8%) 
4 (3%) 
4 (3%) 
 
921 
165 (58%) 
61 (21%) 
26 (9%) 
11 (4%) 
11 (4%) 
11 (4%) 
Total number of interruptions 285  261  546 
Median length of an interruption  
(IQR) 
[range] 
7 
 (6-14)  
[4-88] 
7  
(5-15) 
 [4-248] 
7 
 (6-14) 
[4-248] 
*Percentages are of patients with any interruption 
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In ARROW there was no evidence of a difference in the number of interruptions between 
randomised monitoring strategies (p=0.35), but there was a slightly higher total time off 
treatment per patient in the CD4 monitoring group (p=0.06); however as the difference is 
marginal and the IQRs are similar, monitoring strategies have been grouped together below. 
3.3.5. Reasons for unplanned treatment interruptions (DART and ARROW) 
In both DART and ARROW the reason for an unplanned treatment interruption (UPTI) was 
recorded in nearly all patients. A full breakdown of the reasons for UPTIs is shown in Table 
3.3.6 (DART) and Table 3.3.7 (ARROW).  
In DART the most common reasons for UPTIs were structural (1351, 69%) which mostly 
consisted of patients being unable to attend clinic (1193, 61%) (Table 3.3.6B); other structural 
reasons included being in prison/custody, drugs lost or stolen, or running out of drugs (including 
1 dispensing error, 1 wrong dose instruction and 1 wrong clinic date). This was followed by 
adverse events (432, 22%), of which >50% were due to blood disorders. Adverse events 
included neutropenia, anaemia, hypersensitivity, vomiting (reported as an adverse event), acute 
hepatic failure; a full list is in Table 3.3.6A. There were 65 (3%) UPTIs that were due to illness 
including 12 related to psychosis/mental illness which included hearing voices (Table 3.3.6C). 
There were 102 (5%) UPTIs that were due to voluntary decisions by patient to stop, including 13 
related to divine healing/faith. For 38 (37%) of these voluntary decisions there were no further 
details. In 8 (8%) the patient had forgotten, 3 (3%) were discouraged by relatives and in addition 
12 (12%) were due to vomiting, but these had not been reported as adverse events and were 
simply the reason given by the patient. 
Table 3.3.6 Full description of reasons for UPTIs (adults) 
A: Adverse events 
Adverse event N % 
Neutropenia 108 25% 
Anaemia 104 24% 
Lactic acidosis 71 16% 
Hepatotoxicity 21 5% 
Pancreatitis 12 3% 
Renal failure 12 3% 
Hypersensitivity 11 3% 
Vomiting 11 2% 
Raised LFTs 10 2% 
Hepatitis 6 1% 
Myopathy 5 1% 
Congestive heart failure 4 1% 
Peripheral neuropathy/paraesthesia 4 1% 
Steven Johnson Syndrome 4 1% 
Anaemia & neutropenia 3 1% 
Diarrhoea 3 1% 
Jaundice 3 1% 
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Rash 3 1% 
Abdominal pain 2 0.5% 
Intestinal obstruction 2 0.5% 
Lipodystrophy 2 0.5% 
Lipodystrophy & lactic acidosis 2 0.5% 
Liver failure 2 0.5% 
Nephritis 2 0.5% 
Steatosis 2 0.5% 
Upper GI haemorrhage 2 0.5% 
Bi-polar affective disorder 1 0.5% 
Bone pain 1 0.2% 
Bronchospasms 1 0.2% 
Cardiomyopathy 1 0.2% 
Cardiomyopathy & DVT 1 0.2% 
Cirrhosis 1 0.2% 
Convulsions 1 0.2% 
Hepatic failure (acute) 1 0.2% 
Jaundice & liver failure 1 0.2% 
Metabolic acidosis 1 0.2% 
Muscle toxicity 1 0.2% 
Myopathy & raised CPK 1 0.2% 
Nausea 1 0.2% 
Neutropenia & fatigue 1 0.2% 
Non-fatal trauma 1 0.2% 
Pancytopenia 1 0.2% 
Pruritus 1 0.2% 
Raised bilirubin 1 0.2% 
Raised creatinine 1 0.2% 
Raised LFTs & neutropenia 1 0.2% 
SJS & diarrhoea 1 0.2% 
Total 432  
B: Structural 
 
* There are no other details for these patients;  
† Includes 1 wrong dispense, 1 wrong dose instruction, 1 wrong clinic date 
 
Structural N % 
Unable to attend* 1193 88% 
Patient travelled 55 4% 
Patient failed to return 43 3% 
In prison/custody 19 1% 
Drugs stolen 13 1% 
Ran out of drugs† 8 1% 
Drugs lost 7 1% 
Moved away 6 0% 
No transport 6 0% 
Overdosed 1 0% 
Total 1351 
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C: Illness 
Illness N % 
Patient felt unwell 13 20% 
Psychosis/mental illness 12 18% 
Intercurrent illness 10 15% 
Admitted to hospital 9 14% 
Too ill to take drugs 9 14% 
Anti-TB treatment 8 12% 
Anorexia/diarrhoea/vomiting 2 3% 
Interrupted for palpitations 1 2% 
Paralytic ileus, no oral feed 1 2% 
Total 65  
 
D: Voluntary decision 
Voluntary decision N % 
No further details given 38 37% 
Seeking/has divine healing/faith reasons 13 13% 
Vomiting* 12 12% 
Patient forgot/misunderstood 8 8% 
Discouraged by relatives 3 3% 
Pill burden 3 3% 
Advised by other doctor 2 2% 
Abdominal pain* 2 2% 
Felt depressed 2 2% 
No longer interested 2 2% 
To avoid side effects 2 2% 
Domestic problems 2 2% 
Diarrhoea* 1 1% 
Fear of drugs 1 1% 
Fear of hypersensitivity 1 1% 
Fear of lipodystrophy 1 1% 
Nausea* 1 1% 
Felt well 1 1% 
Has dental wiring 1 1% 
Left without collecting drug 1 1% 
Nausea & night terrors 1 1% 
Patient was fasting - reason unknown 1 1% 
Patient drowsy 1 1% 
Refused to take medicine 1 1% 
Sweating* 1 1% 
Total 102 
 *Not reported as adverse events but as patient reason 
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A full breakdown of reasons for unplanned treatment interruptions in ARROW is shown in Table 
3.3.7. I have categorised the reasons in ARROW as I did in DART, however voluntary reason is 
now presented with the subcategories patient and carer as the carer also plays a role in 
whether or not a child receives treatment. Structural reasons have been split into ‘structural 
patient’ and ‘structural carer’, for the same reason.  
As in DART the most common reasons for a treatment interruption in ARROW were structural, 
here due to the child (335, 61%) which as in DART consisted mostly of being unable to attend 
clinic (271, 50%); other structural patient reasons included no access to drugs, child travelled or 
child had moved. This was followed by structural reasons due to the carer (85, 16%) which 
included loss of drugs by carer, carer travelled or moved or the carer had no transport. The next 
most common reason was a voluntary (child/carer) decision to stop (child 71, 13%; carer 24, 
4%) which mostly consisted of carer or child refusing to give/take drug. Other voluntary reasons 
for the child included pill burden, social reasons/stigma and forgetting to take drug. As in DART 
there were some carers who did not administer drugs to the child due to spiritual healing/faith.  
Table 3.3.7 Details of reasons for interrupting treatment (children) 
A: Adverse event 
Adverse event Total % 
Weakness/dizzy 1 17% 
Hepatitis toxicity 1 17% 
Hypersensitivity reaction 1 17% 
Pre-existing cholesystitis 1 17% 
Raised liver enzymes 1 17% 
Vomiting 1 17% 
Total 6  
 
B: Structural – carer 
Structural - carer N % 
Carer travelled 34 40% 
Carer moved/not around 23 27% 
Carer did not attend 13 15% 
Changed carer 7 8% 
Carer lost drugs/syringes/did not take drugs with them 4 5% 
Carer no transport 4 5% 
Total 85  
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C: Structural – Patient 
Structural - patient N % 
Unable to attend 271 82% 
Patient travelled 22 7% 
Patient did not attend 16 5% 
Patient moved 6 2% 
Patient no transport 6 2% 
No access to drugs 4 1% 
No food 3 1% 
Patient lost drugs 2 1% 
In prison† 1 0.3% 
Total 331  
†Girl aged 13 at randomisation 
D: Illness 
Illness N % 
Carer unwell 11 52% 
Child too unwell 4 19% 
Intercurrent illness 2 10% 
Mother developed psychosis 2 10% 
Drugs causing child to cough 1 5% 
Oral Sores 1 5% 
Total 21  
 
E: Voluntary decision – patient 
Voluntary decision – patient  N % 
Child refused/decided to stop drugs 29 38% 
Child forgot 23 30% 
Pill burden 10 14% 
Social reasons/stigma 8 11% 
Family problems 4 5% 
Got married 1 1% 
Said pills would prevent pregnancy 1 1% 
Total 76  
 
F: Voluntary decision – carer 
Voluntary decision – carer N % 
Carer refused/decided not to give drugs 12 48% 
Carer forgot 9 36% 
Carer used spiritual healing 3 12% 
Not disclosed to spouse 1 4% 
Total 25  
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Table 3.3.8 Reasons for unplanned treatment interruptions 
 Adults Children 
Reason* Number of UPTIs Number of patients Duration of UPTI (days) Number of UPTIs Number of patients Duration of UPTI (days) 
  N % N %* Median (IQR) N % N %* Median (IQR) 
Adverse event 432 22% 358 31% 15 (7-35) 6 1% 6 2% 11 (6-39) 
Structural 
 Patient 
 Carer 
1351 
- 
69% 
- 
660 
- 
57% 
- 
7 (6-16) 
- 
335 
85 
61% 
16% 
190 
72 
52% 
20% 
7 (5-14) 
7(5-13) 
Illness 65 3% 54 5% 12 (7-23) 21 4% 20 5% 7 (6-13) 
Voluntary reason 
 Patient 
 Carer 
102 
- 
5% 
- 
89 
- 
8% 
- 
18 (7-89) 
- 
71 
24 
14% 
4% 
53 
23 
14% 
6% 
11 (6-25) 
12 (7-22) 
Not recorded 5 0.3% 5 0.4% 14 (13-14) 4 0.7% 4 1% 9 (7-12) 
Total 1955  1055†  9 (6-24) 546  285†  7 (6-14) 
*Percentage of patients reporting any UPTI included for all reasons 
†Not equal to column total as patients can occur in more than one category 
 
Table 3.3.8 shows a summary of the main reason categories in adults and children together for ease of comparison. These data are also displayed in Figure 3.3.7. 
Adverse events were a much less common reason for interrupting ART in children compared to adults. Possible reasons could be greater difficulty in ascertaining 
AEs in children, which may then get reported as a voluntary reason for not taking drugs. In these specific analyses, adults in DART all took zidovudine long-term as 
part of their NRTI backbone, whereas only one-third of children in ARROW took zidovudine after 36 weeks. As this drug is known to cause haematological and some 
gastrointestinal toxicity it may be that rates were genuinely lower in ARROW. However, the main ARROW trial found little difference between randomised ART 
groups in overall toxicity rates. Thus children may have lower AE rates regardless of the specific drugs as they tend to tolerate drugs well.  
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In adults the median unplanned total time off treatment per patient per reason differed 
significantly across the different reasons (p<0.001) with the longest time off being for a voluntary 
reason (median 18 days IQR [7-89]), followed by adverse events (15 [7-35]) and illness (12 [7-
23]). The shortest time off was for structural reasons (7 [6-16]). Results were similar in children 
with the median unplanned total time off treatment also differing across the different reasons 
(p=0.01) with the longest time off being for voluntary reasons for not taking drugs (median 11 
days IQR [6-25] for patients and 12 [7-22] for carers) and adverse events (11 [6-39]). The 
shortest unplanned total time off treatment was for non-adverse event illness (7 [6-13]) and 
structural patient (7[5-14]) and structural carer (7[5-13]) reasons. Generally time off treatment 
for UPTIs was shorter for children than for adults (p<0.001). Surprisingly, children had less time 
off for voluntary reasons than adults (median 11 days children vs. 18 days adults, p=0.04) and 
there was a similar pattern for adverse events (median 11 days children vs. 15 days adults, but 
non-significant, p=0.73). Time off treatment due to illness was also less in children than adults 
(median 7 days children vs. 12 days adults, p=0.03). As might be expected, time off for 
structural reasons was similar with a median of 7 days in both adults and children; the median 
test however showed that there was a significant difference in time spent off for structural 
reasons between the two groups based on the data distribution via the sum of ranks (p=0.02). 
Figure 3.3.7 Reasons for unplanned treatment interruptions (DART and ARROW) 
 
3.3.6. Effect of total duration off treatment on long term CD4 in DART 
Here I am interested in the impact of total duration off treatment on long term CD4 in DART; the 
outcome of interest is CD4 at 4 years post ART initiation. There were data on CD4 at 4 years for 
2826 (85%) adults; 339 (10%) had died prior to 4 years, 139 (4%) were lost to follow-up and 12 
(<1%) had no CD4 count available. 
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As discussed in the methods (section 3.2.7) I assessed the effect of total duration off treatment 
first using multivariable fractional polynomials (MFPs) excluding any UPTIs that occurred after 
CD4 at 4 years. All STIs occurred before 4 years. I have adjusted for baseline factors, total 
duration off treatment and whether a patient ever/never interrupted ART (based on my findings 
from the STI sub-study analysis) (Table 3.3.9).  
Table 3.3.9 Modelling effect of total time off treatment on CD4 at 4 years using MFP 
Variable Estimate**  
(95%CI) 
p-value Powers 
Ever/never had an interruption  
(any time off treatment) 
-3 (-17, 11) 0.70  
Total time off treatment (per week)* 0.5 (-0.11, 1.17) 0.11 1 
Sex: Male 
 Female 
0 
55 (43, 67) 
- 
<0.001 
 
1 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 IDI†, Mulago 
 
0 
-18 (-32, -4) 
6 (-4, 20) 
-16 (-37, 4) 
 
- 
0.01 
0.37 
0.12 
 
1 
 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
-19 (-30, -8) 
 
- 
-0.001 
 
1 
Pre ART CD4  
(per 50 cells/µL higher)‡ 
 
26 (21, 30) 
 
<0.001 
1 
Age at ART initiation  
(per 10 years older)‡ 
 
-8 (-15, -0.8) 
 
0.03 
1 
*Both STIs and UPTIs; †Infectious disease Institute; ‡Reference category: pre ART CD4 = 100 cells/µL; 
age=40 years 
**Note there were no transformation of covariates for any covariate 
Number of observations = 2826 (number of patients with CD4 at 4 years post ART initiation) 
 
These results suggest that there is no effect of having had any time off ART and the more time 
off treatment a patient has the higher their CD4 count at 4 years (although not statistically 
significant). Based on the results shown in Table 3.3.2 this contradicts the randomised 
comparison of STI vs. CT suggesting there is unadjusted confounding. Even though they are 
slightly different endpoints, CD4 at 4 years post randomisation should not be too far from CD4 
at 132 weeks post sub-study closure. One issue with MFP is that I have chosen a relatively 
stringent cut off for non-linearity (=0.05 in the notation of section 3.2.8), hence a linear fit has 
been chosen in the model for all participants. If I simply allow the model to choose the “best” 
fractional polynomial for total time off treatment (=1 in the notation of section 3.2.8) then a FP2 
model with the power p1=-1 and p2=-1 is chosen; i.e. it has fit total duration off treatment using a 
FP of order 2 (fitting two FPs) which both have powers of the order of -1. Comparing the AICs 
for these two models (36121.97 and 36114.29 respectively) would suggest that the FP(-1,-1) 
model is a modestly better fit to the data. Figure 3.3.8 shows how this model has been fit to the 
total time off treatment data. 
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Figure 3.3.8 MFP fit for total time off treatment in all patients (CD4 at 4 years) 
 
The results suggest that there is an initial rapid decrease in CD4 count at 4 years for patients 
taking any time off ART (Figure 3.3.8; red line) followed by a fairly consistent CD4 for increasing 
time off treatment. I have investigated this further, first by fitting the same model to the CD4 at 
132 weeks post STI sub-study closure endpoint in just the STI/CT sub-study patients to see 
whether I found a similar result (Table 3.3.10).  
Table 3.3.10 Modelling the effect of total time off treatment on CD4 at 132 weeks post 
sub-study closure using MFP (STI sub-study patients only). 
Variable Estimate** for STIs 
(95%CI) 
p-value Powers 
Ever/never had an interruption  
(any time off treatment) 
-77 (-133, -22) 0.007 1 
Total time off treatment (per week)* 1.0 (-0.90, 2.91) 0.30 1 
Sex: Male 
 Female 
0 
86 (54, 117) 
- 
<0.001 
1 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 IDI†, Mulago 
 
0 
-11 (-48, 26) 
-9(-41, 23) 
-53 (-112, 6) 
 
- 
0.56 
0.08 
0.79 
 
1 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
-4 (-31, 24) 
 
- 
0.79 
 
1 
Pre ART CD4  
(per 50 cells/L higher) ‡ 
20 (7, 32) 0.002 1 
Age at ART initiation  
(per 10 years older)‡ 
0.1 (-0.1, 0.4) 0.30 1 
*For STIs and UPTIs in STI sub-study patients only; †Infectious disease Institute; ‡Reference category: pre 
ART CD4 = 100 cells/µL; age=40 years 
**Note there were no transformations of covariates for any covariate 
Number of observations = 741 (number of patients with CD4 at 132 weeks post sub-study closure in the 
STI/CT patients) 
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In contrast to the overall model, this model suggests that ever having any time off treatment 
results in a significant decrease in CD4 and that as total time off increases there is a non-
significant increase in CD4 count. The model estimates for the impact of ever having had an 
interruption are very different. 
Tables 3.3.9 and 3.3.10 show that for both CD4 at 4 years and CD4 132 weeks after sub-study 
closure when including the ever/never off ART variable and allowing the MFP model to fit any 
transformation to the total time off, the best fit for the total time off is in fact a linear model. 
However, both models suggest a non-significant increase in CD4 for more time off treatment 
which is not expected. One possibility is that there is perhaps something different about patients 
having unplanned treatment interruptions. I fitted several models to investigate the effect of total 
duration off treatment, considering STIs and UPTIs separately and also the total duration off 
treatment for all TIs. I used both CD4 132 weeks post STI sub-study closure in STI/CT patients 
only (Table 3.3.11) and CD4 at 4 years post randomisation in all patients (Table 3.3.12) as 
endpoints. In all models I have fit an ever/never off ART variable and allowed MFP to choose 
the “best” model. This does mean that results cannot necessarily be compared across models; 
however, MFP consistently chose linear functions meaning this was possible.  
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Table 3.3.11 Effect of duration off treatment on CD4 132 weeks after sub-study closure (STI/CT patients only) 
Total duration off treatment 
 
 CD4 at 132 weeks after 16th March 2006  
n=741 
  Number of STIs 
(Table 3.3.2) 
Total duration of 
STIs  
Total duration of 
unplanned 
interruptions‡  
Total duration of 
all interruptions  
  
Total duration of all 
interruptions 
STI and UPTI separately 
Ever/never had an 
interruption 
or 
Number of STI cycles 
 
0 (CT) 
1 
2 
3 
4 
0 
-58 (-107, -9) 
-55 (-93, -18) 
-47 (-85, -8) 
-18 (-88, 52) 
 
-77 (-133, -22) 
 
 
1 (-38, 39) 
 
-39 (-81, 2) 
 
 
UPTI: -2 (-40, 37) 
STI: -77 (-133, -22) 
 
heterogeneity p=0.02 
Total duration off treatment 
per week 
(modelled as chosen by 
MFP*) 
  
 n/a 
 
1 (-1, 3) 
 
0 (-4, 5) 
 
-0 (-2, 1) 
 
UPTI: 1 (-4, 5) 
STI: 1 (-1, 3) 
 
heterogeneity p=0.88 
Sex  Male 
  Female 
 0 
86 (54, 118) 
0 
86 (54, 118) 
0 
86 (54, 119) 
0 
85 (53, 117) 
0 
86 (54, 118) 
Centre Entebbe 
  Kampala 
  Harare 
  IDI† 
 0 
-14 (-51, 24) 
-9 (-41, 24) 
-53 (-113, 6) 
0 
-11 (-48, 26) 
-9 (-41, 23) 
-53 (-112, 6) 
0 
-16 (-53, 22) 
-10 (-42, 23) 
-51 (-110, 9) 
0 
-12 (-49, 26) 
-10 (-43, 22) 
-49 (-108, 10) 
0 
-11 (-49, 26) 
-9 (-41, 23) 
-54 (-113, 5) 
Monitoring strategy  
  LCM 
  CDM 
  
0 
-4 (-31, 23) 
 
0 
-4 (-31, 24) 
 
0 
-4 (-31, 24) 
 
0 
-4 (-31, 23) 
 
0 
-4 (-31, 24) 
Baseline CD4 (per 50 
cells/µL3, centred at 100) 
  
20 (7, 32) 
 
20 (7, 32) 
 
19 (7, 32) 
 
21 (8, 33) 
 
20 (7, 32) 
Age at baseline (per 10 
years, centred at 40) 
  
-0 (-18, 17) 
 
-0 (-18, 18) 
 
1 (-17, 19) 
 
0 (-17, 18) 
 
-0 (-18, 18) 
Constant (mean CD4 in 
reference category) 
  
431 (394, 469) 
 
452 (409, 496) 
 
415 (378, 452) 
 
439 (396, 481) 
 
453 (408, 498) 
*MFP has chosen a linear model of order 1 for each model 
†Infectious Disease Institute 
‡Ignoring time off for STIs 
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Looking across rows of Table 3.3.11 (STI/CT patients only) I note first that all other effects remain similar to 
that from my original analysis (Table 3.3.2, repeated in the first column of Table 3.3.11 for reference). 
However, the impact of treatment interruptions (TIs) varies depending on whether I consider all TIs, planned 
TIs (STIs) or unplanned TIs (UPTIs). The model where I include STI and UPTI as separate covariates shows 
different effects for ever/never interrupting ART (test for heterogeneity p=0.02); however they are in the 
same direction and differ only in magnitude. The effects of total time off treatment are small and there is no 
evidence of a difference for UPTI and STI (heterogeneity p=0.88). Results are similar in Table 3.3.12 (all 
patients) where effects of all other factors are similar regardless of whether all TIs, planned TIs or unplanned 
TIs are modelled but again the effects of STIs and UPTIs appear to be different; this time the effect of STIs is 
in the opposite direction for the ever/never off depending on whether unplanned or all TIs are modelled, 
however these effects are small.  
Further, even when I have included UPTIs and STIs separately in one model the estimate of effect suggests 
CD4 at 4 years is 57 cells/µL higher in those who have undertaken STIs. Again, as with the patients 
receiving all 4 cycles of STIs, those who were randomised into the STI/CT sub-study would be a selected 
sub population who will have been doing better at STI/CT randomisation compared to those not randomised 
to the STI sub-study. I therefore next adjusted for whether or not a patient had been randomised to the 
STI/CT sub-study (5th column of Table 3.3.12). In this final adjusted model those undertaking STIs had lower 
CD4 counts at 4 years than those not undertaking STIs, in agreement with the main STI/CT analysis; 
however the effect of UPTIs has remained the same. I note however that power was too low to exclude 
these differences between STI and UPTIs being compatible with chance. 
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Table 3.3.12 Effect of duration off treatment on CD4 4 years after ART randomisation (all patients) 
Total duration off treatment 
Continuous variable 
CD4 at 4 years 
 Total duration of 
STI cycles STI/CT 
pts only (n=782) 
Total duration of 
unplanned 
interruptions 
(n=2826) 
Total duration of 
all interruptions  
(n=2826) 
Total duration of all 
interruptions STI and 
UPTI separately 
(n=2826) 
Total duration of all interruptions 
STI and UPTI separately - 
adjusting for STI/CT  
randomisation or not 
(n=2826) 
Randomised to STI/CT 
 No 
 Yes 
 
- 
 
- 
 
- 
 
- 
 
0 
128 (113, 144) 
Ever/never had an interruption 
 
-58 (-102, -14) -0 (-14, 14) 
 
0 (-0, 0) 
 
UPTI: 1 (-13, 15)) 
STI: 57 (19, 95) 
heterogeneity p=0.006 
UPTI: 2 (-11, 16) 
STI: -48 (-86, -9) 
heterogeneity p=0.02 
Total duration off treatment per 
week (modelled as chosen by 
MFP*) 
0 (-2, 2) -2 (-3, -1) -19 (-117, 79) UPTI: -2 (-3, -1) 
STI: -1 (-2, 1) 
heterogeneity p=0.11 
UPTI: -2 (-3, -1) 
STI: -0 (-2, 1) 
heterogeneity p=0.11 
Sex  Male 
  Female 
0 
54 (29, 79) 
0 
55 (43, 66) 
0 
55 (43, 67) 
0 
54 (42, 65) 
0 
49 (38, 60) 
Centre  Entebbe 
  Kampala 
  Harare 
  IDI 
0 
21 (-8, 50) 
36 (10, 61) 
-11 (-58, 36) 
0 
-18 (-31, -4) 
6 (-8, 19) 
-15 (-36, 5) 
0 
-18 (-32, -4) 
6 (-7, 20) 
-16 (-37, 4) 
0 
-15 (-28, -1) 
7 (-7, 20) 
-12 (-33, 8) 
0 
-3 (-16, 11) 
11 (-2, 24) 
-3 (-23, 17) 
Monitoring strategy  
  LCM 
  CDM 
 
0 
-13 (-34, 9) 
 
0 
-18 (-29, -8) 
 
0 
-19 (-29, -8) 
 
0 
-18 (-29, -7) 
 
0 
-18 (-28, -8) 
Baseline CD4 (per 50 cells/µL3, 
centred at 100) 
 
5 (-5, 15) 
 
27 (22, 31) 
 
26 (21, 30) 
 
24 (19, 29) 
 
15 (11, 20) 
Age at baseline (per 10 years, 
centred at 40) 
 
-3 (-17, 11) 
 
-9 (-16, -2) 
 
-8 (-15, -1) 
 
-9 (-16, -2) 
 
-7 (-13, -0.1) 
Constant (mean CD4 in reference 
category) 
 
370 (336, 405) 
 
281 (268, 296) 
 
282 (268, 297) 
 
272 (257, 287) 
 
248 (234, 263) 
*MFP has chosen a linear model of order 1 for each model, †Infectious Disease Institute 
132 
 
As in section 3.3.4, UPTIs differed from STIs in length as well as their unplanned vs planned 
nature (median [IQR] 18 [7-49] days for UPTIs in DART vs 84 [56-84] days for STIs). In fact 75 
(7%) STIs were 84 days or longer and 765 (70%) were 70 days or longer; and the median (IQR) 
duration of STIs <70 days was only 7 (7-43) days. As described in section 3.2.9, fractional 
polynomials are better at modelling broad or global non-linearities, whereas other methods, 
such as natural cubic splines can be better models for local non-linearity. To further try to 
understand whether there was any evidence for local non-linearity here I tried to estimate the 
effects of duration of STIs and UPTIs using cubic splines, but they gave no additional insight 
(data not shown). Unfortunately, none of the additional non-linear spline terms were significant, 
making it difficult to distinguish signal from noise. There was certainly no evidence to support 
major non-linearity in effects at low durations of treatment interruptions. 
As the STI/CT population is so different and for example Tables 3.3.11 and 3.3.12 suggest that 
the effect of other factors may differ somewhat between them and patients never randomised to 
STI/CT, I have therefore decided to fit two separate models, one for patients in the STI/CT sub 
study and one for all other patients, which I have then combined using meta-analysis 
techniques to give an overall estimate for UPTIs.  
I have first fit my model for the impact of STIs and UPTIs on CD4 4 years after ART initiation in 
STI/CT patients (Table 3.3.13) adjusting for the other factors as in Table 3.3.9. I have then fitted 
a model for UPTIs in all other patients who are not part of the STI/CT sub-study (Table 3.3.14), 
adjusting for the other factors in Table 3.3.9.  
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Table 3.3.13 CD4 4 years from ART initiation: impact of STIs and UPTIs in STI/CT patients 
(n=782) 
Variable* Estimate (95%CI) p-value 
Ever/never had an interruption  
(any time off treatment STIs) 
-54 (-98, -10) 0.02 
Linear total time off treatment (STIs)  
(per extra week off ART) 
-0.1 (-1.6, 1.4) 0.89 
Ever/never had an interruption  
(any time off treatment UPTIs) 
5 (-25, 34) 0.76 
Linear total time off treatment (UPTIs)  
(per extra week off ART) 
-0.3 (-3.2, 2.7) 0.86 
Sex: Male 
 Female 
0 
54 (29, 79) 
- 
<0.001 
Centre:  
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Infectious Diseases Institute, Mulago 
 
0 
20 (-9, 50) 
36 (11, 61) 
-13 (-58, 36) 
 
- 
0.17 
0.01 
0.65 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
-13 (-34, 9) 
 
- 
0.25 
Pre ART CD4 (per 50 cells/µL higher)† 5 (-5, 15) 0.29 
Age at ART initiation (per 10 years older)† -3 (-17, 11) 0.70 
Mean CD4 in reference category 367 (332, 404) <0.001 
*Using backwards elimination (alpha=0.05) the following terms are independent predictors for CD4 at 4 years 
post ART initiation: any time off ART for STIs, sex and centre; †Reference category: pre ART CD4 = 100 
cells/µL; age=40 years 
Note: there is no interaction between STI/CT randomisation and total time off treatment for UPTIs or having 
ever had any time off for UPTIs (p=0.124 and p=0.668, respectively) 
 
 
Table 3.3.14 CD4 4 years from ART initiation: impact of UPTIs in non-STI/CT patients 
(n=2044) 
Variable* Estimate (95%CI) p-value 
Ever/never had an interruption  
(any time off treatment UPTIs) 
0.5 (-14, 15) 0.95 
Linear total time off treatment (UPTIs) 
(per extra week off ART) 
-2.1 (-3.5, -0.7) 0.001 
Sex: Male 
 Female 
0 
47 (35, 59) 
- 
<0.001 
Centre:  
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Infectious Diseases Institute, Mulago 
 
0 
-13 (-28, 1) 
-2 (-17, 13) 
-5 (-26, 16) 
 
- 
0.08 
0.81 
0.62 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
-19 (-30, -8) 
 
- 
0.001 
Pre ART CD4 (per 50 cells/µL higher)† 19 (14, 24) <0.001 
Age at ART initiation (per 10 years older)† -8 (-16, -1) 0.03 
Mean CD4 in reference category 266 (250, 281) <0.001 
*Using backwards elimination (alpha=0.05) the following terms are independent predictors for CD4 at 4 years 
post ART initiation: total time off for UPTIs, pre-ART CD4, sex and monitoring strategy; †Reference category: 
pre ART CD4 = 100 cells/µL; age=40 years 
Figure 3.3.9 shows the effects of UPTIs in STI/CT patients and non STI/CT patients.  
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Figure 3.3.9 Effect of UPTIs on CD4 at 4 years post randomisation for STI/CT and non-
STI/CT patients 
 
In non-STI/CT patients the more time off treatment for UPTIs a patient has the lower the CD4 
count at 4 years. In STI/CT patients there is a similar trend but it is less pronounced. Using 
meta-analysis techniques (where each population is like a trial in a meta-analysis; STI/CT or 
non STI/CT patients) I have combined the two estimates for UPTIs to give an overall estimate of 
-1.8 cells/μL per extra week off ART (95%CI -3.0, -0.5, p=0.006). This suggests that for every 
cumulative month off ART for a UPTI, CD4 4 years post ART initiation was 8 cells/µL lower 
(95%CI 2-13, p=0.001). There was no evidence of heterogeneity in this estimate between those 
who were randomised to the STI/CT sub-study and those who were not (p=0.27). In those 
patients randomised to STI/CT the model in Table 3.3.13 suggests that CD4 at 4 years was 54 
cells/µL (10-98) lower in those who had STIs (p=0.02), however there was no additional effect of 
longer STIs (p=0.89).  
3.3.7. Effect of total duration off treatment on long term CD4 in ARROW 
Here I am interested in the impact of total duration off treatment on long term CD4 in ARROW 
(children); the outcome of interest is CD4 at 3 years post monitoring strategy randomisation. 
There are two different ways of analysing the CD4 count, either as an absolute count (cells/µL) 
as I have done for adults or as a percentage of the total lymphocyte count (CD4%). In 
uninfected children the CD4 count is strongly dependent on age; it is very high (around 4000 
cells/µL) when children are born and then drops considerably to around 1000 cells/µL at around 
4/5 years of age. The CD4% is much more stable with age. As described in section 3.2.7 I have 
therefore modelled the CD4% at 3 years. 
There are data on 1145 patients for CD4 at 3 years (CD4% and absolute CD4 count); 45 (4%) 
died prior to 3 years and 16 (1%) were lost to follow-up. For every extra cumulative week off 
ART (all UPTIs), in a multivariable model CD4% 3 years after ART initiation was 0.4% lower 
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(0.07-0.6%, p=0.01) (Table 3.3.15) with no additional effect of having any time off treatment 
(p=0.28), consistent with the UPTI effect in adults. 
Table 3.3.15 Modelling the effect of duration off treatment on CD4% 3 years after ART 
randomisation 
Variable Estimate  
(95%CI) 
p-value 
Ever/never had an interruption (UPTIs) -0.8 (-2.3, 0.7) 0.28 
Total time off treatment per week -0.4 (-0.6, -0.07) 0.01 
Sex: Male 
 Female 
0 
2 (1, 3) 
- 
<0.001 
Centre: Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 PIDC* 
0 
2 (1, 4) 
4 (2, 5) 
2 (1, 4) 
- 
0.001 
<0.001 
0.008 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
-1 (-2, 0.2) 
 
- 
0.11 
First-line treatment strategy†: 
 Arm A 
 Arm B 
 Arm C 
 
0 
0.4 (-0.8, 2) 
-1 (-2, 0.2) 
 
- 
0.54 
0.11 
Pre ART CD4% (per 5% higher)‡ 2.5 (2.0, 2.5) <0.001 
Age at ART initiation (per 5 years older)‡ -4.0 (-4.5, -3.5) <0.001 
Mean CD4% in reference category 29 (27, 31) <0.001 
*Paediatric Infectious Disease Clinic  
†Arm A: NNRTI+3TC+ABC -> NNRTI+3TC+ABC, Arm B: NNRTI+3TC+ABC+ZDV -> 
NNRTI+3TC+ABC, Arm C: NNRTI+3TC+ABC+ZDV -> 3TC+ABC+ZDV 
‡Reference category: pre ART CD4%=10, Age=5 
 
There was no evidence of a significant effect of monitoring strategy or first-line treatment 
strategy (p>0.1) on CD4% three years after ART initiation. As expected there was an effect of 
baseline CD4% (2.5% higher for every 5% higher at baseline) and also age at ART initiation, 
with CD4% 4.0% lower for every 5 years older at baseline (both p<0.001). There was also a 
centre effect with patients in Zimbabwe having the highest CD4% at 3 years after ART initiation 
(+4% vs. Entebbe, p<0.001), followed by Kampala with a 3% greater CD4% than Entebbe and 
PIDC with a 2% greater CD4% than Entebbe (both p<0.001). 
3.3.8. Effect of cumulative time off treatment on clinical outcomes in adults (DART) 
As outlined in the methods (section 3.2.10) I first assessed the effect of cumulative time off 
treatment on clinical outcomes in adults using the MFP approach; the best power was FP(1). In 
a multivariable time-dependent Cox model having any time off treatment increased mortality risk 
(HR=3.12 [95%CI 2.34-4.13], p<0.001) but there was no independent effect of (time-updated) 
cumulative time off ART on mortality (HR=1.01 per week [0.99-1.03], p=0.17) (Table 3.3.16). As 
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expected there was a significant effect of pre-ART CD4 with a higher CD4 at baseline leading to 
a decrease in the risk of death (p<0.001) and an increase in the risk of death for those in the no 
CD4 monitoring group (p=0.002). There was no overall significant effect of centre (global 
p=0.14) although there was some evidence to suggest an increase in the hazard of death for 
patients at the Infectious Diseases Institute compared to those in Entebbe (p=0.02). 
Table 3.3.16 Modelling the effect of cumulative time off treatment on mortality in adults 
Variable* HR (95%CI) p-value 
Any time off ART (ever vs. never) 3.12 (2.35, 4.13) <0.001 
Cumulative time off treatment (weeks) 1.01 (0.99, 1.03) 0.17 
Sex: Male 
 Female 
1.00 
0.88 (0.71, 1.09) 
 
0.24 
Centre: Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Infectious Diseases Institute, Mulago 
1.00 
1.08 (0.83, 1.41) 
1.16 (0.88, 1.51) 
1.49 (1.07, 2.07) 
- 
0.58 
0.29 
0.02 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
1.00 
1.37 (1.12, 1.68) 
 
- 
0.002 
Pre ART CD4 (per 50 cells/L higher)† 0.67 (0.61, 0.73) <0.001 
Age at ART initiation (per 10 years older)† 1.07 (0.94, 1.22) 0.32 
†Reference category: pre ART CD4=100cells/µL, age=40 years 
*After model selection using backwards elimination with exit p=0.1 (BE(0.1)) the following variables remain 
independent predictors of mortality: monitoring strategy (p=0.002), any time off ART and pre ART CD4 (both 
p<0.001) 
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Table 3.3.17 Modelling the effect of cumulative time off treatment on mortality in adults (STI and UPTI separately for STI/CT and non-STI/CT patients) 
 STI/CT pts only Non STI/CT pts only Meta-Analysis combined  
(All patients) 
Tests for heterogeneity, p 
STI 
 Any time off ART 
 Total time off ART* 
 
1.78 (0.46, 6.83) 
1.00 (0.95, 1.06) 
 
- 
- 
 
- 
- 
 
- 
- 
UPTI** 
 Any time off ART 
 Total time off ART* 
 
1.24 (0.36, 4.35) 
1.03 (0.91, 1.15) 
 
3.81 (2.90, 5.00) 
1.03 (1.01, 1.04) 
 
3.62 (2.77, 4.72) 
1.03 (1.01, 1.04) 
 
p=0.09 
p=0.98 
Heterogeneity, p 
 Any time off ART 
 Total time off ART* 
 
p=0.70 
p=0.74 
 
- 
- 
 
- 
- 
 
- 
- 
*Effect of cumulative time off ART per week 
**There is no interaction between STI/CT randomisation and total time of ART or any time off ART (p=0.62 and p=0.65, respectively) 
Note: adjusted for other factors in Table 3.3.16 
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Assessing the effect of cumulative time off treatment for STIs and UPTIs separately (Table 
3.3.17) showed a non-significant trend towards an increased risk in mortality for any time off 
treatment for STIs in STI/CT patients (HR=1.78 [0.46, 6.83], p=0.40; only 27 events). There was 
no evidence of an increased risk in mortality for cumulative time off treatment for STIs in STI/CT 
patients (HR=1.00 per week, 95%CI 0.95, 1.06; p=0.90). 
There was a trend towards an increased risk in mortality for any time off treatment for UPTIs in 
STI/CT patients, this again was non-significant (HR=1.24 [0.36, 4.35], p=0.34). In addition there 
was no significant evidence of an increased risk in mortality for cumulative time off treatment for 
UPTIs in STI/CT patients although the point estimate indicated harm (HR=1.03 per week, 95% 
CI 0.91, 1.15; p=0.43). Tests for heterogeneity suggested there was no difference in the effect 
of cumulative time off ART for STIs and UPTIs (p=0.74) or for any time off treatment (p=0.70).  
In a separate model in non STI/CT patients, there was significant evidence of an increased risk 
in mortality for any time off treatment for UPTIs (HR=3.81 [2.90, 5.00], p<0.001) and there was 
significant evidence of an increased risk in mortality for more time off ART for UPTIs (HR=1.03 
per week [1.01, 1.04], p<0.001). Using meta-analysis techniques to combine estimates for 
STI/CT patients and non STI/CT patients, overall there was evidence of an increased risk of 
mortality for any time off ART for UPTIs (HR=3.62 [2.77, 4.72], p<0.001) and there was 
significant evidence of an increased risk in mortality for more time off ART for UPTIs in all 
patients (HR=1.03 per week [1.01, 1.04], p<0.001). Tests for heterogeneity suggested there 
was no difference in the effect of any time off ART or cumulative time off ART for UPTIs on risk 
of mortality for STI/CT patients and non-STI/CT patients (p=0.09 and 0.36 respectively).   
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Table 3.3.18 Modelling the effect of cumulative time off treatment on WHO4 events/death 
in adults 
Variable* HR (95%CI) p-value 
Any time off ART (ever vs. never) 2.83 (2.33, 3.43) <0.001 
Cumulative time off treatment  
(per week) 
1.01 (0.99, 1.02) 0.09 
Sex: Male 
 Female 
0 
0.90 (0.78, 1.04) 
- 
0.16 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Infectious Disease Institute, Mulago 
 
0 
1.14 (0.95, 1.37) 
1.25 (1.04, 1.50) 
1.23 (0.96, 1.58) 
 
- 
0.16 
0.02 
0.10 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
1.32 (1.15, 1.52) 
 
- 
<0.001 
Pre ART CD4 (per 50 cells/µL higher)† 0.66 (0.62, 0.71) <0.001 
Age at ART initiation  
(per 10 years older)† 
1.00 (0.91, 1.09) 0.97 
†Reference category: pre ART CD4=100cells/µL, age=40 years 
*After model selection using BE(0.1) the following variables remain independent predictors of mortality: 
monitoring strategy, any time off ART and pre ART CD4 (all p<0.001) and centre (p=0.08) 
 
Results were similar for WHO4 events/death (HR (ever vs. never off)=2.83 95%CI [2.33-3.43], 
p<0.001; HR 1.01 per extra week off ART [0.99-1.02], p=0.09) (Table 3.3.18). As with mortality 
there was a significant effect of pre-ART CD4 with a higher CD4 at baseline leading to a 
decrease in the risk of a WHO4 event/death (p<0.001) and there was an increase in the risk of a 
WHO4 event/death for those in the no CD4 monitoring group (p<0.001). There was no overall 
significant effect of centre (global p=0.08) although there was some evidence to suggest an 
increase in the hazard of a WHO4 event/death for patients at the University of Zimbabwe, 
Harare compared to those in Entebbe (p=0.02). There was no effect of age or sex (both p>0.1). 
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Table 3.3.19 Modelling the effect of cumulative time off treatment on WHO4 event/death in adults (STI and UPTI separately for STI/CT and non-STI/CT 
patients) 
 STI/CT pts only Non STI/CT pts only Meta-Analysis combined  
(All patients) 
Tests for heterogeneity, p 
STI 
 Any time off ART 
 Total time off ART* 
 
2.69 (1.19, 6.10) 
0.97 (0.92, 1.02) 
 
- 
- 
 
- 
- 
 
- 
- 
UPTI** 
 Any time off ART 
 Total time off ART* 
 
1.27 (0.55, 2.92) 
0.99 (0.89, 1.11) 
 
3.37 (2.78, 4.10) 
1.03 (1.02, 1.04) 
 
3.19 (2.65, 3.88) 
1.03 (1.01, 1.04) 
 
p=0.03 
p=0.55 
Heterogeneity, p 
 Any time off ART 
 Total time off ART* 
 
p=0.19 
p=0.71 
 
- 
- 
 
- 
- 
 
- 
- 
*Effect of cumulative time off ART (per week) 
**There is no interaction between STI/CT randomisation and total time of ART or any time off ART (p=0.35 and p=0.60, respectively) 
Note: adjusted for other factors in Table 3.3.16 
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Assessing the effect of cumulative time off treatment for STIs and UPTIs separately showed 
good evidence to suggest an increased risk of a WHO4 event/death for any time off treatment 
for STIs in STI/CT patients (HR=2.69 [1.19, 6.10], p=0.02) (Table 3.3.19); however there was no 
evidence of an increased risk of a WHO4 event/death with increasing cumulative time off 
treatment for STIs in STI/CT patients (HR=0.97 per week [0.92, 1.02]; p=0.22). There was a 
trend towards an increased risk in mortality for any time off treatment for UPTIs in STI/CT 
patients, however this was non-significant (HR=1.27 [0.55-2.92], p=0.57) and there was no 
evidence of an increased risk in mortality for cumulative time off treatment (HR=0.99 per week 
[0.89-1.11; p=0.90). Tests for heterogeneity suggested that there was no difference in the effect 
of cumulative time off treatment or anytime off ART on the risk of a WHO4 event/death for STIs 
and UPTIs (p=0.19 and p=0.71 respectively). 
In non STI/CT patients there was an increased risk of a WHO4 event/death with any time off 
treatment for UPTIs (HR=3.37 [2.78, 4.10], p<0.001) and an increased risk of a WHO 4 
event/death with more time off ART for UPTIs (HR=1.03 per week [1.02, 1.04], p<0.001).  
Using meta-analysis techniques to combine estimates for STI/CT and non STI/CT patients, 
there was an increased risk of a WHO4 event/death for any time off treatment for UPTIs in all 
patients (HR=3.19 [2.65, 3.88]) with this risk being higher in the non STI/CT patients (p=0.03). 
There was significant evidence of an increased risk of a WHO4 event/death for more time off 
ART for UPTIs in all patients (HR=1.03 per week [1.01, 1.04]. However, there was no evidence 
that this differed for STI/CT patients compared to non-STI/CT patients (p=0.55). 
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Table 3.3.20 Modelling the effect of cumulative time off treatment on CD4<100 cells/µL 
after 48 weeks in adults 
Variable HR (95%CI) p-value 
Any time off ART (ever vs. never) 1.82 (1.52, 2.19) <0.001 
Cumulative time off treatment  
(per week) 
1.01 (0.99, 1.02) 0.25 
Sex: Male 
 Female 
0 
0.68 (0.58, 0.79) 
- 
<0.001 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Infectious Disease Institute, Mulago 
 
0 
1.15 (0.95, 1.40) 
1.11 (0.91, 1.36) 
1.18 (0.91, 1.53) 
 
- 
0.15 
0.29 
0.22 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
1.00 (0.86, 1.16) 
 
- 
0.98 
Pre ART CD4 (per 50 cells/L higher)† 0.47 (0.43, 0.51) <0.001 
Age at ART initiation (per 10 years older)† 0.90 (0.82, 1.00) 0.05 
†Reference category: pre ART CD4=100cells/µL, age=40 years 
*After model selection using BE(0.1) the following variables remain independent predictors of mortality: age at 
ART initiation (p=0.06) and any time off ART, pre ART CD4 and gender (all p<0.001) 
 
The effects of cumulative time off ART were also similar to mortality for CD4<100 cells/µL after 
48 weeks, with having any time off treatment associated with an increased risk of CD4<100 
cells/µL after 48 weeks (HR=1.82 [1.52, 2.19], p<0.001) but no independent effect of (time-
updated) cumulative time off ART (1.01 per week [0.99, 1.02], p=0.25) (Table 3.3.20). Like 
mortality and WHO4 events/death there was an effect of pre-ART CD4 on CD4<100 cells/µL 
after 48 weeks with a higher pre-ART CD4 associated with a decreased risk of a CD4 count 
<100 cells/µL after 48 weeks (p<0.001). Unlike the other clinical endpoints there was a gender 
effect with a decreased risk of CD4<100 cells/µL after 48 weeks for women (p<0.001) and there 
was some evidence (p=0.05) to suggest a small decrease in the risk of CD4<100 cells/µL with 
increasing age. There was no evidence of a monitoring strategy effect or an effect of centre on 
CD4<100 cells/µL after 48 weeks (all p>0.1).  
  
  
143 
 
Table 3.3.21 Modelling the effect of cumulative time off treatment on CD4<100 cells/μL after 48 weeks in adults (STI and UPTI separately for STI/CT and 
non-STI/CT patients) 
 STI/CT pts only Non STI/CT pts only Meta-Analysis combined  
(All patients) 
Tests for heterogeneity, p 
STI 
 Any time off ART 
 Total time off ART* 
  
4.72 (2.06, 10.78) 
0.97 (0.93, 1.02) 
 
- 
- 
 
- 
- 
 
- 
- 
UPTI 
 Any time off ART 
 Total time off ART* 
 
2.17 (1.03, 4.54) 
0.92 (0.79, 1.07) 
 
1.87 (1.56, 2.24) 
1.03 (1.02, 1.04) 
 
1.89 (1.58, 2.25) 
1.03 (1.02, 1.04) 
 
p=0.71 
p=0.15 
Heterogeneity, p 
 Any time off ART 
 Total time off ART* 
 
p=0.17 
p=0.49 
 
- 
- 
 
- 
- 
 
- 
- 
*Effect of cumulative time off ART (per week) 
**There is no interaction between STI/CT randomisation and total time off ART or any time off ART (p=0.78 and p=0.36, respectively) 
Note: adjusted for other factors in Table 3.3.16 
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Assessing the effect of cumulative time off treatment for STIs and UPTIs separately showed 
there was strong evidence to suggest an increased risk of immunological failure (CD4<100 
cells/µL) with any time off ART for STIs in STI/CT patients (HR=4.72 [2.06, 10.78], p<0.001) but 
no evidence of an increased risk of immunological failure for increasing cumulative time off ART 
for STIs in STI/CT patients (HR=0.97 per week [0.93, 1.02], p=0.25) (Table 3.3.21). For UPTIs 
in STI/CT patients there was significant evidence to suggest an increased risk of immunological 
failure for any time off ART for UPTIs in STI/CT patients (HR=2.17 [1.03-4.54], p=0.04; 63 
events) but no evidence to suggest an increased risk of immunological failure for increasing 
cumulative time off ART (HR=0.92 per week [0.79, 1.07], p=0.28). Tests for heterogeneity 
suggest that there was no difference in the effect for STIs and UPTIs for any time off ART 
(p=0.17) nor cumulative time off ART on immunological failure (p=0.49).  
In non STI/CT patients there was strong evidence to suggest an increased risk of immunological 
failure for any time off ART for UPTIs in non STI/CT patients (HR=1.87 [1.56, 2.24], p<0.001) 
and for increased cumulative time off ART for UPTIs, (HR=1.03 [1.02, 1.04], p<0.001).  
Using meta-analysis techniques to combine estimates for STI/CT patients and non STI/CT 
patients, there was evidence to suggest an increased risk of immunological failure for any time 
off ART for UPTIs in all patients (HR=1.89 [1.58, 2.25]), which did not differ between STI/CT 
and non STI/CT patients (p=0.71). There was also evidence to suggest an increased risk of 
immunological failure for increasing cumulative time off ART for UPTIs in all patients (HR=1.03 
[1.02, 1.04]), which again did not differ between STI/CT and non STI/CT patients (p=0.15). 
3.3.9. Effect of cumulative time off treatment on clinical outcomes in children (ARROW) 
In a multivariate time-dependent Cox model, having ever interrupted ART showed a similar 
trend towards increased mortality in children (Table 3.3.22) (HR=3.42 [95% CI 1.44, 8.08], 
p=0.005), similar to adults, with no independent effect of (time-updated) cumulative time off ART 
(HR=1.05 per week [0.91, 1.22], p=0.51). As in DART there was an effect of pre-ART CD4 with 
a higher pre-ART CD4% associated with a decrease in the risk of mortality (HR=0.59 per 5% 
higher [0.47, 0.74], p<0.001). There was no evidence of an effect of gender, age, monitoring 
strategy, centre or first-line treatment strategy (all p>0.1). 
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Table 3.3.22 Modelling the effect of cumulative time off treatment on mortality in children 
Variable  HR (95%CI) p-value 
Any time off ART (ever vs. never) 3.42 (1.44, 8.08) 0.005 
Cumulative time off treatment per week 1.05 (0.91, 1.22) 0.51 
Sex: Male 
 Female 
0 
0.91 (0.53, 1.55) 
- 
0.72 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Paediatric Infectious Disease 
Clinic 
 
0 
0.35 (0.14, 0.89) 
0.80 (0.36, 1.76) 
0.81 (0.36, 1.86) 
 
- 
0.03 
0.58 
0.63 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
0.86 (0.50, 1.46) 
 
- 
0.57 
First-line treatment strategy†: 
 Arm A 
 Arm B 
 Arm C 
 
0 
0.65 (0.33, 1.29) 
1.04 (0.56, 1.93) 
 
- 
0.22 
0.90 
Pre ART CD4% (per 5% higher)‡ 0.59 (0.47, 0.74) <0.001 
Age at ART initiation (per 5 years older)‡ 1.08 (0.74, 1.57) 0.73 
†Arm A: NNRTI+3TC+ABC -> NNRTI+3TC+ABC, Arm B: NNRTI+3TC+ABC+ZDV -> NNRTI+3TC+ABC, Arm 
C: NNRTI+3TC+ABC+ZDV -> 3TC+ABC+ZDV 
‡Reference category: pre ART CD4%=10, Age=5 years 
*After model selection using BE(0.1) the following variables remain independent predictors of mortality: pre 
ART CD4% (p<0.001) and any time off ART (p=0.001)  
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Table 3.3.23 Modelling the effect of cumulative time off treatment on WHO 4 events/death 
in children 
Variable  HR (95%CI) p-value 
Any time off ART (ever vs. never) 1.33 (0.57, 3.12) 0.51 
Cumulative time off treatment (per week) 1.08 (0.89, 1.30) 0.43 
Sex: Male 
 Female 
0 
0.90 (0.59, 1.38) 
- 
0.63 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Paediatric Infectious Disease 
Clinic 
 
0 
0.71 (0.35, 1.42) 
0.66 (0.33, 1.30) 
1.12 (0.56, 2.22) 
 
- 
0.34 
0.23 
0.75 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
1.22 (0.80, 1.87) 
 
- 
0.36 
First-line treatment strategy†: 
 Arm A 
 Arm B 
 Arm C 
 
0 
0.87(0.52, 1.45) 
0.96 (0.57, 1.61) 
 
- 
0.58 
0.88 
Pre ART CD4% (per 5% higher)‡ 0.62 (0.52, 0.74) <0.001 
Age at ART initiation (per 5 years older)‡ 1.31 (0.99, 1.75) 0.06 
†Arm A: NNRTI+3TC+ABC -> NNRTI+3TC+ABC, Arm B: NNRTI+3TC+ABC+ZDV -> NNRTI+3TC+ABC, Arm 
C: NNRTI+3TC+ABC+ZDV -> 3TC+ABC+ZDV 
‡Reference category: pre ART CD4%=10, Age=5 years 
*After model selection using BE(0.1) the following variables remain independent predictors of mortality: pre 
ART CD4% (p<0.001) and cumulative time off ART (p=0.08) 
 
In children, having ever interrupted ART showed a non-significant trend towards an increased 
risk of WHO4 events/death (HR=1.33 [0.57, 3.12], p=0.51) with no evidence of an increased risk 
of WHO4 events/death with increasing time off ART (HR=1.08 per week [0.89, 1.30] p=0.43) 
(Table 3.3.23). There was a significant effect of pre-ART CD4%, with a decrease in the risk of 
WHO4 events/death with a higher pre-ART CD4% (HR=0.62 per 5% higher [0.52, 0.74], 
p<0.001). There was no evidence of an association of centre, monitoring strategy, gender, first-
line treatment strategy or age at ART initiation (all p>0.05). 
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Table 3.3.24 Modelling the effect of cumulative time off treatment on immunological 
failure§ in children  
Variable* HR (95%CI) p-value 
Any time off ART (ever vs. never) 1.61 (0.86, 3.00) 0.14 
Cumulative time off treatment (per week) 1.06 (1.01, 1.10) 0.009 
Sex: Male 
 Female 
0 
1.14 (0.70, 1.86) 
- 
0.60 
Centre: 
 Entebbe, MRC/UVRI 
 Kampala, JCRC 
 University of Zimbabwe, Harare 
 Paediatric Infectious Disease 
Clinic 
 
0 
0.40 (0.18, 0.87) 
0.60 (0.29, 1.26) 
0.58 (0.26, 1.26) 
 
- 
0.02 
0.18 
0.17 
Monitoring strategy: 
 LCM (CD4 monitoring) 
 CDM (no CD4 monitoring) 
 
0 
1.80 (1.09, 2.98) 
 
- 
0.02 
First-line treatment strategy†: 
 Arm A 
 Arm B 
 Arm C 
 
0 
0.53 (0.29, 0.95) 
0.60 (0.33, 1.10) 
 
- 
0.03 
0.10 
Pre ART CD4% (per 5% higher)‡ 0.33 (0.25, 0.44) <0.001 
Age at ART initiation (per 5 years older)‡ 1.49 (1.04, 2.14) 0.03 
†Arm A: NNRTI+3TC+ABC -> NNRTI+3TC+ABC, Arm B: NNRTI+3TC+ABC+ZDV -> NNRTI+3TC+ABC,  
Arm C: NNRTI+3TC+ABC+ZDV -> 3TC+ABC+ZDV 
‡Reference category: pre ART CD4%=10, Age=5 years 
§Defined as in section 3.2.6 of the methods: aged 3-<5 years confirmed CD4%<10% and aged 1-<3 years 
confirmed CD4%<15%; children aged ≥5 years: confirmed CD4 50-99 cells/µL or single CD4 <50 cells/µL 
*After model selection using BE(0.1) the following variables remain independent predictors of mortality: pre 
ART CD4% (p<0.001), cumulative time off ART, monitoring strategy and age (all p=0.02) and first-line 
treatment strategy vs Arm A (Arm B p=0.03, Arm C p=0.08)) 
 
In children, there was a significant evidence to suggest an increased risk of immunological 
failure after 48 weeks for increasing cumulative time off ART (HR=1.06 per week [1.01-1.10], 
p=0.009); however, there was only a modest non-significant trend towards an increased risk for 
having ever interrupted ART (HR=1.61 [0.86-3.00], p=0.14) (Table 3.3.24). There was a 
significant effect of monitoring strategy (increased risk of immunological failure after 48 weeks 
with no CD4 monitoring (HR=1.80 [1.09, 2.98], p=0.02) and first-line treatment strategy 
(increased risk of immunological failure after 48 weeks in Arm A compared to both Arm B and 
Arm C (although marginal/non-significant) (p=0.03 and p=0.10 respectively; global (2df) 
p=0.07). In addition there was a highly significant effect of pre-ART CD4% with a substantially 
decreased risk of CD4<100 cells/µL after 48 weeks with a higher pre-ART CD4% (0.33 per 5% 
higher [0.25, 0.44], p<0.001). There was evidence of an age effect with an increased risk of 
immunological failure after 48 weeks with older age at ART initiation (1.49 per 5 years [1.04, 
2.14], p=0.03) but no effect of gender (p=0.60). 
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Figure 3.3.10 shows all estimates for effect of cumulative time off ART and any time off ART for 
STIs and UPTIs in STI/CT patients and non-STI/CT patients in DART and all patients in 
ARROW. 
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Figure 3.3.10 Effect of cumulative time off treatment on mortality, WHO 3/4 or death or immunological failure in DART and ARROW  
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3.4. Discussion 
In this analysis I have assessed the effects of structured treatment interruptions (STIs) on CD4 
counts and clinical endpoints after returning to continuous therapy (CT); extending results from 
the DART STI sub-study which was terminated early due a detrimental effect of STIs on clinical 
disease progression within the trial [128]. Interestingly, when assessing the number of cycles of 
STIs patients could have had and the number of cycles they did have, I found that, even if the 
trial had not been terminated, patients were stopping undergoing STIs. The main reasons for 
this were low CD4 counts and WHO 3/4 events which is in keeping with the detrimental effects 
of STIs shown in other studies [119-121, 123-127, 130, 131], and demonstrates that this was 
unlikely to be a feasible long-term strategy. In addition to STIs I have assessed the effects of 
unplanned treatment interruptions (UPTIs) on CD4 counts and clinical outcomes and have 
explored the reasons for these unplanned treatment interruptions. I have also compared the 
long term effects of STIs and UPTIs on clinical outcomes. 
I started by investigating what happened to CD4 counts when patients had returned to CT. I 
found that after STIs, returning to CT increased a patient’s CD4 count, consistent with other 
studies in both high- and low/middle-income settings as shown by Kranzer et al. in their 
systematic review [150]. The SMART study [126] found that CD4 guided ART interruption 
significantly increased the risk of opportunistic disease or death from any cause compared with 
CT and the trial was terminated early. As in DART those patients in the STI arm were advised to 
restart therapy and follow-up continued [129]. Similar to DART, CD4 cell counts increased with 
re-initiation of ART but unlike DART they found that CD4 cell counts recovered to that at 
randomisation in just 6 months. In DART I have estimated that this would take around 16 
months. This difference between the trials could be due to the fact that the SMART data are 
from high-income settings where patients generally have better prognosis; however, it is most 
likely that this is related to the higher pre-interruption CD4 cell counts in SMART than in DART 
(597 cells/μL in SMART vs. 358 cells/μL in DART). Those DART patients who were off 
treatment at the time of sub-study closure had a steeper increase in CD4 count on returning to 
ART, consistent with that shown in naïve patients [151]. After 12 weeks on CT their CD4 had 
increased to the same levels as STI patients on ART when the sub-study was terminated, but 
both remained well below CD4 counts in CT. The first increase in CD4 after therapy is started is 
due to the redistribution of CD4 cells into the peripheral blood circulation. Several studies [150, 
152, 153] have shown that the effects of ART on CD4 after restarting treatment follow a 
biphasic pattern and that the effects of ART are indeed greater in the first months of restarting 
ART. Mussini et al. [153] also found that subjects who resumed ART with a higher viral load 
experienced a more rapid rate of CD4 increase during the first 3 months after returning to 
treatment. I was not able to assess the change in viral load as those assays were not routinely 
done in DART; I am therefore unable to say whether CD4 increases were greater in those with 
higher VL in DART. 
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I found that the CD4 deficit associated with having undertaken fixed-length STIs persisted for at 
least 4-5 years when back on CT, even though patients did reconstitute immunologically. 
Interestingly, I did not find that undertaking progressively more STIs led to progressively greater 
CD4 deficits back on treatment – rather, having undertaken one or multiple STIs led to similar 
deficits. I also found that the effect of treatment interruptions on long term CD4 counts showed 
no increasing detriment for more time off treatment but having ever interrupted ART had a 
detrimental effect on CD4 cell counts. This emphasises the importance of maintaining ART 
supplies and accessibility. The fixed duration strategy of 2 months off, 4 months on used in the 
TRIVICAN trial (the only other trial in low/middle-income settings of planned treatment 
interruptions) was able to continue until the end of the trial but the 12 weeks on 12 weeks off 
strategy in DART stopped early. This raises the question as to whether CD4 would have taken 
less time to return to that of the CT arm in TRIVICAN, with shorter time off relative to on ART. 
Unfortunately there are no data to assess this. In DART, however, I showed that any time off 
treatment had a detrimental effect on CD4 and clinical outcomes and that there was little effect 
of duration of time off treatment, therefore the shorter relative time may have been unlikely to 
affect reconstitution. Patients in the TRIVICAN trial also had higher pre-ART CD4 cell counts 
(median 460 cells/µL) vs. pre-CT/STI randomisation CD4 of 358 cells/µL in DART which may 
have helped faster reconstitution. There was also a higher threshold for stopping a treatment 
interruption in TRIVICAN (250 cells/μL vs. 50 cells/μL in DART). Thus a more selected patient 
group will have had repeated interruptions in TRIVICAN, and so the impact of repeated STIs will 
be less.  
As expected, CD4 monitoring strategy had a significant effect on mortality, WHO3/4 
events/death and switch to second-line; however, it did not have an effect on immunological 
failure. This differential effect of monitoring strategy on immunological failure and clinical 
outcomes could be due to the fact that in the CDM group, patients did not have their CD4 
monitored routinely, therefore clinicians were unable to anticipate when a patient is going to 
have an event; however, in the LCM group they did know the CD4 count and were able to 
anticipate a clinical event, making the effect of monitoring strategy different for endpoints that 
potentially rely on a clinician knowing a patients CD4. Specifically, in the LCM group observing 
CD4<100 cells/μL would likely result in a switch to second-line treatment, or focussed 
interventions to improve adherence, and hence a reduction in the risk of clinical events, 
whereas CDM patients would continue on (failing) first-line treatment. There is a clear benefit of 
identifying patients with immunological failure in terms of subsequent mortality [109]. However, 
until the point at which a patient’s CD4 drops to below 100 cells/μL, LCM and CDM are in fact 
managed the same (simply taking someone’s blood is not going to make them do better or 
worse), which likely explains the lack of effect of monitoring strategy on immunological failure as 
defined here. 
In contrast to adults, I found that in children total time off treatment resulted in progressively 
decreasing CD4% and increased risk of immunological failure for more time off treatment, but 
there was no additional effect of having had any time off treatment. This suggests that children 
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may tolerate at least short interruptions immunologically; however, this should not be for too 
long. However, as in adults, in children there was an increase in the risk for all clinical outcomes 
for ever interrupting ART with no evidence of increasing risk for increasing time off ART, in 
contrast to the effects on CD4%. In contrast, PENTA 11 showed that children who underwent 
CD4 guided STIs achieved similar clinical outcomes compared to those who were on CT [134] 
both during and after STIs finished. However at the end of PENTA 11, participants who had had 
STIs had lower CD4%, lower CD4 cell counts and were less likely to be virologically suppressed 
than those in the continuous therapy arm. Two years post trial (when children in the STI arm 
had returned to CT), immunological and virological outcomes were similar in the two arms. [154] 
The lack of difference in clinical outcomes seen in PENTA 11 may be explained by the 
difference in trial populations: in ARROW (low/middle-income) median pre-ART CD4 was 
around 250 cells/μL (CD4% around 12%) whereas in PENTA 11 (high-income) it was 627 
cells/µL (IQR 320-1050) (CD4% 18% (IQR10-27)), with median CD4 before interruption 966 
cells/μL (CD4% 37%). It is known that CD4 recovery on ART is directly correlated with pre-ART 
CD4 [155]; this was also found in PENTA 11, and I have shown that there is a significant effect 
of pre-ART CD4 on long term CD4 count and clinical outcomes. In PENTA 11 the treatment 
interruptions were also guided by CD4 and patients returned to treatment when their CD4 had 
dropped below 20% or they returned to treatment at 48 weeks. It is possible in ARROW that a 
child’s CD4 could have dropped to a lower than safe level before they restarted treatment. 
However, I found that the median time off treatment for UPTIs in ARROW was 13 days per 
patient and the median time for each UPTI was just 7 days so this is probably unlikely.  
Having any time off ART may have less of an effect on children than adults as, being younger, 
they have lower incidence of traditional risk factors for mortality such as hypertension, diabetes 
and smoking; they are generally healthier. However, they are growing and so may be more 
sensitive to the effects of replicating HIV, for example in the brain, effects that will not be 
identified through the clinical outcomes I considered here. The main difference between PENTA 
11 and ARROW is that the interruptions assessed in ARROW were unplanned and in PENTA 
11 they were planned. I showed in DART that the effects of UPTIs and STIs were different, 
plausibly due to unmeasured confounding, so this could also contribute here.  
In adults, I found no evidence that the relative harm from STIs vs. CT in terms of clinical events 
decreased after return to CT, although overall clinical event rates continued to decline in both 
STI and CT with longer time on ART, reflecting the enormous benefits of antiretroviral therapy. 
Interestingly, I did not find that undertaking progressively more STIs led to progressively greater 
CD4 deficits back on treatment – rather, having undertaken one or multiple STIs led to similar 
deficits, also independently of whether STIs were halted for clinical/CD4 reasons or sub-study 
closure. My analysis of unplanned treatment interruptions found that any interruption was 
associated with an increased risk of poorer clinical outcomes, and that increasing time off 
treatment had an additional effect, increasing risk. These results are similar to the doubling of 
risk of interruption in care or death associated with unstructured ART interruptions found by 
Pasquet et al. [119]. The effect of treatment interruptions on mortality was greatest for UPTIs in 
non-STI/CT patients; however there was little evidence that the effects of UPTIs on clinical 
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outcomes differed in the STI/CT patients, nor that the effects of STIs and UPTIs differed in 
STI/CT patients, demonstrating challenges with power to detect heterogeneity in effects. The 
overall effect was a three-fold increase in the risk of death for any time off treatment of any kind. 
For more time off ART, there was no increase in the detrimental effect on mortality for patients 
having STIs and those having UPTIs in the STI/CT group but for UPTIs in the non-STI/CT 
patients, I found evidence of an increase in the risk of death for more time off treatment. 
However, again, heterogeneity tests demonstrated that it was difficult to be certain that similar 
effects did not exist in other groups, rather the study was underpowered to detect them. These 
results are consistent with the EuroSIDA study [123] which showed that the risk of death was 
increased more than two-fold for patients stopping ART for ≥3 months for unplanned treatment 
interruptions. Results from Pasquet and EuroSIDA also showed an increase in opportunistic 
infections, mortality, immunological and virological changes associated with unplanned 
treatment interruptions highlighting the importance of drug and patient management in 
low/middle-income settings. In some support of what I have found, a review of trials and studies 
that have investigated structured treatment interruptions, CD4 count guided or fixed period 
interruptions [132], concluded that interrupting treatment results in a variable degree of harm; 
the authors concluded that some strategies are less harmful than others and that interrupting 
and restarting treatment at higher thresholds for CD4 guided treatment, and reducing the time 
off treatment in each interval could reduce the risks. It also concluded that the benefits of a 
short period of time off treatment may potentially outweigh the risks. This is reflected somewhat 
in my results showing different point estimates of the effects of TIs depending on whether or not 
they are planned or unplanned and whether or not patients are included in a STI sub-study or 
not, although, as above, I cannot exclude lack of power also playing a role. Based on my 
results, any interruptions need to be carefully considered and should really be avoided where 
possible. 
In addition, I found that there was more switching to second-line in those adults randomised to 
STI vs CT, including after returning to continuous ART. This is likely due to the detrimental 
effects of interruptions on CD4 and the increase seen in immunological failures in the STI group 
compared to the CT group. This could also be due to an association between treatment 
interruptions and drug resistance creating the need for patients to switch from first-line 
regimens. Associations between treatment interruptions and drug resistance have been 
demonstrated in 86 patients in Kampala, Uganda [156], as well as in high-income settings [157, 
158], particularly for NNRTI resistance. However, in DART, STIs were undertaken using a two 
week NRTI tail for nevirapine, which should be sufficient to cover the slow decline in blood level 
[159]. No tail was used with tenofovir-containing regimens (3 NRTIs), but there was no 
resistance observed in 18 STIs assayed [160]. However, unplanned interruptions of NNRTI-
containing ART done without using an NRTI tail do likely increase the risk of resistance. 
As part of the main DART and ARROW trials I have been able to assess the effects of UPTIs as 
these data were requested as part of the data collection process together with the reasons for 
these interruptions, which are less commonly collected in observational studies. 32% of adults 
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and 24% of children had a UPTI lasting more than 4 days, although more UPTIs might have 
been expected in the children as both the child and the carer have reasons not to adhere to 
treatment. The most common reason for missing treatment in both adults and children/carers 
was being unable to attend clinic. My results are consistent with Roura et al. [161] who found 
that in discussion with patients, structural factors were consistently ranked as posing the biggest 
barrier to clinic attendance and hence adherence. They also highlighted the importance of 
addressing sociocultural and psychosocial factors, all reasons that I also found for people 
missing ART. Kranzer et al. [150] carried out a systematic review of the frequency, reasons, risk 
factors, and consequences of unstructured ART interruptions. The review included 16 studies 
from Africa, 14 from North America, 32 from Europe and 8 from the rest of the world. Twenty-
two of these studies investigated reasons for treatment interruptions (18 from high income 
countries and 4 from Africa). In two studies from Nigeria they found that costs were the main 
reason for treatment interruptions followed by pharmacy stockouts which were reported in three 
of the four studies from low/middle-income settings. Challenges of multiple formulations to 
accommodate changes in dose as children grow make supply chain management even more 
challenging in children. However, these reasons were not relevant to DART or ARROW as 
drugs were free and stockouts did not occur due to the nature of a randomised trial. Perhaps for 
this reason results from DART and ARROW lay somewhere in the middle of these two settings, 
with the most common reasons for interruption being unable to attend clinic due to transport 
issues. Tweya et al. [120] found that the most common reason for interrupting treatment in 
Malawi was running out of drug whilst travelling (46% of patients), other reasons included 
forgetting to attend clinic or take treatment (17%), also highlighting the importance of reminders 
to attend clinic. A study carried out in Tanzania reported that during participatory group 
discussions, structural factors were consistently ranked as the most hard to control barriers to 
clinic attendance [162]. However, whilst numerically smaller in number, my results also 
demonstrate the role of mental health issues; domestic problems including discouragement by 
friends and relatives; and ongoing challenges of pill burden and fatigue with treatment to 
treatment interruptions. Faith and divine healing were also amongst the reasons given; 
highlighting that education is still needed in to how important these drugs are in reducing deaths 
from HIV and AIDS. Similar barriers were also highlighted by Roura et al. [161] who concluded 
that whilst removing structural obstacles is essential, addressing sociocultural and psychosocial 
factors is also required.  
In 2013 Mann et. al [163] assessed the impact of ART interruptions in the Kenyan post-election 
crisis. Here political crises led to UPTIs caused by supply disruption, population displacement, 
unsafe travel and the inability to obtain medications. They defined an UPTI to be an interruption 
of ≥1 week (slightly longer than the 4 days I used in DART). They showed that the interruptions 
were associated with virological failure; two years after the UPTI patients were 5 times more 
likely to have failed virologically than those who took ART continuously. However, they found 
that any effect of interruption on CD4 percentage disappeared when allowing for pre-crisis CD4 
count. 
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One advantage of my analysis is that much of the adult interruption data come from a 
randomised comparison  and hence patients were similar in all ways except receipt of STIs vs. 
continuous therapy. The early termination of the STI sub-study, after which patients returned to 
CT, allowed me to assess the long-term impacts of prior STIs on CD4 and clinical outcomes. I 
supplemented this with a parallel analysis of unplanned treatment interruptions in adults and 
children, for which there were detailed reasons for interruption, unlike in many studies. I found 
some challenges when fitting some of my models involving STIs and UPTIs suggesting 
selection biases in who interrupts may be very strong making observational analyses 
challenging.  
However, the fact that I used data from randomised trials is also a limitation, since patients 
received travel refunds, drugs were free and drug stockouts did not occur, thus substantially 
reducing the barriers to avoiding treatment interruptions compared to national programmes. 
Nevertheless unplanned interruptions still occurred in a substantial proportion of adults and 
children, suggesting results should be generalisable. It is unlikely that more or longer 
interruptions in ART programmes would be associated with lower or no risk compared to the 
increased risk of poorer outcomes identified in my study. There is also no clear mechanism by 
which stockouts could have a different effect on CD4/clinical outcomes compared to STIs, since 
both involve ART interruption. If anything, use of the NRTI tail with NVP in STIs undertaken in 
DART should lead to less harm being observed than if UPTIs occur in treatment programs. A 
further limitation is the likely inability to adjust for all confounders when considering the impact 
of unplanned treatment interruptions on outcome. In fact the substantial impact of ever vs. never 
previously interrupting ART, together with the lack of additional impact of increasing time off 
ART does suggest that interrupting ART may also be associated with poorer adherence or 
poorer health-seeking behaviour, that is that the association may not be wholly direct, but may 
also reflect other indirect pathways to poorer outcome.  
3.5. Conclusions 
In conclusion, interrupting ART is associated with lower CD4 counts and poorer clinical 
outcomes over the long-term even after returning to ART. These findings suggest that 
substantially greater efforts should be devoted to reducing the risk of any treatment interruption. 
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Chapter 4: Discussion 
In this thesis I have investigated cause specific mortality (Chapter 2) and the effects of planned 
and unplanned treatment interruptions on long term outcomes (Chapter 3) for patients with HIV 
who are on antiretroviral therapy (ART) in the DART (adult) and ARROW (paediatric) trials [54, 
58]. In this chapter I will discuss the results from my thesis, what they mean for people with HIV 
who are on ART and the key remaining challenges for delivering HIV treatment in low- and 
middle-income countries (LMIC). 
Mortality in DART and ARROW 
I have shown that for all-cause mortality and major individual causes of death, including those 
that are not traditionally thought of as immunodeficiency-related, the hazard of death declines 
similarly and significantly with increasing CD4 count (with the possible exception of deaths from 
cardiovascular disease). I have also shown that the associations between CD4 and mortality 
are similar whether patients are monitored with or without CD4 counts, apart from tuberculosis 
where in the CD4 monitoring group there was a stronger association between dying from 
tuberculosis and CD4 than in the no CD4 monitoring group. After assessing the change in risk 
of TB death as CD4 increases, there was a quicker decline in the risk of TB death in the CD4 
monitoring group as CD4 increases above ~50 cells/µL. This could be due to one of two 
reasons – first clinicians may keep patients in the CD4 monitoring group with TB and with higher 
CD4s on failing first-line regimen while they treat TB, as this has fewer drug-drug interactions 
and may allow more successful TB treatment. Second, in the no CD4 monitoring group they do 
not know the CD4 so may assume it is low and switch the patient to second-line treatment 
which makes the treatment of TB more complicated. 
In DART, 47% of deaths occurred in the first year after ART initiation. Similarly, Etard et al. [71] 
showed that 51% of deaths occurred in the first 12 months after ART initiation in a Senegalese 
cohort. These relatively large proportions of deaths in the first 12 months are likely attributed to 
the low CD4 counts at ART initiation (all patients in DART had CD4 <200 cells/µL and the 
median CD4 at baseline in Etard et al was 128 cells/µL). The majority of deaths in DART were 
judged primarily related to HIV. Similar results were seen in ARROW with 74% of deaths 
occurring in the first year after ART initiation. One strength of these data from DART and 
ARROW is that they have come from randomised controlled trials, with more consistent and 
complete data collection (7% and 3% lost to follow-up respectively), particularly regarding 
ascertainment of death and its causes. There was also a more consistent drug supply, including 
concomitant medications, giving good ‘on ART’ estimates of mortality. However, one limitation in 
estimating the causes of mortality and the change over time is the relatively low number of 
deaths despite the size of the trials. 
A few studies from my literature search investigated the change in hazard over time in overall 
mortality using smoothing non-parametric hazard estimates from Cox regression [71, 72, 74, 93, 
94] or Weibull piecewise models [79, 92, 108]. In contrast to the relatively strong assumptions of 
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e.g. parametric Weibull models, the method I have used here, FPMs, is a much more flexible 
approach which allows for the continuous changing hazard without over fitting change points to 
the specific data. 
In addition to the DART results shown in Figure 2.4.1, using flexible parametric models (FPMs) 
to model the changing hazard of death over time, I showed that the hazard of death dropped 
very quickly after a few months on ART; there is a very rapid decline in hazard around 30-60 
days. This was also the case for individual causes of death, with septicaemia and tuberculosis 
having the highest early hazard of death. The varying estimates found by Etard [71] and 
Hoffmann [93] show that any modelling strategy that fixes change points on the basis of 
observed data runs the risk of over fitting, as it does not seem plausible that genuine changes in 
risk occur at different times in different studies. However, even though the FPMs are able to 
model the hazard continuously and they do not abruptly cut the data they are not without their 
limitations. As I found when modelling the individual causes of death, the models appeared to 
be very sensitive to when the first event occurred and the timing of subsequent events 
(discussed further below). I tried to overcome this by modelling from 1 year after ART initiation; 
however I still found instability in the boundaries of the models even after 1 year of ART. 
Looking at the changing effect of baseline predictors over time using these models may have 
given me more insight into the changing hazard over time.  
I chose FPMs instead of the standard Cox proportional hazards model or the simple Poisson or 
piecewise exponential model because I wanted to give a more precise estimation of the cause-
specific hazards for each cause of death over time. FPMs allowed me to obtain an estimate of 
the hazard function and its uncertainty which varied smoothly over time, but was not unduly 
restricted by the strong assumptions underpinning many parametric survival models (e.g. 
monotonicity). Lack of monotonicity in the underlying hazard was particularly important in my 
application, since I observed hazards increasing shortly after ART initiation (randomisation) then 
decreasing (discussed further below). When the goal of a survival analysis is to simply estimate 
hazard ratios (e.g. between CD4 vs no CD4 monitoring) then the precise form of the baseline 
function is less important, and a Cox model can then be used appropriately as the baseline 
hazard function is not directly estimated but treated as a nuisance parameter in the estimation 
of the other coefficients from the partial log likelihood.  One assumption of the Cox model is that 
any hazard ratio predicted by the model is proportional over time, for example that the hazard 
ratio is the same at 1 week, 1 month, 1 year etc. An advantage of FPMs is that they do allow 
smoothly varying non-proportional hazards as can be seen in Figure 2.3.8 where the difference 
between CD4 and no CD4 monitoring is not constant over time. CVD is a good example of non-
proportional cause-specific hazards and the FPM has been able to model this appropriately 
(Figure 2.3.6).  
 
A recent review [164] of the only 12 prognostic studies that have used FPMs since their 
introduction in 2002 stated that the most common benefit of FPMs was improved model 
accuracy and the key advantage of FPMs was their ability to model the baseline log cumulative 
hazard flexibly with restricted cubic splines. They found only two studies that reported limitations 
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of the models, which included overfitting and difficulties in model interpretation when there was 
more than one time dependent effect. No study reported sensitivity to when the first events 
occurred as I have found here.  
Miladinovic et al. [165] made a comparison between the Cox proportional hazards model and 
FPMs using a dataset from a hospice on patient survival. They used internal validation to 
assess the validity of the models (i.e. with the same data as with they fit their original models) 
and found that FPMs were closer in fit to the Kaplan-Meier curve than estimates of survival from 
the Cox model. They concluded that both the robust modelling of the baseline survival and 
overall model fit gave better survival estimation using FPMs. 
As with all model selection there is the danger of overfitting; with FPMs this could be due to 
several factors, the number of knots chosen, there not being enough data or the splines being 
sensitive to outliers. FPMs are reasonably robust to changes in the knot positions and so the 
default knot positions used (similar to those outlined in Table 2.2.2) should not have effected 
this [98]. I chose the number of knots using the AIC (-2logL + 2k, where k is the number of 
parameters in the statistical model, and L is the maximised value of the likelihood function for 
the estimated model). An alternative would have been the BIC (-2logL + klogn, where k is the 
number of observations in the model) which penalises the number of parameters (here knots) 
more in model selection. I may then have chosen different models with a smaller number of 
knots which may then have meant I did not estimate an initial peak in hazard.  
The models appeared to be very sensitive to when the first events occurred, e.g. in Figure 2.3.6 
those causes of death with very early deaths around for example 9 days had a very high early 
peak but when the first event was later at ~50 days the peak in hazard was much less 
pronounced. When comparing fitted models it is difficult to be confident that the estimated 
differences are real; for example septicaemia/neutropenia, neurological and cryptococcal 
causes of death all have similar timings of first events and yet the estimated hazards are very 
different. This may well be an artefact of the rather arbitrary timing of the first event, given the 
fact that provision of written informed consent to join the trial meant that patients who were 
essentially close to death should not have been enrolled. To understand whether the peak in 
risk was a result of the statistical modelling rather than being clinically meaningful I could have 
carried out a sensitivity analysis where I moved the time of deaths that occurred in the first 2 
weeks to, for example 14 days post randomisation and assessed the effect this had on the 
estimated hazards. However, one important limitation is lack of data, despite the size of the trial. 
When analysing these data I considered individual causes of death which had at least 10 
deaths; however in the future if I were to use these models again I would probably suggest 
having at least 20 events (approximately 10 in each randomised group).  
Analysis of mortality risk changes using FPMs following admission in the FEAST trial found a 
similar pattern to my analyses, in that the baseline hazard rose to a high peak around 1.6 hours 
and then declined sharply through to 5.2 hours and then more slowly beyond and out to 48 
hours with a steady slow decline past 31 hours (personal communication with L George). In 
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FEAST, this early high peak in hazard was investigated using simulations. A piecewise hazard 
model was fitted to the FEAST data assuming a high constant hazard for the first 1 hour from 
randomisation which then dropped. This model was then used to simulate datasets to which 
FPMs were then fitted. A number of estimated hazard profiles were found with some having a 
flatter peak and some having no peak at all or some with a sharp peak. Moving the knot 
positions did not remove the peak unless the first interior knot was at >48 hours compared to a 
median uncensored survival time of 8 hours. In addition, fitting the FPMs to the log hazard on 
the observed time scale rather than the log time scale showed a monotonically decreasing 
hazard which better reflected the piecewise exponential hazard. Together these findings also 
suggest sensitivity analyses checking both time scales are important in future applications. 
Identifying and treating HIV-positive individuals 
A higher percentage of deaths, a higher hazard of death and an association between low CD4 
and a higher rate of deaths in the first year after ART initiation are consequences of late 
presentation to care which highlights the importance of identifying HIV-positive individuals early 
and making sure all HIV-positive individuals receive treatment. These are all challenges that still 
stand in delivering HIV treatment in LMIC, as discussed below. 
UNAIDS 90-90-90 targets 
In 2014 UNAIDS launched their 90-90-90 treatment target to end AIDS globally, which aims at 
90% of people living with HIV knowing their status, 90% of HIV diagnosed people receiving 
treatment and 90% of those on HIV treatment achieving viral suppression by 2020 [20]. This is 
equivalent to 81% of people living with HIV receiving ART and 73% of people living with HIV 
being virally suppressed on ART. Progress was assessed at the end of 2016 based on the 
latest epidemiological and programme data from 168 countries worldwide. Approximately 37 
million people were living with HIV, including 64% in sub-Saharan Africa. An estimated 70% 
[plausibility bound; 51-84%] knew their HIV status; among those who knew their HIV status, 
77% [57->89%] were accessing antiretroviral therapy, and 82% [60->89%] of people accessing 
treatment had suppressed viral loads [40]. 
Current coverage of ART 
Making sure as many people as possible are receiving ART is key to reducing deaths from 
AIDS, other HIV-related illnesses and even non HIV-related illnesses, as shown by my analysis 
of causes of death. At the end of 2016, an estimated 19.5 million people were receiving ART 
globally. However, in the majority of sub-Saharan Africa this was still less than 60% of people 
with HIV compared to more than 80% in high-income countries such as Australia, Italy and 
Sweden [166]. The global scale up of ART has been the primary contributor to a 48% decline in 
deaths from AIDS-related causes from 2005 to 2016. The number of children dying of AIDS-
related illnesses has been cut in half in just six years from 210,000 (160,000-260,000) in 2010 
to 120,000 (79,000-160,000) in 2016 with increased access to paediatric ART playing a 
significant role alongside improved coverage of effective prevention of mother to child 
  
161 
 
transmission. In addition increasing ART coverage has been shown to substantially reduce the 
incidence of new HIV infections among heterosexual serodiscordant couples [167]. Modelling 
suggests further reductions in HIV transmission are achievable with high uptake of regular HIV 
testing and universal ART initiation at diagnosis [168], although the practical issues and 
implementation barriers remain huge and further work is needed to realise the benefits (see 
below for discussion of the ANRS 12249 trial). 
There has been a very successful scale up of treatment across sub-Saharan Africa; for example 
in Uganda, just 12% of HIV-positive individuals were receiving ART in 2006 compared to 69% in 
2016 [169]. In eastern and southern Africa, there was an almost three fold increase in the 
number of people on ART in 2016 compared to 2010. Because the number of people living with 
HIV in sub-Saharan has increased and eligibility for ART has widened, this scale-up is 
equivalent to an increase in coverage of treatment of 23% (19-27%) in 2010 to 60% (48-68%) in 
2016 [40]. However, as outlined above, this is still low compared to other parts of the world.  
There is a significant problem with HIV-positive adolescents, worldwide, not just in LMIC. An 
estimated 2.1 million (1.4 million-2.6 million) adolescents were living with HIV in 2016, with 150 
dying from AIDS-related causes every day. Between 2000 and 2015, AIDS-related deaths 
declined in all age groups apart from adolescents where mortality more than doubled (8,000 to 
41,000) [170]. Adolescents remain vulnerable to sexual acquisition of HIV and have low rates of 
testing and linkage to care [171]. Additional challenges in this group of patients are higher rates 
of loss to follow-up and poor adherence as well as an increased need for psychosocial support 
[172-176]. Adolescents continue to be underserved by current HIV services and have 
significantly worse access to and coverage of ART.  
Test and treat  
Despite progress in ART scale-up there are still a significant number of people in sub-Saharan 
Africa who have tested HIV-positive but are not on treatment and a further number who do not 
know that they have HIV and therefore do not seek the treatment they need. In October 2015, 
the World Health Organisation (WHO) released new treatment guidelines that encouraged 
starting ART immediately, removing all limitations on eligibility for starting treatment and aiming 
to avoid the high losses from pre-ART care [177]. With this, the number of patients referred for 
treatment at the time of diagnosis has increased, but helping individuals overcome the 
immediate barriers to ART initiation remain critical. Further, these referrals increase the burden 
on the limited resources that already exist in LMIC. Sub-Saharan African countries do not 
always have the resources or funding to provide a higher percentage of ART coverage with 
these extra barriers that need to be addressed.  
A number of trials have evaluated strategies for universal test and treat [178]. The test and treat 
approach was evaluated in Swaziland through the MaxART implementation study which found 
that some patients delayed initiating ART and had often tested positive for HIV several times 
before initiating ART [179]. This delay was associated with a desire to come to terms with their 
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diagnosis and prepare for lifelong treatment. Some participants had heard that ART was non-
essential and taking care of one’s self through other means was sufficient. People also worried 
about ART-related adverse events and disclosure and the impact on social and economic 
relationships. Whilst logistical barriers can potentially be avoided, if someone needs to come to 
terms with their diagnosis before starting treatment this can be hard to accommodate [180]. 
Other barriers to test and treat are access to HIV testing, the costs of the drugs and the 
persistent stigma of HIV infection [181].  
HIV incidence in South Africa remains high with around 380,000 adults and children newly 
infected in 2016 [182]. Mathematical modelling had suggested that expanded use of ART could 
be the key to reducing the rate of new HIV infections at the population level. The hypothesis that 
universal test and treat would reduce HIV incidence was tested in the ANRS 12249 treatment 
and prevention trial [183]. The trial aimed to investigate whether universal ART initiation offered 
to all HIV-positive individuals reduced HIV incidence in a rural hyper-endemic region of South 
Africa by comparing standard of care (national ART initiation guidelines were to initiate 
treatment for those with CD4 count <350 cells/µL or WHO stage 3/4 or pregnancy until 
December 2014 and then <500 cells/µL since January 2015) with test and treat. The trial found 
no significant population-level effect of universal ART on incidence despite HIV testing uptake 
being very high and repeat testing acceptable. The issue identified by the trial was linkage to 
HIV care, which was slow and poor (only 30% of individuals had registered at the trial clinic 
within 6 months of home HIV diagnosis), therefore leading to lower than anticipated ART 
coverage with no significant difference in ART coverage between the two randomised groups. 
These findings suggest that the conditions required for a policy of test and treat to translate into 
a reduction in HIV incidence were not met. The overall HIV cascade did not vary between 
groups and fell short of the 90-90-90 target. There was a lower mortality rate in the test and 
treat group, however the difference was not significant. Delayed linkage to care was related to a 
number of factors; being young, more educated, newly diagnosed, not knowing anyone else 
with HIV, and increased distance between their home and the clinic. Either mobile clinics closer 
to people’s homes or home initiation of ART may have improved this, although studies have 
shown that these often have lower rates of linkage to care than facility based testing (see 
below) [184, 185].  
Although all HIV-positive individuals are now eligible for ART [177], large challenges remain in 
linking individuals to HIV care and treatment services. Studies prior to new recommendations to 
treat regardless of CD4 showed that between 32% and 50% of HIV-positive individuals 
assessed at public sector hospitals and clinics as ART-eligible did not initiate treatment. A study 
carried out at a South African clinic assessed demographic and psychological factors 
associated with ART readiness in patients referred for ART by an online health clinic in Cape 
Town [186]. They considered three key components, (i) an awareness that treatment will be 
beneficial, (ii) motivation to initiate treatment and (iii) the intention to start treatment soon. The 
study showed that ART readiness was significantly lower among individuals who reported good 
health (asymptomatic) and those who did not think they would test HIV-positive when tested. A 
positive diagnosis being a surprise can be associated with denial and this finding may explain 
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why denial is often identified as a barrier to ART initiation. Readiness was also associated with 
knowledge of ART or knowing someone already on ART who had had positive effects of 
treatment. Although not statistically significant they found a small association between stigma 
and readiness to treat. Rates of linkage to care and treatment are particularly poor from 
community-based HIV-testing services, such as mobile clinics and home-based testing services 
[184, 185]. While community-based testing services are effective at reaching previously 
undiagnosed HIV-positive individuals [187-189], it may be more difficult to ensure that those 
individuals begin ART. Self-testing is now recommended by WHO as a way to achieve the first 
of the 90-90-90 targets, in particular to reach first-time testers [190, 191]; encouraging results 
have been demonstrated in particular in Malawi where early trials were carried out [192]. 
However, further research is needed in how to help individuals overcome their lack of readiness 
to start treatment once they have received a positive diagnosis. Effective education is important 
along with removing stigma and uncertainty regarding side effects of treatment. Some people 
may think starting treatment is a greater risk than any benefit to a person’s immediate quality of 
life. The SEARCH study which is a research project working in 32 rural communities in Kenya 
and Uganda has shown exceptional results, demonstrating that the 90-90-90 target can be 
achieved within these kind of populations [40]. They have a mobile and home based testing 
system, they hold fairs near where people live, which are for different diseases not just HIV and 
educators are able to provide health-related counselling. The systems they have in place mean 
that providers can reach a large proportion of the community in a short space of time. For those 
who test HIV positive they prioritise service delivery, they give people a friendly environment, a 
telephone hotline and texting service, and they also counsel people on viral load suppression. 
Whether the costs of sustaining this kind of system long-term are viable is however an important 
question. 
Many countries were able to start the test and treat policy straight away but for LMIC this was 
harder due to funding. In sub-Saharan Africa it was started first in Kenya, South Africa and 
Malawi. Greater stigma and lower health literacy add barriers to the uptake of testing. However, 
in 2016, 45 LMIC had adopted the test and treat all recommendations and 31 other LMIC had 
said that they would start the test and treat during 2017 [193].  
Late presentation to care with HIV infection 
Late presentation to care with HIV infection is still a problem worldwide, even where ART has 
been readily available for years. COHERE defined late presentation as CD4 count <350 cells/µL 
[194], demonstrating that there are differing views about what is considered “late”: in LMIC <200 
cells/µL or <100 cells/µL is considered late [114]. In 2014, IeDEA and ART-CC showed that 20-
25% of people in LMIC were still starting ART with CD4 counts <100 cells/µL [114], even though 
the median CD4 count at initiation is rising [40] and more people are initiating ART. Lablite also 
showed that in Zimbabwe, despite increased ART initiations across all patient groups after 
raising the CD4 threshold for initiation to 500 cells/ µL and introducing treatment for all 
pregnant/breastfeeding women, 24% men and 13% non-pregnant women had pre-ART 
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CD4<100 cells/ µL [195]. It is known that those who present late have a higher risk of death and 
poorer ART response [196]. Late presentation is also associated with an increased risk of HIV 
transmission, ART drug resistance [197] and healthcare expenses [198]. The prevalence of late 
presentation to HIV care ranges from around 30% in high-income countries to >70% in some 
studies in African countries [198-200], depending on definitions. The issue with early deaths 
seen in my analysis highlights the need to reduce the impact of late presentation on mortality 
which is where the results of the REALITY trial are key [201].  
The REALITY trial looked at ways to reduce deaths in the early stages of treatment for people 
starting ART with low CD4 counts (<100 cells/µL). It tested three 12 week strategies, in addition 
to standard HIV treatment with 2NRTI+NNRTI. The three interventions were enhanced 
prophylaxis to prevent infections, increasing the potency of ART by adding the anti-HIV drug 
raltegravir to reduce the amount of virus in the blood faster and ready to use supplementary 
food to improve nutritional status. The trial found that giving enhanced prophylaxis reduced the 
risk of death by 25%, and those in this group were also less likely to have new WHO stage 4 
events, new tuberculosis, new cryptococcal disease, grade 4 adverse events or require 
admission to hospital. Therefore the researchers recommend that people starting HIV treatment 
with low CD4 counts (that is late presenters) should be given enhanced prophylaxis for the first 
few weeks of treatment. Using this approach will hopefully go some way to reducing the risk of 
these early deaths. However, the other two strategies, supplementary food and increasing the 
potency of ART, did not show any benefit [202, 203]. 
As discussed above there are still several ongoing issues with identifying HIV-positive 
individuals. Once identified, the need for treatment is not always seen by the patient and in 
some LMIC is not always possible straight away. With not everyone with HIV being treated, 
there is still the issue of transmission to other people and a significant number of people are still 
dying from HIV. Treatment is key, meaning that there is the need for more resources to test, 
treat and keep people on their drugs.  
Delivering long-term treatment 
In chapter 3 of my thesis, I assessed the long-term effects of structured treatment interruptions 
(STIs) on CD4 counts and clinical endpoints after returning to continuous therapy; extending 
results from the DART STI sub-study which was terminated early due a detrimental effect of 
STIs on clinical disease progression within the trial [56]. In addition, I assessed the effects of 
unplanned treatment interruptions on CD4 counts and clinical outcomes, and explored the 
reasons for these unplanned treatment interruptions.  
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Impact of time off ART 
When ART is stopped there is a drop in CD4 count which increases again with the re-initiation 
of ART [56]. I found it would take around 16 months back on continuous therapy for the CD4 
counts to return to those at randomisation following the detrimental effect of the STIs in DART. 
Rather than the fixed interruptions in DART, the SMART trial [204] investigated CD4-guided 
ART interruptions, and found that these significantly increased the risk of opportunistic disease 
or death from any cause compared with continuous therapy. Similarly to the DART STI sub-
study, SMART was also terminated early. As in DART those patients in the STI arm were 
advised to restart therapy and follow-up continued [129]. Similar to DART, CD4 cell counts in 
SMART increased with re-initiation of ART but recovered to that at randomisation in just 6 
months. This difference between the trials could be due to the fact that the SMART trial was 
conducted in high-income settings where patients generally have better prognosis; most 
importantly the pre-interruption CD4 cell counts were greater in SMART than in DART (median: 
~600 cells/μL in SMART vs. ~400 cells/μL in DART); as were the nadir CD4 counts (median: 
250 cells/µL and 86 cells/µL, respectively). Those patients who were off treatment at the time of 
sub-study closure in DART had a steeper increase in CD4 count on returning to ART. This 
finding is consistent with that in naïve patients starting ART [151], most likely due to the 
redistribution of CD4 cells into the peripheral drug circulation; after 12 weeks on continuous 
therapy the CD4 count for patients in DART had increased to the same levels as STI patients 
on ART when the sub-study was terminated, but both remained well below CD4 counts with 
continuous therapy. Using mixed models I was able to predict that the CD4 deficit associated 
with having undertaken fixed-length STIs persisted for at least 4-5 years when back on 
continuous therapy, even though patients did reconstitute immunologically. I found that after 
sub-study closure rates of switch to second-line were greater than during the randomised phase 
in both the STI group and the continuous therapy group with a trend towards greater rates in the 
STI group; there were no switches to second-line in the continuous therapy group during the 
study so I was unable to estimate this rate. 
I found that there was no increasing detriment in terms of CD4 cell counts for more time off 
treatment in unplanned interruptions but having ever interrupted ART in an unplanned way had 
a detrimental effect on CD4 cell counts. In contrast, ever interrupting treatment and the longer 
the time off treatment were generally associated with poorer clinical outcomes in adults (Figure 
3.3.10). This supports how important it is to maintain ART supplies and accessibility to avoid 
patients in treatment programmes having to stop ART. Interestingly, I showed in DART that the 
effects of unplanned treatment interruptions and STIs were different, plausibly due to 
unmeasured confounding.  
In contrast I found that in children there was an increasing detriment in terms of CD4% for more 
time off treatment due to unplanned treatment interruptions but no additional effect of any time 
off treatment. This suggests that children may tolerate at least short interruptions 
immunologically; however this should not be for too long, as demonstrated by generally poorer 
166 
 
clinical outcomes associated with interruptions, although power was low in these analyses. The 
PENTA 11 trial [154] (providing the only randomised evidence of the effects of planned 
treatment interruptions in children) showed that although interruptions could not generally be 
recommended, due to children’s’ greater potential for immune recovery they may be an 
acceptable option for children, particularly when there is a high risk of unplanned treatment 
interruptions. Children are at a lower risk compared to adults for cardiovascular, renal and liver 
complications due to their younger age. Children also have a lower incidence of traditional risk 
factors such as hypertension, diabetes and smoking; these are all factors whose risks increase 
substantially in HIV-positive adults stopping ART. 
One limitation of my analyses is that VL was not measured routinely in either the DART or 
ARROW trials, but was measured only in specific subsets of patients to answer specific 
scientific questions. The effect of treatment interruptions on CD4 counts is mediated through its 
effect on VL, since stopping treatment means VL becomes unsuppressed and rises, and CD4 
cells start to die, as in untreated HIV. Tong et al. showed that detectable VL (>300 copies/mL) 
was significantly associated with treatment interruption for more than two consecutive days 
among patients who had been on ART for at least 6 months. A negative effect on virological 
suppression increases the risk of transmission and has a detrimental effect on the plan to 
eliminate HIV infection, highlighting again the importance of maintaining drug supplies and 
keeping people on life-long ART. 
I assessed the effect of number of STIs on CD4 count at 132 weeks using standard regression 
models (e.g. Table 3.3.2), adjusting for factors at trial baseline and randomisation to CT/STI. 
These analyses assumed no unmeasured confounding; that is, that there are no common 
causes of receiving more or fewer STIs and having a higher or lower CD4 count at 132 weeks 
which are not included in my models. This assumption is valid for a randomised intervention, 
such as comparing CT vs. STI, but patients were randomised to a strategy of receiving repeated 
STIs, not to a specific number, so my exposure of interest is not randomised. I found a negative 
effect of any time off treatment on CD4 at 132 weeks but not an increasing effect of more time 
off treatment; that is, having 4 STIs was not any worse than having 1 STI. However, in practice 
patients had variable numbers of STIs (Figures 3.3.1 and 3.3.2), and this is therefore an 
average effect of STIs across the number of STIs that were actually undertaken. A key limitation 
of my analysis is that I did not account for the fact that some patients could have had more 
cycles but did not. In particular, I found that those who had 4 cycles were highly selected 
compared to those who had 1 or 2 cycles (Figure 3.3.2), and that those who received fewer 
cycles than they should have done generally did so due to low CD4 or WHO 3/4 events, 
suggesting that those who were more healthy received more STI cycles. This plausibly means 
that I may have missed a dose-response effect and that my estimate of the effect of STIs on 
CD4 at 132 weeks is an underestimate of the risk of repeated STIs due to unmeasured 
confounding from patients with low CD4/large CD4 decreases stopping STIs early. One 
possibility would have been to directly adjust for time-updated confounders between 
randomisation to STIs and sub-study closure such as CD4 as these would have affected 
whether the subsequent (2nd, 3rd or 4th STI cycles) occurred. However, the problem with this 
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approach is that time-updated CD4 (and likely other confounders) are not only related to 
whether a patient has more cycles of STIs, but are also related to the outcome, that is CD4 at 
132 weeks, and are affected by previous STI cycles.  
To appropriately account for time dependent confounders affected by prior treatment (here 
STIs) I could have used a causal inference model. A number of causal inference methods have 
been developed over recent years including dynamic marginal structural models (MSMs) which 
aim to estimate the effect of a treatment regime by “artificially” censoring patients who become 
non-compliant with a given treatment regime and upweighting those who remain compliant 
using inverse-probability-of-censoring (or equivalently inverse-probability-of-treatment) weights 
and estimating risk in the weighted population; dynamic MSMs have most commonly been used 
to look at “when to start” treatment questions [205, 206].   
I could in theory have used a similar approach to estimate the causal effect of regimes such as 
“one STI”, “two STIs” on subsequent CD4 in the same way Crook et al. estimated the effect of 
contraceptive method on risk of HIV acquisition [207]. For example, in order to estimate the 
causal effect of having had four STIs I could have censored those in the STI arm who did not 
receive all four STIs at the first time at which they should have started the next STI cycle and 
did not as follows (Figure 4.1). 
Figure 4.1 Estimating the causal effect of having had four STIs 
 
Here patients are ‘artificially censored’ at the time at which they would have started their next 
cycle of STI (that they did not start), meaning that they do not contribute to the outcome model 
for CD4 at 132 weeks. Instead in the outcome model those who received 4 STIs are up-
weighted to account for all patients in the STI arm using inverse-probability-of-censoring 
weights which reflect the probability that each person received 4 STIs given their baseline and 
time-updated covariates. Weights could potentially be estimated from a pooled model; 
alternatively separate models for each STI might be needed, essentially considering at each 
1 STI cycle censor
2 STI cycles censor
3 STI cycles censor
4 STI cycles
STI cycle 1 break         STI cycle 2 132 weeks
STI cycle 1 break        STI cycle 2        break       STI cycle 3 132 weeks
STI cycle 1 break        STI cycle 2        break       STI cycle 3 break   STI cycle 4              132 weeks
STI cycle 1 break        STI cycle 2        break       STI cycle 3 break   STI cycle 4              132 weeks
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start of an STI cycle what was the probability of each individual having the STI as planned vs. 
not having the STI as planned. The initial weights are 1 for everyone as everyone included had 
1 cycle. But at the second cycle patients who had the second cycle will get upweighted to 
account for those that did not (with higher weights given to the less common patients (e.g. those 
who continued with STIs despite low CD4)) and similarly at the third and fourth cycles. The 
weighting models (but not the outcome model) would include time-updated covariates like most 
recent CD4 and disease stage, as well as baseline covariates. A similar approach could have 
been used to censor and upweight STI patients to look at 1, 2 or 3 STIs and I could have 
compared all 4 regimes to continuous ART in a single weighted outcome model. 
This approach is problematic if there is a predictor or combination of predictors which is very 
strongly (or completely) associated with a regime (e.g. if no patients whose CD4 drops below x 
continue on STIs); this may have made the above theory difficult to apply in practice particularly 
within the DART trial where there was good adherence to a strict protocol [208]. Other causal 
methods are also difficult to use in this case although g-computation (where the relationships 
between all variables in the data are modelled) may be possible with extrapolation of models 
outside the data [206].  
Another limitation of my work is that I only included a relatively small number of covariates up to 
STI randomisation in my standard regression models for the association between number of STI 
cycles and CD4 count at 132 weeks. Other factors that I could have included include 
socioeconomic status, missed trial visits prior to the STI randomisation, history of weight, BMI, 
haemoglobin, WHO 3/4 events and ART history since trial entry and prior to STI randomisation. 
In addition I could have included data available in DART from a symptoms checklist of 26 
symptoms that were collected every 4 weeks. This could have reduced the impact of standard 
unmeasured confounding. I could also have included these factors in my weighting models. 
In addition I assessed the effects of STIs and UPTIs (and total duration off treatment) on 
CD4/CD4% and clinical outcomes in both DART and ARROW patients. In DART I found the 
effects of STIs and UPTIs on CD4 at 4 years were different (Table 3.3.12) which is very likely 
due to unmeasured confounding. The results in Table 3.3.12 suggest that there is a decrease in 
CD4 at 4 years for more time off treatment due to UPTIs but I cannot distinguish whether this is 
a result of the time off treatment or a result of underlying reasons for the UPTIs; thus my effect 
estimate should not be interpreted as a causal effect but may still be useful for clinical 
management. While in theory, causal models could have been used to adjust for confounders 
associated with UPTIs and subsequent CD4 (or other outcomes), addressing the issues with 
UPTIs is more complicated than for STIs: firstly, the specific reasons UPTIs were undertaken 
were only recorded very broadly (and are unlikely to be captured as well as predictors of patient 
management); secondly, whereas STIs were a fixed length, UPTIs were variable in length thus 
the duration of the UPTI also needs to be considered. There are few examples in the causal 
literature which estimate the effect of an exposure which cannot be assigned [209, 210] as is 
the case with a UPTI or include intermittent exposure where (as here) the reasons for stopping 
exposure (here ending a UPTI) as well as starting exposure (starting a UPTI) are needed [211]. 
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The most common reason for UPTIs was being unable to attend clinic, but this could be for 
several different reasons each with a different relationship with outcome, or no relationship at 
all. For example, there is no reason why you should be sicker or healthier just because you 
have no access to transport, but if the reason for not attending clinic is that you are too unwell to 
travel this would clearly have an effect on outcome. In contrast, if you are too busy to attend 
clinic this may be because you are well. Correctly constructing weighting models (or modelling 
relationships using a g-computation approach) to account for both starting and stopping UPTIs 
would  require a larger number of more detailed covariates than were collected in the trial. 
ART adherence in adults 
As discussed above, the global targets for scaling up of ART therapy include ensuring that 90% 
of patients on ART achieve viral suppression. This new target emphasises the need to ensure 
optimal levels of adherence. Poor adherence includes both sporadic taking of ART (e.g. missed 
doses) and unplanned treatment interruptions. Structured treatment interruptions are no longer 
recommended in guidelines but unplanned treatment interruptions are common. My findings 
that the consequences of treatment interruptions include lower CD4 counts and poorer clinical 
outcomes even after returning to ART suggest that substantially greater efforts should be 
devoted to reducing the risk of any treatment interruption, including strengthening supply chain 
management to ensure continuous drug supplies, early contact of patients not attending drug 
refill visits (e.g. by mobile phone text, although the effects of this have been mixed with positive 
effects in some studies [212, 213] and negative effects in others [214, 215]) and making short 
supplies of ART available for patients who travel.  
In both DART and ARROW, I found the most common reasons for unplanned treatment 
interruption were structural, such as being unable to attend clinic. The second most common 
reason for unplanned treatment interruptions was adverse events/toxicity; however, this 
accounted for only 22% of all unplanned interruptions in DART and in ARROW this was even 
lower with only 6 patients interrupting ART due to toxicity. In DART more than 50% of the 
adverse events were due to blood disorders and included neutropenia and anaemia, likely due 
to zidovudine and low CD4 counts at ART initiation. This relatively low rate of stopping 
treatment for adverse events is likely due to the nature of the trials with more regular 
assessment of patients and more patient support and might be higher in contemporary patients 
on the same/similar ART outside of trials. The drugs in DART are now old drugs which were 
given twice daily. The current WHO recommendation, as preferred first-line ART for adults, is a 
better once daily regimen containing efavirenz and tenofovir with either lamivudine or 
emtricitabine. Mouton et al. [216] carried out a review that focused on the key toxicity issues 
arising from the use of this WHO recommended first-line ART in adults. They assessed those 
toxicities that are seen both at the onset of ART, as well as the long-term toxicities seen after 
prolonged use in large cohorts. Where possible they focussed on sub-Saharan Africa. They 
found that it was uncommon for these drugs to result in toxicity and the benefits of ART far 
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outweighed the risk of toxicity. In addition, they found that recognising drug toxicity in HIV-
infected persons is challenging as patients may have multiple comorbidities.  
With even newer drugs, rates of adverse events/toxicity may be lower currently and in the 
future. The integrase inhibitor dolutegravir is a less toxic alternative to efavirenz. It was 
previously only recommended in high-income countries due to its high cost but with a new low 
cost deal [217] that has been put in place its use in LMIC is increasing with more than 20 LMIC 
having initiated dolutegravir procurement. It is expected that WHO will recommend it in the next 
treatment guidelines (revision planned during 2018) as a safe and well tolerated first-line agent 
that has a higher probability of virological suppression than other first-line agents [218, 219].  
A recent study carried out in sub-Saharan Africa found that in adults in South Africa, poor ART 
adherence was related to patient and family factors, stigma and discrimination, substance 
abuse, socioeconomic challenges, health care and systems [220]. Another study carried out in 
24 countries in sub-Saharan Africa including South Africa, Uganda, Ethiopia and Kenya found 
that the most frequently identified barrier to ART adherence was forgetting, followed by lack of 
access to adequate food, stigma and discrimination, side effects and being outside the house or 
travelling [221]. These are slightly different to the most important reasons I found for unplanned 
treatment interruptions in DART, perhaps because DART was a randomised controlled trial and 
patients came to clinic very frequently (4 weekly) for check-ups meaning they received 
continuous reminders. Further, as the trial was early in ART treatment (2003-2008), there was 
substantial reinforcement of the need for drugs. DART participants were therefore probably less 
like to simply forget; rather it was a case of running out of drugs when they were unable to 
attend clinic. Croome et al. [221] also reported on facilitators to adherence; these being, social 
support, reminders, feeling better after taking ART, disclosing their HIV status and having a 
good relationship with their healthcare provider. Many of these would have applied to DART trial 
participants who set up social clubs in clinic, which they attended frequently. In contrast, Merten 
et al. [117] highlighted that experiences of low quality services and access constraints can 
undermine trust in health care services, and that provider’s attitudes, the time they spend with 
patients and low communication can also decrease adherence to ART. DART and ARROW 
participants were fortunate to receive ART within relatively well-funded trials. 
Longer-term suboptimal adherence levels lead to negative outcomes including increased risk of 
disease progression [222], drug resistance [223], high viral load and consequent risk of 
transmission [224, 225] and death [121, 226]. At the end of 2016 only 50% of people living with 
HIV in southern and eastern Africa had achieved viral suppression [40]; this is equivalent to 
83% of those who were receiving ART being virally supressed. Despite the high percentage of 
people receiving ART who are virally supressed, adherence to treatment is still a major 
challenge as the only way to achieve viral suppression is to take continuous ART. Patients on 
ART face multiple barriers to adherence and no single intervention is sufficient to ensure high 
levels of adherence. Following a systematic review carried out in 2016, Shubber et al. [227] 
suggested that healthcare providers should consider a triage approach that first identifies 
patients at risk of poor adherence and then seeks to establish the support that is needed for 
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them to overcome their most important barriers to adherence. The adherence literature often 
divides these barriers into structural barriers and social barriers. Tweya et al. [120] found that 
the most common reason for interrupting treatment in Malawi was running out of drug whilst 
travelling (46% of patients), other reasons included forgetting to attend clinic or take treatment 
(17%), also highlighting the importance of reminders to attend clinic. A study carried out in 
Tanzania reported that during participatory group discussions, structural factors were 
consistently ranked as the most hard to control, including barriers to clinic attendance [162]. In 
my analysis I also found that the most common reason for missing treatment in both adults and 
children/carers was being unable to attend clinic i.e. a structural reason. Similarly, Roura et al. 
[161] found that when discussing barriers to clinic attendance with patients, structural factors 
were consistently ranked as the main barrier, which ultimately leads to poor adherence. They 
also highlighted the importance of addressing sociocultural and psychosocial factors, all 
reasons that I also found for people missing ART. The DART data also demonstrate the role of 
mental health issues; domestic problems including discouragement by friends and relatives; and 
ongoing challenges of pill burden and fatigue with treatment to treatment interruptions. Faith 
and divine healing were also amongst the reasons given; highlighting that education is still 
needed into how important these drugs are in reducing deaths from HIV and AIDS.  
Adolescents 
Globally adolescents and young adults account for more than 40% of new HIV infections and 
HIV-related deaths amongst adolescents increased by 50% from 2005-2012. However, there is 
very little research on adherence amongst the growing population of adolescents in Southern 
Africa. Kim et al. [228] found that nearly half (45%) of all adolescents living with HIV in Malawi 
reported non-adherence to ART in the past month. Commonly reported barriers to adherence 
were in fact similar to adults and included forgetting (40%), travel from home (14%), busy with 
other things (11%), feeling depressed/overwhelmed (6%), feeling stigmatized by people outside 
(5%) and within the home (3%). Factors found to be independently associated with missing a 
dose in the past week were drinking alcohol in the past month, missed clinic appointment in the 
past 6 months, witnessed or experienced violence in the home and poor treatment self-efficacy. 
Other reasons included being away from home, too tired, didn’t want others to know, couldn’t 
deal with it that day or ran out of drugs. Unpublished data from the AALPHI cohort based in the 
UK found that 27% of adolescents reported missing any doses in the last 3 days and 31% 
reported missing more than 2 days in a row in the last month (40% reporting either outcome). 
Predictors of both outcomes were poorer quality of life (PedsQL), poorer self-perception of HIV, 
more years on ART and surprisingly an increase in the number of other young people they had 
told. They also found that adolescents with HIV found it harder to take doses of ART at the 
weekend, suggesting that perhaps less routine and being more social have an effect on 
adherence. Family background did not appear to predict adherence [229]. These results 
highlight that the issues around mental stability, stigma and the burden of long-term treatment in 
fact are very similar in adolescents, adults and children; rather the effects of these factors are 
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accentuated in adolescents. In ARROW I showed that the main reason for children interrupting 
ART was being unable to attend clinic, just as in adults, and the same reasons likely apply.  
Issues with drug supply 
Although having enough antiretroviral treatment was not highlighted as a reason for interruption 
in DART due to the nature of the trial, it was highlighted as a key issue by Kranzer et al. [150] in 
their systematic review and remains challenging in some LMIC. Tong et al. [230] investigated 
ART interruption for more than two consecutive days in 19 health service centres in Cameroon. 
They found that 52% of the HIV services that participated in their study recorded stock-outs of 
at least one of the three most prescribed ART regimens during the previous year. In another 
study in Cameroon, 85% of the health care facilities reported ART stock-outs [231]. There are 
also several studies that have reported ART stock-outs as the main reason for missing doses 
[119, 232-235]. Chan et al. showed that ART stock-outs were more common in paediatric care 
compared to adult care 23% vs. 7%, respectively [236]. Clinic staff in the study by Tong et al. 
reported several ways of dealing with stock-outs: switching regimens to use an available similar 
class drug, splitting a delivered dose or sending patients to another HIV service. These 
strategies were also reported by a study in Tanzania [237]. Worryingly, splitting delivered doses 
runs a serious risk of suboptimal drug levels which may lead to resistance. 
Retention in care 
In order for HIV-infected people to adhere to treatment, they have to be in care. However, 
recent estimates show that just over half of those diagnosed with HIV may be engaged in and 
retained in care at any one time. In fact, retention in care has been estimated to be as little as 
67% in sub-Saharan Africa [238], highlighting that it is still a critical challenge for all HIV 
treatment programmes especially where resources are limited. Preparing patients for treatment 
and treating them for just a few months before losing them to follow-up is also an inefficient use 
of resources. Cost-effectiveness is important, as programmes seek to maximise the impact of 
limited resources; lack of attention to loss to follow-up is as costly as failures in ensuring good 
adherence. Patients who do not remain in care may need to move on to second-line treatment 
which is generally more expensive, or they may fall ill as a result of being off ART and therefore 
require hospitalisation. All of these things place further stress on an already overburdened 
health care system [239].  
Reducing the burden on healthcare systems 
When WHO broadened its guidelines to recommend that all identified people living with HIV 
should initiate ART irrespective of immunological or clinical status, this had a substantial impact 
on the already burdened health systems in sub-Saharan Africa. Current research is aiming to 
develop systems that should improve the efficiency of healthcare delivery by reducing 
unnecessary burdens on the health care systems, which could potentially increase retention in 
care. Several interventions such as tracing of patients lost to follow-up, task shifting and 
differentiated care all have implications on resources such as staffing and clinical capacities and  
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these may not easily be scaled up or contracted in response to changes in demand. Revill et al. 
[240] highlighted that in most cost-effectiveness studies, there is the assumption that unit costs 
of resources suitably reflect the value of those resources in the health care system and that it 
does not matter which particular resource is utilised or released in the delivery of alternative 
interventions. However, when the availability of those resources cannot easily be adjusted to 
the changes in demand because of local variability, these assumptions cannot be made. This 
has potentially important consequences for how economic evaluation is undertaken and the way 
in which results are used in formulating health policy and are implemented by programmes in 
health care delivery.  
Frequency of clinic visits and differentiated care 
Patients typically attend clinic every 1-3 months for clinic assessment and to collect drugs. This 
is largely historical but also exacerbated by the difficulties in keeping sufficient drug supplies to 
routinely issue drugs for longer time periods. Needing to frequently collect ART refills may lead 
to suboptimal adherence and disengagement from care due to the time spent waiting at clinics 
and cost to patients of frequent clinic visits, particularly for those who have to travel long 
distances [241]. Frequent clinic visits also place a high demand on the healthcare system due to 
the costs of providing personnel and infrastructure. Less frequent dispensing of ART and 
community-based ART-delivery models are potential strategies to reduce the load on 
overburdened healthcare facilities and reduce the barriers for patients to access treatment. 
Mathematical modelling has shown that reducing the frequency of clinic visits for stable patients 
is expected to be cost-effective in sub-Saharan Africa [242]. Observational research in Zambia 
has shown that 2- and 3-monthly visit intervals were associated with decreased loss to follow-up 
and decreased visit lateness compared to patients who attended monthly [243]. As a result, 
WHO has recommended that stable ART patients require less frequent medication pick-ups and 
clinic visits (3- to 6-monthly) [244, 245]. However, the available data supporting the 
effectiveness of this strategy is sparse and the quality of evidence is low due to potential for 
bias. A recent systematic review found that reduced frequency of clinic visits and medication 
pick-up for ART patients may lead to improvements in program retention and patient outcomes 
[246]. A single, pilot cluster-randomised trial that included a comparison of clinic visit 
frequencies (maximum 3-monthly) for ART patients has been conducted in low-income settings, 
but included only 96 participants in the intervention group [247]. No larger scale randomised 
trials have been conducted, and little cost data are available. Fatti et al. [248] plan to carry out a 
cluster randomised trial to investigate the effectiveness and cost-effectiveness of 3- vs. 6-
monthly dispensing of ART for stable HIV patients in community ART-refill groups in Zimbabwe. 
They highlight that clinics that are relieved of stable ART patients may be able to increase the 
rate of new ART initiations and thus scale up ART coverage.  
Differentiated care, whereby patients who are stable on ART attend clinic even less frequently 
(6-12 monthly and may collect their drugs at alternative pick-up points) has been recommended 
in the latest WHO treatment guidelines [171] to further reduce clinic burden; those who have 
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recently started ART or have any toxicity or indication of lack of virological suppression continue 
to attend more regularly [249]. CD4 count may be used to triage patients to different care 
pathways but there is an increasing emphasis on using viral load which provides a more direct 
measure of the current treatment effect on the virus. Over the last decade WHO 
recommendations in LMIC have moved towards using viral load for monitoring treatment, and 
since 2013 viral load monitoring has been recommended as the preferred monitoring approach 
to diagnose and confirm treatment failure [35]. In 2016 these guidelines were updated and 
WHO now recommends that routine viral load monitoring be carried out at 6 months, at 12 
months and then every 12 months thereafter if the patient is stable on ART, to synchronise with 
routine monitoring and evaluation reporting. “Viral-load-informed differentiated care” tailors care 
so that those with suppressed viral load visit the clinic less frequently and attention is focussed 
on those with unsuppressed viral load to promote adherence and timely switching to a second-
line regimen. Routine viral load testing has been available for some time in South Africa but is 
gradually being rolled out in a number of other African countries [250], mostly by collection of 
dried blood spot samples in clinic which are then tested in regional laboratories. Phillips et al. 
[242] used mathematical modelling to evaluate the cost-effectiveness of viral-load-informed 
differentiated care, accounting for the limitations of dried blood sample testing. They found that 
viral-load-informed differentiated care using dried blood samples was cost-effective (provided it 
led to reduced clinic visits) and recommended it as a strategy for patient management; however 
further real life evidence as the approach is rolled out is needed. The difference between 
models and real-world experience of “test and treat” discussed above emphasises the 
importance of this. 
Community based ART delivery models 
Community-based ART models are another approach to reduce burden on healthcare systems. 
Murray et al [251] carried out a systematic review on improving retention in HIV care among 
adolescents and adults in low- and middle-income countries. They found that interventions 
involving the delivery of community-based services had the strongest evidence based on the 
quality and the number of studies. Eight studies examined shifting the delivery of HIV care and 
treatment from health facilities to communities. These interventions relocated ART distribution to 
the community and engaged community health workers or peers to distribute ART and monitor 
symptoms, resulting in fewer patient visits to a clinic. Two community-based service 
interventions also incorporated directly observed therapy i.e. making sure someone takes their 
tablets by watching, or counselling. Overall, the results of community-based service 
interventions were positive: six found positive associations between the interventions and 
retention in care, and two found no association. Community ART-refill groups are a novel 
strategy that has been introduced with the intent to reduce barriers to patients accessing regular 
treatment and to limit health facility congestion [252]. Community ART-refill groups are groups 
consisting of 6-12 stable ART patients who meet at a community venue to receive ART refills, 
and who provide mutual support to each other. Retrospective observational studies of 
community groups receiving monthly ART refills have shown encouraging results [253, 254]. 
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Follow-up between clinic visits  
Another way to improve retention in care is to increase the amount of contact between patients 
and clinics between visits. Results from one of the first mobile health trials in Africa [212] 
(referred to in the section on importance of adherence), WelTel Kenya1, showed that patient–
clinician text messaging significantly improved treatment adherence and viral suppression 
among individuals who had initiated ART [212]. The WelTel intervention involved sending 
weekly interactive text messages, which were followed up by telephone calls if a patient 
indicated that they had an issue with adherence. This was in addition to their usual care, which 
consisted of a clinic appointment two weeks after the positive HIV test followed by a once a 
month visit for the first six months, then if adherent a visit every two/three months, with those 
who were non-adherent continuing to be seen every month. Anyone who did not attend was 
called by clinic staff, twice if necessary. They found no effect of the intervention on retention, 
which may be due to the regularity of usual care. However, in addition to the benefits on 
adherence and viral suppression above, they did identify improvements in quality of life with text 
messaging.  
Comorbidities 
As treatment improves, HIV-positive people are living longer and are therefore experiencing 
other comorbidities found in the general population such as cardiovascular disease, 
malignancies, cognitive impairment and reduced bone mineral density, which impact disability 
and everyday functioning [255]. Improving the management of these comorbidities in LMIC is 
essential, including screening and diagnosis. Managing HIV as a long-term chronic condition 
alongside other comorbidities and providing integrated care is increasingly being recognised as 
key for the patient but also for healthcare providers [256]. 
4.1. Conclusions 
In conclusion, delivering ART to people in low- and middle-income countries still has major 
challenges, including starting patients on treatment early in order to reduce the risk of early 
deaths, and retaining people on treatment to reduce the detrimental effects of treatment 
interruptions. The contribution of HIV-related-malignancies to deaths, likely triggered by pre-
cancerous events occurring before ART initiation to longer-term ART mortality highlights the 
importance of earlier HIV diagnosis and access to care. Low but increasing risk of death from 
trauma/suicide in adults highlights the importance of long-term psychosocial support and 
empowering patients to manage their own treatment. Greater efforts should be devoted to 
reducing the risk of any treatment interruption, including strengthening supply chain 
management, early contact of patients not attending drug refill visits and making extra supplies 
of ART available for patients who travel. Access to care for people with HIV needs to be a 
priority; treatment needs to be started in a timely manner, patients need to be retained on 
treatment and sufficient monitoring is key if the 90-90-90 target is to be met by 2020.  
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